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BIOSIMILAR BIAS:

A BARRIER TO ADDRESSING AMERICAN
DRUG COSTS
CYNTHIA M. Hot
ABSTRACT

Forty percent of spiraling drug costs in the United States stem from a
mere 2% of all drugs-biologic drugs (biologics) made from living cells
and administered by injection or infusion. Drug costs will continue to rise
as new biologics are approved by the Food and Drug Administration. Biologics are expensive because they cannot be mass-produced, and the consequence of their high prices is that important treatments for conditions
such as arthritis and cancer remain out of reach for many Americans. Fortunately, just as there are lower cost generic versions of brand-name pills,
there are lower cost biosimilars of original biologics-the lower cost is
made possible by an expedited regulatory approval process. Despite the
lower cost and a decade of safe biosimilar use globally, U.S. adoption of
biosimilars remains minimal, in stark contrast to widespread use of generic
drugs.
This Article provides the first comprehensive explanation of how
U.S. laws, industry actions, and cognitive biases work together to impede
the use of biosimilars in the United States. This Article argues that doctors
and patients currently have unfounded misperceptions concerning the
safety and efficacy of biosimilars based on misinformation propagated by
companies that builds upon an existing cognitive bias against cheaper
drugs. These misperceptions keep drug costs high and lead to worse health
outcomes for patients-studies have shown that these unfounded misperceptions can have negative physical manifestations. Although there is a
similar misperception against generic drugs, generic drugs do not face the
structural barriers in regulatory laws and insurance coverage that exacerbate biases against biosimilars. For example, U.S. regulatory law requires
an additional regulatory designation to permit a pharmacist to substitute a
biosimilar without doctor intervention. No such additional regulatory designation is required for substituting generics.

t Clifford E. Vickrey Research Professor, Loyola University Chicago School of Law;
cho@luc.edu. The author acknowledges the support of the Loyola University Chicago School of Law
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After revealing the existence and extent of the bias against biosimilars, this Article proposes solutions to effectively promote and increase
biosimilar use. It suggests a multipronged approach to encourage biosimilar use, including legal changes to support biosimilar substitution, education to specifically tackle biases, and financial incentives to encourage biosimilar use. Addressing barriers to biosimilar use would not only expand
access to treatment but would also save the United States an estimated $50
billion in the next decade.
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INTRODUCTION

There is a major problem with containing costs for the most expensive drugs in the U.S. market. In particular, complex drugs made from living biological compounds (biologics) constitute about 40% of drug costs,'
despite being only 2% of drugs used. 2 Biologics include revolutionary
treatments such as the mRNA-based COVID-19 vaccines by Pfizer and
Moderna, 3 Humira for arthritis,4 and Herceptin for some types of breast
cancer.5 However, biologic costs can be substantial, with retail prices that
are easily $10,000-$70,000 per year per patient and some costing

1.

IQVIA, BIOSIMILARS IN THE UNITED STATES 2020-2024: COMPETITION, SAVINGS, AND
3 (2020); see also ASSISTANT SEC'Y FOR PLAN. & EVAL., MEDICARE PART B

SUSTAINABILITY

DRUGS: TRENDS IN SPENDING AND UTILIZATION, 2006-2017 9 (2020) [hereinafter ASPE SPENDING
TRENDS] (finding biologics administered in medical offices constitute almost 80% of Medicare Part

B drug costs).
2.

E.g., Avik Roy, Biologic Medicines: The Biggest Driver of Rising Drug Prices, FORBES

(Mar. 8, 2019, 8:20 PM), https://www.forbes.com/sites/theapothecary/2019/03/08/biologic-medicines-the-biggest-driver-of-rising-drug-prices.
3.
proval

E.g., Pfizer and BioNTech InitiateRolling Biologics License Application for U.S. FDA Apof
Their
COVID
19
Vaccine,
PFIZER
(May
7,
2021,
6:45
AM),

https://www.pfizer.com/news/press-release/press-release-detai/pfizer-and-biontech-initiate-rollingsubmission-biologics; Moderna InitiatesRolling Submission of Biologics License Application for its
COVID-19 Vaccine, BIOPHARM INT'L
(June 2,
2021), https://www.biopharminterna-

tional.com/view/moderna-initiates-rolling-submission-of-biologics-license-application-for-its-covid19-vaccine.
4.

E.g., Benita Lee, What are Biologics? 5 Examples of Drugs You May Already Be Taking,

GOODRX (June 13, 2018), https://www.goodrx.com/blog/biologics-biological-drugs-examples
(discussing biologics such as Humira and Botox); Kathlyn Stone, Top 10 Biologic Drugs in the United
States, VERYWELL HEALTH (Oct. 11, 2021), https://www.verywellhealth.com/top-biologic-drugs2663233.
5. See George W. Sledge, Eleftherios P. Mamounas, Gabriel N. Hortobagyi, Harold J.
Burstein, Pamela J. Goodwin, & Antonio C. Wolff, Past, Present and Future Challenges in Breast

Cancer Treatment, 32 J. CLINICAL ONCOLOGY 1979, 1979, 1983 (2014). In addition, biologics have
recently been developed as a preventative treatment to reduce debilitating migraines by up to 50%.
E.g., Philip Harvey, Pooja Shah, & Scott Shipley, An Overview of New BiologicsforMigraineProphylaxis, 45 U.S. PHARMACIST 21, 21 (2020).
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hundreds of thousands per year or more. 6 Even after insurance, biologics
can cost patients $8,000-$40,000 per year.7 High costs are a barrier to effective treatment because patients forgo or ration treatment, leading to
poor health outcomes,8 including unnecessary deaths for diabetic patients
who skip insulin doses.9 Moreover, expensive biologics may exacerbate
known income disparities in accessing drugs because those with fewer resources are often unable to afford recommended treatment. 0 This is especially true if doctors prescribe originator biologics-the first-to-market biologic medicine, analogous to the first-to-market brand drug that precedes
a generic-instead of lower-cost biosimilars, which are highly similar,
subsequent to the originators, and intended to lower prices, similar to generic versions of traditional drugs.
Although competition generally results in lower prices, effective
competition is currently stymied for U.S. biologics. A streamlined regulatory approval process for traditional drugs results in many low-cost generic drugs, which account for 90% of prescriptions." However, a decade
after the United States finally adopted a similar process for subsequent
biologics, biosimilars constitute less than 30% of the U.S. biologics

6.
See Favour Danladi Makurvet, Biologics vs. Small Molecules: Drug Costs and PatientAccess, 9 MED. DRUG DISCOVERY 100075, at 4 (2021) (noting that the daily cost of biologics is twentytwo times that of other drugs); Mike Z. Zhai, Ameet Sarpatwari, & Aaron S. Kesselheim, Why are
BiosimilarsNot Living Up to Their Promise in the US?, 21 A.M.A. J. ETHICS 668, 668 (2019) (noting
costs in excess of $100,000 peryear); Victor L. Van de Wiele, Aaron S. Kesselheim, & Ameet Sarpatwari, Barriers to US Biosimilar Market Growth: Lessons from Biosimilar Patent Litigation, 40
HEALTH AFFS. 1198, 1198 (2021) (observing that many biologics cost more than $100,000, including
some newer ones costing severalfold higher). Biologics are the most expensive drugs covered by Medicare, representing 43% of drug spending for physician-administered drugs. ALEX BRILL, SHARED
SAVINGS

DEMONSTRATION FOR BIOSIMILARS

IN MEDICARE:

AN OPPORTUNITY TO PROMOTE

BIOLOGIC DRUG COMPETITION 5 (2020).
7.
See ASPE SPENDING TRENDS, supra note 1, at 11; see also WAYNE WINEGARDEN,
PROMOTING BIOSIMILAR COMPETITION TO REDUCE PATIENTS' OUT-OF-POCKET COSTS 7-11 (2020)

(comparing annual costs of originator biologics ($4,000 to over $60,000) to biosimilars ($30,000 to
over $40,000)); Sonal Parasrampuria & Gerald F. Anderson, ComparingPatient OOP Spending for
Specialty Drugs in MedicarePartD and Employer-SponsoredInsurance, 26 AM. J. MANAGED CARE

388, 391 (2020) (noting out-of-pocket costs for originatorbiologics range from around $200 to nearly
$2,000 a month); Sarah Jane Tribble, Why the U.S. Remains the World's Most Expensive Marketfor
Biologic' Drugs, KAISER HEALTH NEWS (Dec. 20, 2018), https://khn.org/news/u-s-market-for-bio-

logic-drugs-is-most-expensive-in-the-world.
8.
Patient compliance with drug treatment is negatively correlated to cost. E.g., Jack Burks,
Thomas S. Marshall, & Xiaolan Ye, Adherence to Disease-Modifying Therapies and Its Impact on
Relapse, Health Resource Uutilization, and Costs Among Patients with Multiple Sclerosis, 9

CLINICOECONOMICS & OUTCOMES RES. 251, 259 (2017); Parvaneh Heidari, Wendy Cross, & Kimberley Crawford, Do Out of Pocket Costs Affect Medication Adherence in Adults with Rheumatoid
Arthritis?A Systematic Review, 48 SEMINARS ARTHRITIS & RHEUMATISM 12, 18-20 (2018).
9.
See Bram Sable-Smith, Insulin 's High Cost Leads to Lethal Rationing, NPR (Sept. 1, 2018,
8:35 AM), https://www.npr.org/sections/health-shots/2018/09/01/641615877/insulins-high-cost-

leads-to-lethal-rationing.
10.

High drug costs are known to exacerbate racial and income disparities in medication use.

See Stephen J. Kogut, Racial Disparitiesin Medication Use: Imperatives for Managed Care Pharmacy, 26 J. MANAGED CARE SPECIALTY PHARMACY 1468, 1468 (2020).

11.

21 U.S.C.

§

355(j) (permitting abbreviated applications for approval of generic drugs);
&

&

ASS'N FOR ACCESSIBLE MEDS., SECURING OUR ACCESS & SAVINGS: 2020 GENERIC DRUG
BIOSIMILARS ACCESS & SAVINGS IN THE US REPORT 16 (2020) [hereinafter AAM 2020 ACCESS

SAVINGS] (noting generics are 90% of prescriptions filled).
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market.' 2 Of the seven originator biologics that have a biosimilar in the
United States, only one has biosimilars that capture more than 50% of the
market share.' 3
This Article provides the first comprehensive explanation of how pervasive individual cognitive biases, in conjunction with pharmaceutical
mismarketing and structural components in U.S. law and insurance policies, have perpetuated illogical biases against biosimilars. Marketing may
cause a doctor to refuse to prescribe biosimilars based on a false belief that
biosimilars are not as effective as the originator biologic even though the
Food and Drug Administration (FDA) has determined the biosimilar to be
highly similar to the originator, safe, and effective."' Understanding that
cognitive biases may perpetuate bias against biosimilars is essential because it means that simply ending mismarketing and even dismantling
some structural components may not be fully effective in dispelling the
bias. Studies indicate that cessation of erroneous statements may inadequately correct years of false advertising and even retractions may be ineffective to reduce misinformation. 5 Accordingly, proposed action-such
as the FDA and Federal Trade Commission (FTC) announcement that they
will aim to stop misinformation concerning biosimilars-is alone likely
inadequate to reduce misperceptions and promote desired biosimilar usage.1 6 A better understanding ofthe existence and extent ofthe bias against
biosimilars, as well as cognitive biases and structural issues that perpetuate
these biases, is essential to develop effective and realistic solutions to promote the cost-saving use of biosimilars in the United States."
There are significant structural issues, in addition to influential advertising, that promote and exacerbate bias against biosimilars in a much
more problematic manner than with generics. As this Article explains, although there is a similar bias concerning generics, financial incentives and
federal and state laws incentivize generic use, but disincentivize biosimilar
use. For example, lower cost generics are promoted largely by state laws
12.

ASS'N FOR ACCESSIBLE MEDS., THE U.S. GENERIC & BIOSIMILAR SAVINGS REPORT 21

(2021) (data as of 2020).
13.
NORC, UNDERSTANDING STAKEHOLDER PERCEPTION OF BIOSIMILARS 1 (2021); Katie
Holcomb, Michelle Klein, & Michelle Wang, Biosimilarsin the Medicare PartB Market, MILLIMAN
WHITE PAPER 3 (2021) (noting that Zarxio is over 50% but all other biosimilars are less than 20% and
many less than 10%).
See generally discussion infra Parts II & III.

15.

E.g., Stephan Lewandowsky, Ullrich K. H. Ecker, Colleen M. Seifert, Norbert Schwarz,

&

14.

John Cook, Misinformation and Its Correction: Continued Influence and Successful Debiasing, 13

PSYCH. SCI. PUB. INT. 106, 114 (2012).
16.

See FDA & FTC, JOINT STATEMENT OF THE FOOD & DRUG ADMINISTRATION AND THE

FEDERAL TRADE COMMISSION REGARDING A COLLABORATION TO ADVANCE COMPETITION IN THE

BIOLOGIC MARKETPLACE (Feb. 3, 2020).

17.
Addressing biosimilar use is a complex problem that includes scientific and legal uncertainties as well as anticompetitive conduct by companies that block entry of biosimilars approved by the
FDA. E.g., Michael A. Carrier & Carl J. Minniti III, Biologics: The New AntitrustFrontier, 2018 U.
ILL L. REV. 1, 3 (2018). See generally W. Nicholson Price II & Arti K. Rai, ManufacturingBarriers
to Biologics Competition andInnovation, 101 IOWA L. REV. 1023, 1037-56 (2016). The current discussion complements other proposals because doctor and patient acceptance ofbiosimilars is essential
to their success.
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that encourage or mandate pharmacy substitution of the generic (unless
the prescription indicates otherwise); this cannot happen with most biosimilars because they are not sold in pharmacies.' 8 Rather, because most
biologics are administered by health-care providers in their offices, there
is no opportunity for a pharmacy to promote substitution of a cheaper biosimilar. In addition, for the minority of biologics sold in pharmacies, substitution is challenging because it is only permissible for biosimilars that
meet the regulatory designation of "interchangeable," a designation not
required of generics. 19 However, even biosimilars with the interchangeable designation may still not be substituted due to state laws that impose
additional hurdles, unlike the situation with generics.20 Moreover, payor
incentives (i.e., insurance coverage) often do not favor biosimilars in contrast to incentives for generics. 2' Additionally, although doctors and patients are generally accustomed to generics having the identical active ingredient as their brand counterparts, biosimilars are scientifically incapable of being identical and are far more complex than a single active ingredient.22 Originator biologic manufacturers have capitalized on the fact that
biosimilars are not identical in their marketing materials and have also
suggested falsely that only biosimilars with the unique U.S. regulatory
designation of interchangeable are safe, further fueling unnecessary bias. 23
A better understanding of bias against cost-effective biosimilars is
helpful not only to address unnecessary health costs, but also to lead to
better patient outcomes. Notably, even if financial incentives encourage a
doctor to prescribe a biosimilar, psychological assumptions may cause a
patient to experience negative physical symptoms tied to misperceptions
pursuant to a "nocebo effect." 24 Although such effects can also exist with
generics, they may be exacerbated with biosimilars given that biosimilars
tend to treat more serious diseases and conditions, such that patients may
be particularly attuned to anticipate problems. Understanding and addressing the nocebo effect is essential because it can stymie effective use of
biosimilars, especially when such effects are mistakenly attributed to the
biosimilar as opposed to a negative mindset.25 Addressing the nocebo effect is admittedly difficult because not all doctors recognize the
18.
E.g., Makruvet, supra note 6, at 4 (noting that biologics are usually administered in a hospital or outpatient facility because they are not in pill format); Dana P. Goldman & Tomas J. Philipson,
Biosimilars Competition Helps Patients More than Generic Competition, STAT (Oct. 8, 2021),
https://www.statnews.com/2021/10/08/biosimilars-competition-helps-patients-more-than-genericcompetition (noting that biosimilars are typically injected in a doctor's office); see also infra note 58
and accompanying text.
19.
See discussion infra Section I.A.2.
20. See discussion infra Section IIlA.1.
21. See discussion infra Section III.B.3.
22. See discussion infra Section L.A.
23. See discussion infra Section III.B.1.b.
24.
The nocebo effect is similar to the better-known placebo effect; essentially, patients who
believe they receive a generic or biosimilar experience negative physical symptoms that may reflect
their psychological biases. See discussion infra Section II.B for additional information.
25.
Although it may seem hard to distinguish adverse effects that are due to medication from
nocebo effects, studies show a pronounced nocebo effect with biosimilars, even if patients might perceive them to be due to medication. See discussion infra Section I.C.2.
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phenomenon. 26 Patients report greater side effects when they are told they
received a biosimilar versus blinded studies when they do not know
whether they received a biosimilar or originator biologic. This result is
compelling evidence that perception can cause alleged side effects. 27
Moreover, doctors that recognize a need to combat the nocebo effect must
still recognize their own potential bias and modify their patient communications to combat the effect. 28 Although challenging, initial studies show
that reducing the nocebo effect is possible and is therefore an important
part of addressing biosimilar use. 29
This Article proceeds in four Parts. Part I provides background to biologics and cognitive biases that is essential to understanding the overall
argument that cognitive biases are impeding greater use of biosimilars in
the United States. Section I.A provides background concerning the science
behind biologics, the process for approving biologics for sale and distribution, and the costs of originator biologics versus biosimilars. Section I.B
then introduces cognitive biases that shape how all information is perceived. Section I.C explains how doctors and patients have biases against
generics, which provides a foundation for their biases against biosimilars.
Importantly, this Section reveals that although doctors state that they know
generics are in fact safe and effective, a significant number do not prefer
to prescribe them, thus revealing an unprincipled bias against generics. 30
Part II illustrates the extent to which doctor and patient biases against
biosimilars are stronger than their biases against generics. Because biosimilars have only recently been marketed in the United States, this Part
draws upon studies worldwide to document these biases. This Part concludes with an explanation of how these biases economically favor manufacturers of originator biologics who are then motivated to engage in actions that perpetuate the biases.
Part III explains how biases against biosimilars are perpetuated in the
United States. Section III.A explains how unique aspects of U.S. law and
policy perpetuate biases by unduly emphasizing that biosimilars are different from the corresponding originator biologics. This Section demonstrates that the unique U.S. regulatory designation of an interchangeable
biologic needlessly suggests an important difference, given that there is no

26. See, e.g., Lieven Pouilon, Silvio Danese, Alisa Hart, Gionata Fiorino, Marjorie Argollo,
Carlo Selmi, Carmelo Carlo-Stella, Damien Loeuille, Antonio Costanzo, Anthony Lopez, Elena
Vegni, Simona Radice, Daniela Gilardi, Marie Socha, Maria Fazio, Marien Gonzalez-Lorenzo, Stefanos Bonovas, Fernando Magro, & Laurent Peyrin-Biroulet, Consensus Report: Clinical Recommendationsfor the Preventionand Management of the Nocebo Effect in Biosimilar-Treated IBD Patients,
49 ALIMENT PHARMACOLOGY & THERAPEUTICS 1181, 1181 (2019) (noting nocebo effect is under-

recognized).
27. See discussion infra Section IIB.
28. See Joan O'Callaghan, Margaret Bermingham, Maurice Leonard, Frank Hallinan, J. Michael Morris, Una Moore, & Brendan T. Griffin, 88 REGUL. TOXICOLOGY & PHARMACOLOGY 252,
255-57 (2017).
29. See discussion infra Section IV.B.2.
30. See discussion infra Section IC.1.
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similar designation for generics or for biosimilars approved by other countries. Along similar lines, the United States has required different nonproprietary (not brand) names 3 1 for biosimilars. This requirement suggests a
needless distinction because generics share the identical nonproprietary
name with their brand counterparts and biosimilars approved by other
countries typically share the identical nonproprietary name. Section III.B
explains how some originator biologic manufacturers have capitalized on
nonproprietary name differences-and on fabricated distinctions and fearmongering-to suggest that biosimilars are not safe. Section III.C concludes by explaining why marketing is especially effective due to common
cognitive biases that all individuals have.32
Part IV then turns to the implications of current biases against biosimilars. Section IV.A acknowledges the difficulties of changing biases,
but also notes that structural changes can nonetheless nudge individuals
towards desired action. Section IV.B then proposes a multipronged approach to minimize the existence, or at least the impact, of biosimilar bias.
This Section suggests changing structural impediments and improving education of doctors and patients in light of biases, as well as fixing financial
incentives to favor biosimilars in a manner that has had success with generics.
I. BACKGROUND
Understanding how biologics differ from traditional drugs is necessary to appreciate why doctor and patient biases against biosimilars are
unjustified. This Part first explains the underlying science behind biologics
and how it differs from the science behind generics. Next, this Part explains how biosimilars are approved and distributed. Last, this Part explains how the bias against generics may fuel biases against newer biosimilars.
A. What Are Biologics?
1. Introduction to Biologics and Their Distinction from Traditional
Drugs
Because biologics are often the result of modern biotechnology and
can be tailored in a manner unlike traditional "small molecule"
(i.e., smaller than a biologic) drugs, they can offer important treatments

31.
A nonproprietary name is one that applies to all drugs with the same active ingredient even
if they are sold under different brand names. See Karan B. Thakkar & Gauri Billa, The Concept of
Generic Drugs and Patented Drugs vs. Brand Name Drugs and Non-Proprietary (Generic) Name

Drugs, 4 FRONTIERS IN PHARM. 113, 113 (2013). For example, ibuprofen is the nonproprietary name
that is sold under brand names Advil or Motrin and is alternatively sold as a generic store brand, for
example as Walgreens ibuprofen or CVS ibuprofen.
32. See discussion infra Section IIC; see also Hillel P. Cohen& Dorothy McCabe, Combatting
Misinformation on Biosimilarsand Preparingthe Marketfor Them is Costing the U.S. Billions, STAT

(June 19, 2019), https://www.statnews.com/2019/06/19/misinformation-biosimilars-market-preparation (providing examples of marketing misinformation).

BIOSIMILAR BIAS

2022]

525

that are targeted to a gene or protein. 33 Biologics can provide revolutionary
care for severe and chronic conditions; the importance of biologics is underscored by the fact that they account for half of the drug market in oncology. 34 One type of biologic is a monoclonal antibody, which is designed
to provide targeted treatment for a variety of conditions including cancer,
autoimmune diseases, and COVID-19. 35 Regeneron, for example, treats
COVID-19 with a combination of two different monoclonal antibodies. 36
There are two types of biologics-an originator biologic and a biosimilar. The originator biologic is the biologic first approved by the FDA
to treat a particular condition. 37 A biosimilar is a subsequently approved
biologic that is highly similar to an originator and, although not identical,
close enough to be used in lieu of the originator at a lower cost.38 Since
2010, the United States has provided an abbreviated process for approving
biosimilars to promote market entry of these lower cost biologics-similar
to the abbreviated procedure used for approving generics as lower cost
versions of traditional drugs. 39
All biologics, including biosimilars, are made from living cells and
are generally injected or infused because, unlike traditional drugs, they are
too big to fit in a pill or tablet. 40 Whereas traditional drugs, including generic drugs, are essentially chemical compounds that are easily mass-produced, biologics are complicated to create because cell lines are known to
be unpredictable, and they must be produced in limited quantities under
highly sensitive conditions.4 ' A traditional drug is created by a predictable

33.
E.g., Thomas Morrow & Linda Hull Felcone, Defining the Difference: What Makes Biologics Unique, 1 BIOTECH. HEALTHCARE 24, 24, 26, 28 (2004).
34.
E.g., Eva Rahman Kabir, Shannon Sherwin Moreino, & Mohammad Kawsar Sharif Siam,
The Breakthrough of Biosimilars: A Twist in the Narrative, 9 BIOMOLECULES 410, 410, 9
BIOMOLECULES 1, 1 (2019); Sofia Konstantinidou, Angeliki Papaspiliou, & Eleni Kokkotou, Current
and FutureRoles ofBiosimilarsin Oncology Practice, 19 ONCOLOGY LETTERS 45, 45 (2020).
35.
E.g., Huy X. Ngo & Sylvie Garneau-Tsodikova, What Are the Drugs of the Future?, 9
MEDCHEMCOMM. 757, 758 (2018); What are Monoclonal Antibodies and How Do They Work?,
At.'s BIOPHARMACEUTICAL COS., https://innovation.org/en/diseases/infectious/coronavirus/how-

monoclonal-antibodies-work (last updated Aug. 2021).
36. E.g., D.M. Weinreich, S. Sivapalasingam, T. Norton, S. Ali, H. Gao, R. Bhore, B.J. Musser,
Y. Soo, D. Rofail, J. Im, C. Perry, C. Pan, R. Hosain, A. Mahmood, J.D. Davis, K.C. Turner, A.T.
Hooper, J.D. Hamilton, A. Baum, C.A. Kyratsous, Y. Kim, A. Cook, W. Kampman, A. Kohli, Y.
Sachdeva, X. Graber, B. Kowal, T. DiCioccio, N. Stahl, L. Lipsich, N. Braunstein, G. Herman, & G.D.
Yancopoulos, REGN-COV2, A NeutralizingAntibody Cocktail, in Outpatients with COVID-19, 384
NEW ENG. J. MED 238, 238 (2020).
37.
See generally Biosimilar and Interchangeable Products, FDA (Oct. 23, 2017),

http://www.fda.gov/drugs/biosimilars/biosimilar-and-interchangeable-products.
38.

See 42 U.S.C.

§ 262(i); see also Biosimilarand InterchangeableBiologics:More Treatment

Choices, FDA (Oct. 12, 2021), https://www.fda.gov/consumers/consumer-updates/biosimilar-and-interchangeable-biologics-more-treatment-choices (stating that biosimilars have no clinically meaningful differences from comparable original biologics).
39.
This pathway was enacted as part of the Affordable Care Act. 42 U.S.C. § 18001. As with
the generic approval process, biosimilar approval cannot happen until after a certain term of regulatory
exclusivity for the originator. However, the exclusivity period for biosimilars is more than twice as
long as that for generic drugs-twelve years instead of five. 21 U.S.C. § 355(j)(5)(B)(iv); 42 U.S.C. §
262(k)(7)(A).
40.
E.g., Markuvet, supranote 6, at 4.
41.
Id.
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chemical process that can be reverse engineered from the drug. 42 The
chemical process can guarantee identical results at low cost, enabling companies to cheaply create generic versions of brand drugs. The process for
creating a biologic is complex and expensive; a generic drug may cost
$1-$5 million to develop, while a biosimilar may cost $250 million. 43
Moreover, the process for making a biologic is generally a trade secret,
making it especially hard to manufacture a biosimilar. 44 Even when the
process used is the same, there may be differences between batches. 45 In
other words, even the originator biologic manufacturer may not get identical results each time. 46
While biologics can provide powerful treatments, their strength can
result in immune reactions that do not exist with traditional drugs. A biologic drug can be perceived as a foreign invader by the body's immune
system, prompting an immune response. 47 This problem is unique to biologics and does not occur with traditional drugs because biologics are
much larger than traditional drugs and are synthesized differently in the
body. 48 Immune reactions are a potential complication for all biologics and
can result in serious adverse effects when they arise. 49
2. Biologics Approval and Distribution
Although biologics involve more complexity and sensitivity to manufacture, distribute, and administer than traditional drugs, it does not follow that it is unsafe for manufacturers to create biosimilars of biologics.
With increasing technological development and greater scientific certainty, countries have increasingly initiated streamlined regulatory procedures to approve lower cost biosimilars.50 The streamlined regulatory
42.
See Arvind K. Bansal & Vishal Koradia, The Role ofReverse Engineeringin the Development of Generic Formulations,29 PHARM. TECH. 50, 50, 54 (2005).
43.
See FTC, Preface to EMERGING HEALTH CARE ISSUES: FOLLOW-ON BIOLOGIC DRUG
COMPETITION iii (2009); Erwin A. Blackstone & Joseph P. Fuhr, Jr., The Economics ofBiosimilars, 6
AM. HEALTH & DRUG BENEFITS 469, 470-71 (2013).
44.
See Price & Rai, supranote 17, at 1028.

45.

See Rahman Kabir et al., supra note 34, at 1, 2, 9.

46.
See Arnold G. Vulto & Orlando A. Jaquez, The Process Defines the Product: What Really
Matters in Biosimilar Design and Production?, 56 RHEUMATOLOGY 14, 15 (2017); Jill Coghlan,
Hongliang He, & Anna S. Schwendeman, Overview ofHumira Biosimilars: CurrentEuropean Landscape and Future Implications, 110 J. PHARM. SCI. 1572, 1574 (2021); Fernando de Mora, Alejandro

Balsa, Maria Cornide-Santos, Jose-Manuel Carrascosa, Sara Marsal, Javier P. Gisbert, Miguel-Angel
Abad, Rafael F. Duarte, Michael Wiechmann, & Rafael Martinez, Biosimilar and Interchangeable:
InseparableScientific Concepts?, 85 BRITISH J. CLINICAL PHARMACOLOGY 2460, 2460 (2019) (not-

ing that even different batches of the original reference biologic are not identical to each other).
47.
See J.M. Carrascosa, Immunogenicity in Biologic Therapy: Implicationsfor Dermatology,
104 ACTAS DERMO-SIFILIOGRAFICAS 471, 471 (2013).
48.
See Alison Smith, Hugh Manoli, Stacey Jaw, Kimberley Frutoz, Alan L. Epstein, Leslie A.
Khawli, & Frank-Peter Theil, Unraveling the Effect oflmmunogenicity on the PK/PD, Efficacy, and
Safety of Therapeutic Proteins, 2016 J. IMvfUNOLOGY RSCH. 1, 1 (2016).
49.
E.g., David A. Khan, Hypersensitivity and Immunologic Reactions to Biologics: Opportunitiesfor the Allergist, 117 ANNALS ALLERGY ASTHMA & IMMUNOLOGY 115, 115 (2016).
50.
E.g., Hye-Na Kang, Robin Thorpe, & Ivana Knezevic, The Regulatory Landscape of Biosimilars: WHO Efforts and ProgressMade from 2009 to 2019, 65 BIOLOGICALS 1, 3 (2020) (noting
that the European Union was the first to provide guidelines and since then, a number of countries have

guidelines in place).
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process provides cost savings because the shortened approval process is
less expensive than the lengthy process required for the originator biologic. 5 ' Notably, the regulatory procedure for biosimilar approval requires
substantially more evidence for approval than generics to account for the
scientific complexity of biologics. 2 A generic is chemically equivalent to
its corollary drug, meaning that a proposed manufacturer of a generic can
show "bioequivalence" 5 3 through routine studies; if a drug is bioequivalent, the FDA infers that the generic will be as safe and effective as its
corollary brand drug.54 A biosimilar, in contrast, scientifically cannot be
identical. 55 Accordingly, the regulatory pathway for biosimilars uses the
"highly similar" standard in conjunction with a requirement that there be
"no clinically meaningful differences" in terms of safety, purity, and potency, even though there may be differences in clinically inactive components. 56 These standards are roughly parallel to the FDA requirement that
generic drugs have the same active ingredient, strength, and route of administration for the same intended use.57
The U.S. biosimilar approval pathway creates a distinction among
different types of biosimilars dispensed at the pharmacy (as opposed to
those infused in health-care provider settings) that does not exist with generics. Currently, most biosimilars are dispensed from health-care providers rather than pharmacies. 58 Unlike generic drugs that can be easily
51.
See Blackstone & Joseph, supra note 43, at 470-71, 473 (noting the cost to develop a new
biologic was $1.9 billion compared to $250 million for biosimilar development).
52.
E.g., Stacy Elder Dalpoas, Mariana Socal, Celia Proctor, & KennethlM. Shermock, Barriers
to Biosimilar Utilization in the United States, 77 AM. J. HEALTH-SYS. PHARMACISTS 2006, 2008

&

(2020); see also Thomas J. Moore, Morgane C. Mouslim, Jenna L. Blunt, G. Caleb Alexander,
Kenneth M. Shermock, Assessment ofAvailability, Clinical Testing, and US Foodand Drug Administration Review of BiosimilarBiologic Products, 181 J. AM. MED. ASSOC. INTERN. MED. 52, 58

(2021) (noting that approval process for biosimilars may be as rigorous as for originator drugs). The
FDA will typically require tests to show it has the same biological activity and purity as well as the
same underlying skeletal structure. See U.S. DEP'T HEALTH & HUM. SERVS., FOOD & DRUG ADMIN.,
CTR. FOR DRUG EVALUATION & RSCH. (CDER), & CTR. FOR BIOLOGICS EVALUATION & RSCH.
(CBER), SCIENTIFIC CONSIDERATIONS IN DEMONSTRATING BIOSIMILARITY TO A REFERENCE
PRODUCT: GUIDANCE FOR INDUSTRY 3-4, 10-11 (2015).

53.
E.g., Shein-Chung Chow, Bioequivalencein DrugDevelopment, 6 WILEY INTERDISC. REV.
COMPUTATIONAL STAT. 304, 304-05 (2014) (explaining bioequivalence refers to similar absorption
in the blood).
54.
21 U.S.C. § 355(j)(2)(A).
55.
See Celia Lu & Elsen C. Jacob, Biosimilars: Not Simply Generics, 44 U.S. PHARMACIST
36, 38 (2019); see also Jonathan Kay, Are There Benefits and Risks to Biosimilarsfrom a Patient
Perspective?, 45 RHEUMATIC DISEASE CLINIC N. AM. 465, 466 (2019) (noting that a biosimilar is

similar to another batch of the originatorbiologic albeit by a different manufacturer); supra notes 4647 and accompanying text (discussing differences between batches).
56.
See 21 U.S.C. § 262(i)(2)(A).
57.

See GenericDrugs: Questions & Answers, FDA, https://www.fda.gov/drugs/questions-an-

swers/generic-drugs-questions-answers#ql (last visited Mar. 16, 2021).
58.
E.g., SAYANTAN NIYOGI, NICHOLAS ADOLPH, & ARTEM PASHCHINSKIY, IQVIA,
BIOSIMILARS IN THE U.S.: REIMBURSEMENT AND IMPACTS TO UPTAKE 3 (2021) (noting that except for

insulins and anticipated tumor necrosis factor (TNF) inhibitors, most approved biosimilars are not
available at pharmacies); BRILL, supra note 6, at 5 (noting most biologics administered by physicians
and all biosimilars covered by Medicare are administered by physicians under Part B); Jeff Baldetti,
What's Nextfor the BiosimilarsMarket in the U.S.?, MANAGED HEALTHCARE EXEC. (Nov. 22, 2021),

https://www.managedhealthcareexecutive.com/view/what-s-next-for-the-biosimilars-market-in-the-
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substituted at a pharmacy, only biosimilars that meet additional requirements to be classified as interchangeable can be substituted at a pharmacy,
despite the fact that every biosimilar is highly similar to the originator biologic. 59 The interchangeable designation is only given to a biosimilar that
is supported by additional data showing that any risks in terms of safety or
diminished efficacy associated with switching between the originator and
the biosimilar is no greater than not switching. 60
So far, there are only two biosimilars approved as interchangeable in
the United States and both approvals are recent. The first approval was in
July 2021 for an insulin product sold under the brand name Semglee; however, despite its status as a biosimilar, Semglee's list price of $100 per vial
is still high. 61 In October 2021 the FDA approved Cyltezo as the first interchangeable biosimilar to Humira for inflammatory diseases. 62 The impact of this interchangeable on lowering prices may be modest. Although
Humira is widely used, Humira's manufacturer, AbbVie, has negotiated
settlements with companies so that no biosimilars, including the recently
approved interchangeable Cyltezo, can be sold until 2023.63 Moreover, by
then, these biosimilars still may not have an impact if patients prefer
newer, higher concentration versions over approved biosimilars of the
original, lower concentration Humira. 64 The newer concentration of
u-s- (stating that biosimilars have predominantly been administered by health-care providers, with the
interchangeable insulin biosimilar being the first biosimilar with a predominant retail focus).
59.
42 U.S.C. § 262(i)(3) (permitting biosimilar substitution without the intervention of the
health-care provider who prescribed the comparable product).
60.
See id. § 262(k)(4)(B).
61.
See Joshua Cohen, Approval of FirstInterchangeable Biosimilar, Semglee, is Sign of An
Improving U.S. BiosimilarsMarket, Despite Challenges, FORBES (Aug. 1, 2021, 1:43 PM); Joseph
Walker, FDA Lets PharmaciesSubstitute Inulin With Knockoff Product, in Firstfor a Biologic Drug,

WALL ST. J. (July 29, 2021, 4:09 PM), https://www.wsj.com/articles/fda-lets-pharmacies-substitutebranded-insulin-with-knockoff-product-in-first-for-a-biologic-drug-1 1627589200.
62.
See FDA Approves Cyltezo, the FirstInterchangeableBiosimilarto Humira,FDA (Oct. 18,
2021),
https://www.fda.gov/news-events/press-announcements/fda-approves-cyltezo-first-interchangeable-biosimilar-humira. There is another company currently seeking interchangeability status
for its biosimilar while also battling AbbVie patents rather than settling with AbbVie to launch in 2023
as many other companies have done. See Tony Hagen, FDA Grants Interchangeable Status for
Boehringer Ingelheim's Adalimumab Biosimilar (Cyltezo), AM. J. MANAGED CARE: THE CTR. FOR
BIOSIMILARS (Oct. 15, 2021), https://www.centerforbiosimilars.com/view/fda-grants-interchangea-

ble-status-for-boehringer-ingelheim-s-adalimumab-biosimilar-cyltezo-. Other Humira biosimilars
with interchangeable status are also expected from Pfizer (Abrilada) and Amgen (Amjevita). Tony
Hagen, BiosimilarInterchangeability:What's in a Name?, AJMC: THE CTR. FOR BIOSIMILARS (Nov.

11, 2021), https://www.ajmc.com/view/biosimilar-interchangeability-what-s-in-a-name-;

see also

Tony Hagen, Twelve Month Court Battle Will Delay Adalimumab BiosimilarLaunch for Alvotec,
AJMC: THE CTR. FOR BIOSIMILARS (Oct. 6, 2021), https://www.centerforbiosimilars.com/view/al-

votech-agrees-to- 1-year-delay-in-marketing-of-adalimumab-biosimilar.
63.
Draws

See Jason Laday, Market Gears Up for BiosimilarBoom in 2023 as Humira Exclusivity
to a Close, HEALIO (June 18, 2021), https://www.healio.com/news/rheumatol-

ogy/20210617/market-gears-up-for-biosimilar-boom-in-2023-as-humira-exclusivity-draws-to-aclose; Stanton Mehr, Further Dissecting the Launch of Adalimumab Biosimilars in the US,
BIOSIMILARS REV. & REP. (Apr. 21, 2021), https://biosimilarsrr.com/2021/04/21/further-dissectingthe-launch-of-adalimumab-biosimilars-in-the-us.
64.
T ony Hagen, Adalimumab BiosimilarsFace ProductObsolescence Before Launch, AJMC:
THE CTR. FOR BIOSIMILARS (Jan. 6, 2021) (noting AbbVie has introduced Skyrizi and Rinvoq as high
concentrationvariations of the original formulation), https://www.centerforbiosimilars.com/view/adalimumab-biosimilars-face-product-obsolescence-before-launch.
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Humira is an example of a product enhancement that originator biologics,
at times, introduce to maintain market share despite a biosimilar entry into
the market. 65
No other country has a separate regulatory designation for biosimilars
that mirrors the U.S. designation of "interchangeable." 66 Although most
countries do not currently have automatic pharmacy substitution of biologics, countries that permit substitution do not impose an additional regulatory designation that requires additional evidence. 67 Australia strongly
promotes biosimilar use, including permitting pharmacy substitution of
most originator biologics with a biosimilar. 68 In addition, even for countries that do not have automatic substitution at the pharmacy, there have

65.
PER TROEIN, MAX NEWTON, & KIRSTIE SCOTT, IQVIA, THE IMPACT OF BIOSIMILAR
COMPETITION IN EUROPE 6 (Dec. 2021) (noting that manufacturers of originator biologics have intro-

duced new formulations, dosing changes, and product enhancements to retain market share). Whether
the new Humira versions will be successful is unclear because a biosimilar by Alvotech is anticipated
to be available in a high-concentration form and is currently seeking interchangeable status. E.g., Ned
Pagliarulo, AbbVie Holds OffAnother Humira Challengerwith Alvotech Deal, BIOPHARMADIVE (Mar.
9, 2022), https://www.biopharmadive.com/news/abbvie-alvotech-humira-biosimilar-settlementlaunch/620100/.
66.
See Anita Afzali, Daniel Furtner, Richard Melsheimer, & Philip J. Molloy, The Automatic
Substitution ofBiosimilars: DefinitionsofInterchangeabilityare not Interchangeable, 38 ADVANCES
THERAPY 2077, 2078-81 (2021). In other countries, the term "interchangeable" refers to doctors considering biosimilars to be equivalent to the originator and thus, using the biosimilar in lieu of the
originator. See id. at 2081 (noting that Brazil and Japan considerthis term to referto a matter of clinical
practice); see also EUR. MEDS. AGENCY & EUR. COMM'N, BIOSIMILARS IN THE EU: INFORMATION
GUIDE FOR HEALTHCARE PROFESSIONALS 29 (2019) (noting that the term "interchangeability" refers
to the expectation of using a different medicine that yields the same clinical effect and recognizing
that the practice is not governed by the European Medicines Agency, but at the national level); Pekka
Kurki, Leon van Aerts, Elena Wolff-Holz, Thijs Giezen, Venke Skibeli, & Martina Weise, Interchangeability ofBiosimilars:A EuropeanPerspective, 31 BIODRUGS 83, 88 (2017).
67. See EvelienMoorkens, Arnold G. Vulto, Isabelle Huys, Pieter Dylst, Brian Godman, Simon
Keuerleber, Barbara Claus, Maria Dimitrova, Guenka Petrova, Ljiljana Sovic-Brkicic, Juraj Slaby,
Robin Sebesta, Ott Lauius, Allan Karr, Morgane Beck, Jaana E. Martikainen, Gisbert W. Selke, Susan
Spillane, Laura McCullagh, Gianluca Trifiro, Patricia Vella Bonanno, Asbjorn Mack, Antra Fogele,
Anita Viksna, Magdalena Wladysiuk, Helder Mota-Filipe, Dmity Mehkov, Marija Kalaba, Simona
Mencej Bedrac, Jurij Furst, Corrine Zara, Peter Skiold, Einar Magnuson, & Steven Simoens, Policies
for Biosimilar Uptake in Europe: An Overview, PLOS ONE, Dec. 2017, at 9; Cecile Remuzat, Anna

Kapusniak, Aleksandra Caban, Dan Ionescu, Guerric Radiere, Cyril Mendoza, & Mondher Toumi,
Supply-Side and Demand-Side PoliciesforBiosimilars:An Overview in 10 EuropeanMember States,
5 J. MKT. ACCESS & HEALTH POL'Y 1, 8 (2017) [hereinafter Remuzat, Supply Side].
68.
See BiosimilarAwareness Initiative, AUSTRAL. GOV'T DEP'T OF HEALTH (Feb. 1 2022),

https://www 1.health.gov.au/internet/main/publishing.nsf/Content/biosimilar-awareness-initiative
(announcing Australia's promotion of biosimilar use). There are currently eight biosimilars approved
for substitution at Australian pharmacies, including biosimilars to Neupogen, Remicade, Enbrel, and
Rituximab. See Biosimilars in Australia - A-Flagging and Sustainability, GENERICS & BIOSIMILAR
INITIATIVE (Jan. 8, 2021), https://www.gabionline.net/Biosimilars/General/Biosimilars-in-Australiaa-flagging-and-sustainability; Which Biosimilar Medicines are Available in Australia?, AUSTRAL.
GOV'T DEP'T OF HEALTH (Feb. 1, 2022), https://www 1.health.gov.au/internet/main/publish-

ing.nsf/Content/biosimilar-which-medicines-are-available-in-australia. Australia's promotion of biosimilar substitution at the pharmacy occurs in a different manner than that in the United States because
the Australian regulatory agency that reviews biosimilars does not make the substitution determination. See Duncan Longstaff, Switching from Biologic to Biosimilar: Australia's Unique Approach

(May 28, 2020), https://www.spruson.com/patents/switching-from-biologic-to-biosimilar-australiasunique-approach. Instead, the Australian agency that reviews drug coverage as well as pharmacy substitution, in a process called "a-flagging," makes the determination. Id. For an a-flagged biologic,
unless the doctor has checked "substitution not permitted" on the prescription, the prescription may
be substituted with a biosimilar
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been somewhat equivalent policies to promote biosimilar use, such as considering biosimilars to be medically interchangeable, mandating use of
some or all lower cost biosimilars, setting quotas, and using national purchasing policy to purchase the least expensive biologic, typically a biosimilar. 69
Policies that mandate biosimilar use may be more effective than pharmacy substitution for increasing biosimilar use because most biologics are
only provided in health-care settings by intravenous infusion under the supervision of a health-care provider. 70 This is a major difference from generic distribution, which occurs solely at pharmacies where pharmacists
are permitted, or even required, to substitute a generic for the brand that
the doctor prescribed.' This different distribution method for biologics
has implications for promoting biosimilars. With generic drugs, the combination of state substitution laws72 and financial incentives for insurance
companies and other payors to promote generic use result in generics constituting over 90% of prescriptions. 73 In contrast, because biologics are
generally only available from doctors and current payor incentives do not
favor cheaper biosimilars, doctor bias against biosimilars may remain unchecked. 74 Moreover, patients may be more resistant to switching to a biosimilar than a generic of a traditional drug for reasons inapplicable to
drugs dispensed in pharmacies. For example, a patient who is switched to
a biosimilar may need to travel to a different and potentially inconvenient
location for administration, which may also involve support from nurses
the patient is not accustomed to. 75

69.

See INESSS, SAFETY OF SWITCHING BIOLOGICS AND THEIR INTERCHANGEABILITY 35-36,

38 (2020) (noting that Germany and France consider biologic drugs to be interchangeable, while Turkey, Estonia, Poland, and Serbia effectively allow substitution via lack of regulation, and that other
countries have quotas oruse national purchasing policies); see also discussion infra Section IV.A.2.b.i.
(discussing Europe); Tony Hagen, Quebec Makes It Harderto Use OriginatorBiologics, AJMC: THE

CTR. FOR BIOSIMILARS (May 19, 2021), https://www.centerforbiosimilars.com/view/quebec-initiatesa-biosimilar-switching-policy (noting that Quebec became the fourth Canadian province to require
switching patients to biosimilars for insurance coverage).
70. See Susan C. Bolge, Helen M. Eldridge, Jennifer H. Lofland, Caitlin Ravin, Philip J. Hart,
& Michael P. Ingham, PatientExperience With IntravenousBiologic Therapiesfor Ankylosing Spondylitis, Chron's Disease, PsoriaticArthritis, Psoriasis, RheumatoidArthritis, and Ulcerative Colitis,
2017 PATIENT PREFERENCE ADHERENCE 661, 662 (2017). Biologics are a much larger molecule than

traditional drugs and are generally too large to be taken orally. A small number are self-injected and
only available at a pharmacy.
71.
See Jesse C. Vivian, Generic-SubstitutionLaws, 33 U.S. PHARMACIST 30, 34 (2008).
72.
Although most state substitution laws permit the doctor to bar substitution, doctors rarely
do so because payor incentives create a large difference in patient co-pays between brand and generic
drugs which may prompt patients to raise cost issues with their doctor. See Mariana P. Socal, Ge Bai,
& Gerard F. Anderson, FactorsAssociatedwith Prescriptionsfor BrandedMedications in the Medicare PartD Program,4 J. AM. MED. ASS'N NETWORK OPEN, Mar. 2, 2021, at 9 (finding that only 5%

of drugs with available generics are designated to resist substitution in a Medicare sample); see also
discussion infra Section IIlA.1.
73.
AAM 2020 ACCESS & SAVINGS, supranote 11, at 16.
74. See discussion infra Section III.B.2.
75.

See Forcedto Switch: CanadianBiosimilarExperienceSurvey Report, GASTROINTESTINAL

SOCIETY (2020), https://badgut.org/biosimilars-survey-report-2020 (noting that switching to biosimilar means a new health care team and accessibility issues for patients); Tara Gomes, Daniel
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A small, but important, portion of biologics are sold by pharmacists;
these biologics treat common conditions like diabetes and arthritis.7 6 A
pharmacist can substitute a biosimilar for the prescribed biologic if the
biosimilar has obtained an interchangeable designation, but only one biosimilar currently on the market has this status (until 2023 when Cyzelto
can be marketed). 77 As a result, most patients only receive biosimilars at
the pharmacy if a doctor has specifically prescribed a biosimilar. Because
the doctor alone decides whether a patient receives an originator biologic
versus its biosimilar, there is no mechanism similar to pharmacy substitution of generics to promote biosimilar use, especially given that current
payor incentives tend to promote the more expensive originator. When
there is more than one biosimilar available, differences between the available biosimilars may impact which is prescribed, besides price. For example, in Europe the most popular version of the commonly used arthritis
drug Humira is a citrate-free injection pen that reduces pain at the injection
site, but only one of six available biosimilars uses this mechanism.7 8
3. The Cost of Biologics
There is a substantial potential for cost savings in the United States if
biosimilar use increases nationwide. The most recent RAND study, completed in 2017, estimated savings of $54 billion over ten years, representing a $10 billion increase over a 2013 RAND study estimate. 79 In addition,
a recent study by the Office of Inspector General found that spending on
biologics in 2019 could have decreased by $84 million. 80 The United

McCormack, Sophie A. Kitchen, J. Michael Paterson, Muhammad M. Mamdani, Laurie Proulx, Lorraine Bayliss, & Mina Tadrous, ProjectedImpact ofBiosimilarSubstitution Policies on Drug Use and
Costs in Ontario, Canada:A Cross-SectionalTime Series Analysis, 9 CANADIAN MEDICAL ASS'N J.
E1055, E1059 (2021) (noting that mandatory switches can lead to increased anxiety for stable patients
due to loss of aspects of patient care, such as nurses funded by biologic drug manufacturers).
76.
Insulin is unusual because it was not previously approved as a biologic, such that the biosimilar pathway could not be used to expedite biosimilars prior to a March 2020 change to the laws.
See Insulin Gains New Pathway to Increased Competition, FDA (Mar. 23, 2020),
https://www.fda.gov/news-events/press-announcements/insulin-gains-new-pathway-increased-competition.
77.
See discussion supra notes 60-62 and accompanying text.
78.
See Coghlan et al., supranote 46, at 1574 (noting that this new design was an improvement
over earlier models that had larger needles that caused complaints of pain on injection); see also Ariel
Dora Stern, Jacqueline L. Chen, Melissa Ouellet, Mark R. Trusheim, Zeid El-Kilani, Amber Jessup,
& Ernst R. Berndt, Biosimilarsand Follow-On Productsin the United States: Adoption, Prices, and
Users, 40 HEALTH AFF. 989, 997 (2021) (noting that in all product classes, biosimilars are often not
available in identical modalities and strengths as the originator biologic and that this may inhibit their
adoption).
79.

ANDREW W. MULCAHY,

JAKUB P. HLAVKA, &

SPECER R. CASE, BIOSIMILAR COST

SAVINGS IN THE UNITED STATES: INITIAL EXPERIENCE AND FUTURE POTENTIAL 10 (2017) [hereinafter MULCAHY ET AL., 2017]; ANDREW W. MULCAHY, ZACHARY PREDMORE, & SOREN MATTKE, THE
COST SAVINGS POTENTIAL OF BIOSIMILAR DRUGS IN THE UNITED STATES 7 (2014); see also SUZANNE
MURIN, MEDICARE PART D AND BENEFICIARIES COULD REALIZE SIGNIFICANT SPENDING

REDUCTIONS WITH INCREASED BIOSIMILAR USE 17 (2022) (finding that spending on biosimilars cov-

ered by Part D of Medicare could have decreased by $143 million in 2019 if 90% of biologics were
biosimilars).
80.
MULCAHY ET AL., 2017, supra note 79, at 1 (discussing that at the time of 2017 RAND
study, there were only three biosimilars in the U.S. market).

DENVER LAW REVIEW

532

[Vol. 99.3

States currently accounts for 60% of biologic sales, 81 yet uses less than
10% of global biosimilars; the United States is primarily spending money
on more expensive originator biologics.82
The cost of biologics has important health implications for patients.
For example, the high cost of the biologic insulin is known to have compromised the health of diabetic patients. Insulin costs nearly doubled from
2012 to 2016,83 causing some diabetic patients to skip medication doses,
resulting in an increased use of medical services84 or in serious cases, fatalities. 85 Another example exists with degenerative diseases such as arthritis, where lower cost biosimilars could enable patients to start treatment
earlier; earlier treatment could prevent irreversible damage, allowing patients to avoid lost income due to disability or unemployment. 86 In Europe,
where biosimilars have been available since 2007, the introduction of biosimilars has led to increased use, but reduced costs overall. 87 Lower cost
biosimilars could make biologic therapy available for over 1 million additional U.S. patients by 2025.88 This could be especially important for cancer patients because many cancer treatments are biologics and the high
cost of treatment results in noncompliance with treatment regimens, leading to negative clinical outcomes. 89

81.

BIOSIMILARS FORUM, STRUCTURAL MARKET CHANGES NEEDED IN

U.S.

TO ACHIEVE

COST-SAVINGS FROM BIOSIMILARS 6 (2019); DENIS KENT, SARAH RICKWOOD, & STEFANO DI BIASE,

DISRUPTION AND MATURITY: THE NEXT PHASE OF BIOLOGICS 21 (2021). In contrast, Europe accounts

for 90% of global biosimilar sales.
82.
See Van de Wiele et al., supra note 6, at 1203 (discussing how lower U.S. use ofbiosimilars
is due, in part, to patent litigation, which can result in anticompetitive settlements and less biosimilar
availability compared to that in Europe; this, in turn, results in higher prices). For example, the widely
used arthritis biologic sold as Humira has no competition in the United States until 2023, whereas
multiple Humira biosimilars exist in Europe. See Coghlan et al., supra note 46, at 1574.
83.
Ed Silverman, Insulin Costsfor U.S. Patients Nearly Doubledfrom 2012 Through 2016,
but Usage was Flat, STAT (Jan. 22, 2019), https://www.statnews.com/pharmalot/2019/01/22/insulin-

drug-prices-diabetes.
84. See, e.g., Azri Nasruddin, Norsa'adah Bachok, Norul Badriah Hassan, & Nyi Nyi Naing,
InsulinAdherence and AssociatedFactorsin Patientswith Type 2 DiabetesMellitusTreated in Klang
PrimaryHealth Care Centres, 28 MALAYS J. MED. SCI. 76, 78 (2021) (discussing adherence in rela-

tionship to cost).
85.
E.g., Joshua Cohen, Insulin's Out-of-Pocket Cost Burden to DiabeticPatients Continues to
Rise Despite Reduced Net Cost to PBMs, FORBES (Jan. 5, 2021,
11:17 AM),

https://www.forbes.com/sites/joshuacohen/2021/01/05/insulins-out-of-pocket-cost-burden-to-diabetic-patients-continues-to-rise-despite-reduced-net-costs-to-pbms; S. Vincent Rajkumar, The High
Cost ofInsulin in the UnitedStates: An Urgent Call to Action, 95 MAYO CLINIC PROC. 22, 22 (2020).
86.
See, e.g., BIOSIMILARS FORUM, supranote 81, at 6; Jeffrey R. Curtis & Jasvinder A. Singh,
The Use of Biologics in Rheumatoid Arthritis: Current and Emerging Paradigms of Care, 33
CLINICAL THERAPEUTICS 679, 679 (2011); Natlie Boytsov, Xiang Zhang, Kristin A. Evans, & Barbara
H. Johnson, Impact of Plan-Level Access Restrictions on Effectiveness of Biologics Among Patients
with Rheumatoid or PsoriaticArthritis, PHARMACOECONOMICS 105, 110-11 (2020) (finding that ar-

thritis patients with insurance plans that made access to biologics more cumbersome had lower odds
of treatment effectiveness).
87.
See BIOSIMILARS FORUM, supranote 81, at 5.
88.

BIOSIMILARS COUNCIL, BIOSIMILARS IN THE UNITED STATES: PROVIDING MORE PATIENTS

GREATER ACCESS TO LIFESAVINGS MEDICINES 1, 5 (2017).

89.

Jingyan Yang, Kelly Blinzler, Joshua Lankin, Sapna Vijayakumar, Martine C. Maculaitis,

& Ahmed Shelbaya, Evolving Perceptions, Utilization and Real-World Implementation Experiences
of Oncology Monoclonal Antibody Biosimilarsin the USA: Perspectivesfrom Both Payers and Physicians, 36 BIODRUGS 81 (2021).

2022]

BIOSIMILAR BIAS

533

It is important to consider cost savings from biosimilars in the context
of overall cost savings to society. Although biosimilars provide a more
modest percent discount from the originator biologic than a generic from
its branded counterpart, 90 because biologic treatments typically cost thousands per year per patient, even a relatively small percentage discount still
yields substantial savings. 91 This has important implications because the
top ten most expensive drugs for Medicare Part B (which covers drugs for
patients on Medicare that are typically administered by doctors) are all
biologics and account for a large share of Medicare drug spending. 92
The cost savings from available biosimilars are especially important
given that there are many U.S. biologics for which there are no biosimilars
available. 93 This point is underscored by the initial price of the recently
approved Biogen drug Aduhelm, the first to treat Alzheimer's disease by
removing amyloid plaque and the first new Alzheimer's drug since 2003.94
The drug was initially priced at $56,000 a year and, based on that, was
estimated to cost Medicare more than the annual budget for the Environmental Protection Agency or the National Aeronautics and Space Administration and result in a 50% increase in Medicare spending. 95 Such a price
90.
See MULCAHY ET AL., 2017, supra note 79, at 5 (noting that biosimilar prices are 10%-51%
less than that of originator biologics); Dana P. Goldman & Tomas J. Philipson, Biosimilars Competi-

tion

Helps Patients More Than Generic Competition, STAT (Oct. 8, 2021), https://www.stat-

news.com/2021/10/08/biosimilars-competition-helps-patients-more-than-generic-competition (noting
that biosimilars are on average 30% cheaper, resulting in a savings of about $665, while on average
generics result mn a savings of $86); FDA, GENERIC COMPETITION AND DRUG PRICES 2-3 (2019) (noting that there is often more generic competition than biosimilar competition because regulatory approval for generics is faster and less costly to obtain; intense competition can lead to discounts of up
to 90%).

91.
E.g., WINEGARDEN, supra note 7, at 4 (finding patient out-of-pocket costs could be reduced
by 17% to almost 50% with competition). Moreover, out-of-pocket costs can be very important for
the roughly 30% of patients on Medicare without a cap on co-payments. Id. at 6.
92.
MEDPAC, A DATA BOOK: HEALTH CARE SPENDING AND THE MEDICARE PROGRAM 144
(2019); ASPE & DHHS, Medicare PartB Drugs: Trends in Spending and Utilization, 2006-17, at 9,

11 (2020).
93.
See, e.g., Baldetti, supranote 58 (noting that although there are thirty-one FDA-approved
biosimilars, only twenty are marketed); see also Holcomb et al., supra note 13, at 2 (noting launch
date of biosimilars and the seven associated originator biologics); Mario DiPaola, The State of Biosimilars in the United States, BIOANALYSIS ZONE (July

15, 2021), https://www.bioanalysis-

zone.com/the-state-of-biosimilars-in-the-united-statesspotlbiosim_covance (reporting on biosimilars approved and marketed as of 2021); Approval and Launch Date of US Biosimilars- 2021, GABI
(July 5, 2021) https://www.gabionline.net/reports/approval-and-launch-dates-for-us-biosimilars2021.
94.
Jon Hamilton, Cost and Controversy are Limiting Use of New Alzheimer's Drug, NPR
(Nov. 8, 2021, 6:00 AM), https://www.npr.org/sections/health-shots/2021/11/08/1052833252/costand-controversy-are-limiting-use-of-new-alzheimerdrug#:~:text=Aduhelm%20is%20the%20first%
20drug,Alzheimer's%20drug%20approved%20since%202003.
95.
Josh Katz, Sarah Kliff, & Margot Sanger-Katz, New Drug Could Cost the Government as
Much as it Spends on NASA,

N.Y. TIMES: THE UPSHOT (June 23, 2021), https://www.ny-

times.com/2021/06/22/upshot/alzheimers-aduhelm-medicare-cost.html. Even before Medicare decided whether to cover Aduhelm, Medicare premiums increased 15% to potentially cover the drug.
Rebecca Pifer, Biogen's Pricey Alzheimer's Drug Contributes to Major Medicare Premium Hikes,
HEALTHCAREDIVE (Nov. 15, 2021), https://www.healthcaredive.com/news/biogen-aduhelm-alzheimers-drug-medicare-premium-hikes-2022/610027; see also James D. Chambers, Pei-Jung Lin,
Sean R. Tunis, & Peter J. Neumann, Medicare 'Coverage with Evidence Development' ForAducanumab?

How

Might

it

Work?,

HEALTH

AFFS.

(June

30,

2021),

534

DENVER LAW REVIEW

[Vol. 99.3

increase was averted after Biogen halved its annual price and Medicare
decided to limit coverage to only patients in forthcoming clinical trials to
evaluate concerns about Aduhelm's benefits. 96 However, financial exposure for individual patients still looms large since most Medicare patients
will not qualify for coverage and private insurance generally does not
cover the drug. 97 In addition, Medicare costs for other biologics to treat
Alzheimer's currently under review could still be an issue in light of pressure from some members of Congress and patient advocacy groups pushing for coverage.98
In addition, unlike the entry of generic drugs into the market, entry
of biosimilars into the market can help reduce costs of the originator biologic. After generics enter the market, the original brand generally does
not reduce prices and may sometimes even increase prices to profit from
consumers who are less price sensitive. 99 This results in the loss of 70%90% of traditional branded drug sales within the first year after the brand
loses exclusivity.0 0 In contrast, originator biologics tend to drop 4 %-10%
per biosimilar entrant' 0 ' although there is great variation and those that
only minimally reduce prices may lose market share.10 2 Neupogen, a cancer treatment, did not drop its price until after the third biosimilar entrant
and even then, only dropped its price 3%-4%. Neupogen lost about half
https://www.healthaffairs.org/do/10.1377/forefront.20210625.284997
(explaining how Medicare
makes coverage determinations). The premiums might be reduced now that Medicare has announced
limited coverage of Aduhelm. E.g., Rachel Cohrs, Medicare Premiums CouldDecrease "Soon, "After
Decision on Alzheimer's Drug Aduhem,
STAT (Mar. 17, 2022), https://www.stat-

news.com/2022/03/17/medicare-premiums-decrease-alzheimers/
96.
CMS, CMS Finalizes Medicare Coverage Policy for Monoclonal Antibodies Directed
Against Amyloid for the Treatment of Alzheimer's Disease, CMS.GOV (Apr. 7, 2022),

https://www.cms.gov/newsroom/press-releases/cms-finalizes-medicare-coverage-policy-monoclonal-antibodies-directed-against-amyloid-treatment.
97.
Juliette Cubanski & Tricia Neuman, FDA's Approval of Biogen's New Alzheimer's Drug
Has Huge Cost Implicationsfor Medicare Beneficiaries, KAISER FAM. FOUND. (June 10, 2021),

https://www.kff.org/medicare/issue-brief/fdas-approval-of-biogens-new-alzheimers-drug-has-hugecost-implications-for-medicare-and-beneficiaries; Hamilton, supra note 94.
98.
Pam Belluck, Inside a Campaign to Get Medicare Coveragefor a new Alzheimer's Drug,
N.Y. TIMES (Apr. 6, 2022), https://www.nytimes.com/2022/04/06/health/aduhelm-alzheimers-medicare-patients.html.
99.

See Richard G. Frank & David S. Salkever, Generic Entry and the PricingofPharmaceuJ. ECON. & MGMT. STRATEGY 75, 82-83 (1997); Richard G. Frank, Mahnum Shahzad, William B. Feldman, & Aaron S. Kesselheim, Biosimilar Competition: Early Learning 5 (Nat'l Bureau

ticals, 6

of Econ. Rsch., Working Paper No. 28460, 2021) [hereinafter Frank et al., Working Paper 2021].
100.
See Frank et al., Working Paper 2021, supra note 99, at 18.
101.
See id.; see also Alice M. Ellyson & Anirban Basu, Do PharmaceuticalPricesRise AnticipatingBranded Competition?, 30 HEALTH ECON. 1070, 1079 (2021) (finding that in the insulin mar-

ket, originator biologics increased in price before potential biosimilar entry although out-of-pocket
costs did not substantially increase despite 300% increases in overall cost).
102.
See Frank et al., Working Paper 2021, supra note 99, at 18-19; see also id. at 14-16 (showing the change in originator share is fairly substantial for most originators after biosimilar entry except
for Remicade); Luca Maini, Josh Feng, Thomas Hwang, & Jacob Klimek, BiosimilarEntry and the
Pricing of Biologic Drugs (Jan. 4, 2021) (unpublished manuscript at 3, 11-12, 23), https://papers.ssrncom/sol3/papers.cfm?abstractid=3760213 (suggesting that originator biologics decrease
net price by about 20% to compete with biosimilars); WAYNE WINEGARDEN, PAC. RSCH. INST., THE
BIOSIMILAR OPPORTUNITY: A STATE BREAKDOWN 18-20 (2019) (diScussing price impact to Remicade and Neupogen once biosimilar competitors introduced to market); Stern et al., supra note 78, at
997 (noting greater decline in price of originator biologics to more recent biosimilars).
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of its sales volume to biosimilars that were launched at prices 16%-48%
lower. 03 In contrast, the price of Remicade-which treats a variety of conditions including arthritis, Crohn's disease, and psoriasis-dropped nearly
15% after the second biosimilar entered and continued to drop after entry
of a third biosimilar, such that it ultimately dropped about 40%-50% of its
precompetition price, yet maintained a substantial share of the market.0 4
Recently, biosimilars have captured market share more rapidly, resulting
in steeper price reductions of the originator biologic.0 5
Moreover, even if the originator biologic does not significantly decrease its price after biosimilar entry, the increased price competition typically halts previous annual price increases. Without competition, originator biologics tend to annually increase prices at least 5% per year. 0 6 However, in some instances, price increases of originator biologics are much
more substantial. Humira, a top-selling originator biologic, increased in
price by 19% in 2017 and 2018 and by 7% in 2020 and 2021.107 Without
biosimilar competition until 2023, Humira's price is likely to continue to
increase based on past practice, barring intervening changes in state or
federal law. 08
B. Introduction to Cognitive Biases
This Section explains how all individuals, regardless of education,
are susceptible to imperfect processing of information due to cognitive biases, which are essentially mental shortcuts. As will be explained,
103.
See Frank et al., Working Paper 2021, supra note 99, at 16.
104.
Id. at 15 fig.2a. Occasionally the savings are dramatic; AbbVie provided a nearly 80% discount onHumira to remain the exclusive producer in Nordic countries where only the cheapest version
of a drug is available to consumers. Coghlan et al., supra note 46, at 1580.
105.
See Stern et al., supra note 79, at 993 (finding that biosimilars entering the market in 2018
or later showed more rapid market share declines for the originatorbiologic, especially for biosimilars
for bevacizumab and trastuzumab); Yang et al., supra note 89, at 79 (noting that recently launched
oncology biosimilars received 20%-42% uptake within their first year).
106.
See Alvaro San-Juan-Rodriguez, Walid F. Gellad, Chester B. Good, & Inmaculada Hernandez, Trends in List Prices, Net Prices, and DiscountsforOriginatorBiologicsFacingBiosimilarCom-

petition, 2 J. AM. MED. ASS'N NETWORK OPEN, Dec. 2019, at 1/4 (discussing prices of filgastim,
pegfilgrastim, infliximab, and insulin glargine). However, for infliximab and insulin glargine, the net,
rather than list prices, decreased a couple of years before biosimilar entry due to increases in manufacturer discounts. See id. at 2/4-3/4.
107.
Christopher Rowland, Why Price of Humira Keeps Rising Despite FDA Approval of Generic Competition, WASH. POST (Jan. 8, 2020), https://www.washingtonpost.com/business/econ-

omy/why-humiras-price-keeps-rising-despite-fda-approval-of-generic-competition/2020/01/07/549edOce-2e3a-llea-bcb3-ac6482c4a92f_story.html (noting price increases from
2017 through 2020); Sy Mukherjee, Will AbbVie, Maker of the World's Best-Selling Drug, Finally
Face the Music Over Its Price Hikes?, FORTUNE (May 19, 2021, 1:24 PM), https://for-

tune.com/2021/05/19/abbvie-humira-drug-prices-of-medicine-drugmakers-big-pharma-prescriptionprice (notingHumiraprice increase of 7.4%in2021). Infact, a 1.4 billionincrease inU.S. drugspending was due to an unsupported net price increase for Humira over two years without any increased
&

benefit. DAVID M. RIND, FOLUSO AGBOOLA, DMITRIY NIKITIN, AVERY MCKENNA, NOEMI
FLUETSCH, JON CAMPBELL, FRANCESCA BEAUDOIN, & STEVEN D. PEARSON, INST. FOR CLINICAL
ECON. REV., UNSUPPORTED PRICE INCREASE REPORT: UNSUPPORTED PRICE INCREASES OCCURRING

IN 2020 ES2-ES3 (2021) (interim report).
108.
See Rowland, supra note 107; see also Sy Mukherjee, It's the New Year, and PharmaCompanies are Already Hiking Prices of PopularDrugs, FORTUNE (Jan. 4, 2021, 1:35 PM), https://for-

tune.com/2021/01/04/drug-price-increases-abbvie-humira.
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cognitive biases operate in conjunction with marketing, resulting in illogical biases against biosimilars. 0 9 Studies repeatedly show that individuals
often make decisions without a systematic consideration of evidence." 0 In
an information-saturated society, everyone relies on cognitive shortcuts to
deal with time-limited situations and ambiguous information." For example, studies show that doctors repeatedly rely on mental shortcuts to
develop diagnoses because patients often present symptoms that are not
neatly categorized, which creates ambiguity in diagnosis." 2 Although this
practice may seem improper, it is consistent with study findings that individuals use mental shortcuts to fill in incomplete information such as
symptoms that do not readily fit a category. Similarly, because there are
generally no studies comparing new drugs to old drugs, doctors likely rely
on a personal rule of thumb, rather than empirical evidence, to prefer either
new drugs or old drugs.Il 3
These mental shortcuts are highly prevalent and although they have
some utility, they can also result in inaccuracies. Studies indicate that mental shortcuts promote psychological well-being in that they help us to feel
more in control in the world." 4 Their utility is potentially highlighted by
the fact that individuals develop these shortcuts from an early age; studies
have found evidence of children relying on mental shortcuts." 5 Although
it may seem obvious that shortcuts can be unreliable, we do not consciously realize that we are using them and thus can develop views based
on these unreliable shortcuts."16 Problematically, views can be difficult to
modify; studies indicate that it can be challenging to disabuse individuals
of views on a variety of topics including politically charged issues such as
bans on LGBTQ individuals in the military, theories concerning President
Kennedy's assassination, and the safety of vaccines." 7
109.
110.

See infra Section III.B.1.
See DANIEL KAHNEMAN, THINKING FAST AND SLOW 89-90 (2011) (discussing cognitive

processing as primarily influenced by automatic and subconscious thought).
111.
See id. at 79-81; see also Ronald Chen & Jon Hanson, CategoricallyBiased: The Influence
of Knowledge Structures on Law and Legal Theory, 77 S. CAL. L. REV. 1103, 1128 (2004).
112.
E.g., Jessica Mantel, The Myth of the Independent Physician, 64 CASE W. RSRV. L. REV.

455, 480-81 (2013).
113.
See id. at 483 (noting doctors could be biased towards new drugs as presumably better or,
alternatively, older drugs on the presumption that longer use indicates safety).
114.

See Jeffrey J. Rachlinski, The UncertainPsychologicalCasefor Paternalism,97 NW. U. L.

REV. 1165, 1172 (2003); Chen & Hanson, supra note 111, at 1196.
115.
Jonathan Baron, Laura Granato, Mark Spranca, & Eva Teubal, Decision-MakingBiases in
Children and Adolescents: Exploratory Studies, 39 MERRILL-PALMER

Q.

22, 23-25, 34-36 (1993)

(finding similar decision-making biases in children aged seven to fifteen); Steven Novella, Developing
Cognitive Biases in Young Children, NEUROLOGICA BLOG (July 19, 2018), https://theness.com/neurologicablog/index.php/developing-cognitive-biases-in-young-children (noting how young children
utilize mental shortcuts).
116.
E.g., Cynthia Ho, Drugged Out: How Cognitive Biases Hurts Drug Innovation, 51 SAN

DIEGO L. REV. 419, 436-37 (2014) [hereinafter Drugged Out].
117.
E.g., Geoffrey D. Munro, Peter H. Ditto, Lisa K. Lockhart, Angela Fagerlin, Mitchell
Gready, & Elizabeth Peterson, BiasedAssimilation of SociopoliticalArguments: Evaluatingthe 1996
U.S. PresidentialDebate, 24 BASIC & APPLIED SOC. PSYCH. 15, 16 (2002); Jacqueline R. Meszaros,

David A. Asch, Jonathan Baron, John C. Hershey, Howard Kunreuther, & Joanne Schwartz-Buzaglo,
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Although there are a variety of theories and terms from different disciplines concerning how mental shortcuts are initially formed on key issues, a common cognitive bias helps explain how current biases about biosimilars developed.l"8 In particular, doctor and patient bias against biosimilars may stem from the so-called availability bias, whereby more readily available information is assumed true."19 An example of availability
bias is that upon hearing frequent news reports on murders, individuals
may mistakenly believe that death by homicide is more likely than from
stomach cancer because that information is more available, when in fact
death by stomach cancer is nearly twenty times as likely. 20 In the medical
context, although doctors think they believe scientific research over marketing, studies show doctors actually believe marketing-even when it
contradicts scientific research.' 2 ' This has important implications for biosimilars given that self-interested companies that sell originator biologics
have been spreading skepticism concerning biosimilars for years; 2 2 especially because studies show that repeated information is often presumed
correct even if it is from an unreliable source. 23 Although this may seem
counterintuitive, people often remember the content of a message longer
than they remember the source of a message. 2 4
Moreover, the availability bias can be enhanced by a "framing bias,"
pursuant to which people are highly influenced by how an item is explained (i.e., the framing). For example, beef framed as 75% lean is valued
more than beef framed as 25% fat, despite being identical.2 5 The framing
bias stands to have a major impact on the public's perception of drugs
when used in drug advertisements. Originator biologics have been

Cognitive Processes and the Decisions of Some Parents to Forego Pertussis Vaccinationfor Their

Children, 49 J. CLINICAL EPIDEMIOLOGY 697, 701-02 (1996) (discussing the decision processes of
parents who chose to not vaccinate their children from pertussis and the difficulties inpersuading them
to reassess their decisions even when presented with data supporting vaccination).
118.
Mental short cuts include a "schema" (an intuitive rule regarding people and events) and a
"heuristic" (an individual's personal rule of thumb). Mantel, supra note 112, at 477-78, 478 n.97.
Some scholars simply refer to these biases as "misinformation" without categorizing whether the informationbelieved is not true. E.g., Lewandowsky et al., supranote 15, at 107-08.
119.
See KAHNEMAN, supra note 110, at 129-32, 137-41; Cynthia M. Ho, A Dangerous Concoction: PharmaceuticalMarketing, Cognitive Biases, and FirstAmendment Overprotection,94 IND.
L. J. 773, 805-06 (2019) [hereinafterDangerousConcoction].
120.
See ZIVA KUNDA, SOCIAL COGNITION: MAKING SENSE OF PEOPLE 91 (1999).
121.
E.g., Dangerous Concoction, supra note 119, at 815-16; see also Henk G. Schmidt, Silvia

Mamede, Kees van den Berge, Tamara van Gog, Jan L.C.M. van Saase, & Remy M.J.P. Rikers, Exposure to Media Information About a Disease Can Cause Doctors to Misdiagnose Similar-Looking
Clinical Cases, 89 AM. MED. 285, 289 (2014).

122.
See discussion infra Section III.B.1.
123.
E.g., Drugged Out, supra note 116, at 444. This phenomenon is called the "illusory truth
effect," and is its own type of cognitive bias. Gordon Pennycook, Tyrone D. Cannon, & David G.
Rand, PriorExposure Increases PerceivedAccuracy of Fake News, 147 J. EXP. PSYCH. 1865, 1866

(2018); Jonas De Keersmaecker, David Dunning, Gordon Pennycook, David G. Rand, Carmen
Sanchez, Christian Unkelbach, & Arne Roets, Investigatingthe Robustness of the Illusory Truth Effect
Across IndividualDifferences in Cognitive Ability, Need for Cognitive Closure, and Cognitive Style,
46 PERSONALITY & SOC. PSYCH. BULL. 211, 212 (2019).
124.
E.g., Drugged Out, supra note 116, at 443-45.
125.
Irwin P. Levin & Gary J. Gaeth, How ConsumersAre Affected by the FramingofAttribute
Information Before and After Consuming the Product, 15 J. CONSUMER RES. 374, 374 (1988).
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advertised for over a decade before their corresponding biosimilar enters
the market and have likely had a major impact on doctors and patients due
to the substantial availability and framing in favor of the originator biologics. 2 6 As a result, doctors could be unnecessarily hesitant to prescribe
biosimilars and patients unnecessarily hesitant to take them. Further reinforcing skepticism surrounding biosimilars, some "neutral" patient groups
are funded by self-interested biosimilars companies.

'

Once doctors and patients develop a bias concerning biosimilars, the
bias is perpetuated through "confirmation bias," which a host of studies
have shown to exist in individuals.127 Under the premise of confirmation
bias, individuals interpret new information based on existing beliefs and
reject inconsistent information.1 28 Even scientists, who are trained to consider information analytically, are not immune to the phenomenon. For
example, a 2013 study debunked a common belief among scientists that
breakfast is important for weight loss and control, finding that many results lacked probative value or reflected bias. 2 9 Confirmation bias helps
explain why not all individuals recognize climate change despite scientists
in the field repeatedly confirming its existence; someone who does not
recognize climate change will cling to a minority of information and their
own personal experience while disregarding overwhelming relevant evidence. 30 While this may seem illogical, as noted earlier, mental processing is often not entirely logical. In fact, studies show that information
that is inconsistent with one's beliefs is more difficult to process and more
closely scrutinized and as a result, is less likely to be accepted as true.' 3
The impact of confirmation bias is especially prevalent in ambiguous situations; for example, in one classic study, subjects given the same fact
scenario reinforced their beliefs either for or against the death penalty after
reading the same scenario. 3 2 Moreover, as will be explained, the psychological power of confirmation bias may help explain why patients experience positive (placebo) physical effects based on inert substances, as well
as negative (nocebo) physical effects with active substances. 33

126.

The separate "anchoring bias" phenomenon refers to people relying more on initial infor-

mation they receive. Predrag Teovanovic, Individual Differences in Anchoring Effect: Evidence for
the Role ofInsufficient Adjustment, 15 EUR. J. PSCYH. 8, 8 (2019).
127.
E.g., Drugged Out, supra note 116, at 438-41.
128.
See RICHARD NISBETT & LEE ROSS, HUMAN INFERENCE: STRATEGIES AND SHORTCOMINGS
OF SOCIAL JUDGMENT 169 (1980).

129.

See generally Andrew W. Brown, Michelle M. Bohan Brown, & David B. Allison, Belief

Beyond the Evidence: Using the ProposedEffect ofBreakfast on Obesity to Show Two Practicesthat
DistortScientific Evidence, 98 AM. J. CLINICAL NUTRITION 1298, 1298-1301, 1304-06 (2013).
130.
See, e.g., Natasha Bertrand, Why People Don'tBelieve in Climate Change, INSIDER (Nov.

25, 2014, 3:51 PM), https://www.businessinsider.com/public-religion-report-climate-change-201411.
131.
E.g., Lewandowsky et al., supra note 15, at 112.
132.
Charles G. Lord, Lee Ross, & Mark R. Lepper, BiasedAssimilation and Attitude Polarization: The Effects ofPriorTheories on Subsequently ConsideredEvidence, 37 J. PERSONALITY & SOC.
PSYCH. 2098, 2098 (1979).

133.

See discussion infra Section I.C.2.
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Availability bias and confirmation bias can be a powerful combination and can help explain things that otherwise seem illogical. For example, the initial study arguing that the measles, mumps, and rubella vaccine
was linked to autism was published in 1998 but was not retracted for being
based on falsified data until 2010; the flawed study was available to the
public for more than a decade, amplified by news reports ofthe findings. 3 4
Although reviewing scientists noted in 1998 that the study's sample size
was small and that the results could not be replicated, the long period prior
to retraction likely reinforced belief in the study results that were then difficult to dismantle due to confirmation bias. 35 That people continue to believe, based on cognitive biases, something that has been debunked as
fraudulent science suggests that doctors and patients who have been exposed to negative advertisements about biosimilars may continue to view
biosimilars negatively. Simply removing biosimilar misinformation is
likely inadequate to reverse opinions and promote their use, and even affirmatively correcting biosimilar misinformation might still be insufficient
to change biases.
An additional cognitive bias that may contribute to resistance to biosimilars is the conceptually related bias of "loss aversion." Studies indicate
that individuals are sensitive to whether information is framed as a loss,
rather than a gain. 3 6 This bias overvalues possible loss compared to possible gain such that possible gain may need to be twice as valuable for
people to overcome this bias.137 An implication of loss aversion is that
individuals tend to retain the status quo.138 This may play a role in patient
and doctor resistance to changing from an originator biologic to its equivalent biosimilar, especially if the change is framed as a potential loss in
symptom control. 3 9 Biologics treat serious conditions and are often
134.

Paul Offit, Wakefield Study Linking MMR Vaccine, Autism Uncovered as Fraud, HEALIO

(Feb. 1, 2011), https://www.healio.com/news/pediatrics/20120325/wakefield-study-linking-mmrvaccine-autism-uncovered-as-complete-fraud; Julia Belluz, Research Fraud Catalyzed the Anti-Vaccination Movement.

Let's

Not

Repeat

History,

VOx,

(Mar.

5,

2019,

12:06

PM),

https://www.vox.com/20 18/2/27/17057990/andrew-wakefield-vaccines-autism-study.
135.

See Robert T. Chen & Frank DeStefano, VaccineAdverse Events; Causalor Coincidental?,

351 LANCET 611, 611-12 (1998).
136.
See Dawn K. Wilson, Robert M. Kaplan, & Lawrence J. Schneiderman, Framing ofDecisions and Selections ofAlternatives in Health Care, 2 SOC. BEH. 51, 51 (1987) (finding individuals
more likely to select risky medical options when information is worded positively).
137.

See Chris Guthrie, ProspectTheory, Risk Preference, and the Law, 97 NW. U. L. REV. 1115,

1119 (2003) ("In fact, the available empirical evidence suggests that losses generally loom at least
twice as large as equivalent gains."). A similar concept is the endowment effect which refers to overvaluing owned items. Daniel Kahneman, Jack L. Knetsch, & Richard H. Thaler, Experimental Tests
of the Endowment Effect and the Coase Theorem, 98 J. POL. ECON. 1325, 1326-28 (1990). In one

classic study, subjects that owned a mug valued it twice as much as those who did not own a mug
when they were asked what they would pay for it. See id. at 1338-39. Arguably endowment effect
could apply to overvaluing a prescription to a current drug, although the fact that it exists is a function
of loss aversion. See Daniel Kahneman, Jack L. Knetsch, & Richard H. Thaler, Anomalies: The Endowment Effect, Loss Aversion, and Status Quo Bias, 5 J. ECON. PERSP. 193, 194 (1991) [hereinafter
Anomalies].
138.
E.g., Anomalies, supra note 137, at 197-98.

139.
Because studies show that people treat the same scenarios differently if they are framed as
a loss versus a gain, framing a surgery as an 80% survival rate as opposed to a 20% mortality rate has
different outcomes even though the odds are equivalent.
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considered superior treatments such that by the time patients are using biologics, they have tried a variety of inferior drugs in an attempt to treat
their condition and are primed to avoid loss, leading to overvaluing maintaining current therapy. 4 Resistance to a change to a biosimilar seems
especially likely given that studies show a bias for the status quo even
when that status quo is suboptimal.141 Loss aversion bias could explain
why patients taking medications that do not fully control arthritis symptoms sometimes are resistant to changing medications. 42
C. Bias Against Generics

This Section explains how doctor and consumer biases against generics can be explained by cognitive biases. As discussed in the last Section,
cognitive biases influence how we perceive new information such that existing biases against generics likely taint views of biosimilars. A better
understanding of how biases against biosimilars, as well as generics, are
grounded in common cognitive biases is helpful to ultimately provide realistic proposals to address misconceptions, as discussed in Part IV. Because biosimilars are relatively new and analogous to well-known generics, this Section begins with evidence of misperceptions about generics. In
addition, because doctors are presumably more knowledgeable about
drugs than patients and can influence patients, this Section first presents
evidence of misconceptions among doctors followed by misconceptions
among patients.
1. Evidence of Doctor Bias Against Generics
Although most doctors state that generics are safe and effective, the
acknowledgement does not translate to their prescribing preferences, reflecting a possible cognitive bias. A 2016 survey of U.S. doctors found
that although the vast majority considered generics as effective and safe
(89% and 91% respectively), 70% would prefer prescribing brand name
traditional drugs over generic drugs. 43 These results can be explained by
140.
See Pamela Walker, Loss Aversion: Reducing the Risk ofNew Rx Drugs, PHARM EXEC (Jan.
8, 2015), https://www.pharmexec.com/view/loss-aversion-reducing-risk-new-rx-drugs.
141.
See Anomalies, supra note 137, at 198 (discussing a study examining status quo bias in
which a majority of electrical power consumers who experienced unreliable service still preferred to
remain with their current service provider rather than choose a new source).
142.
See Frederick Wolfe & Kaleb Michaud, Resistance of Rheumatoid Arthritis Patients to
Changing Therapy: Discordance Between Disease Activity and Patients' Treatment Choices, 56

ARTHRITIS & RHEUMATISM 2135, 2135 (2007); Kelly Gavigan, W. Benjamin Nowell, Mylene S.
Serna, Jeffrey L. Stark, Mohamed Yassine, & Jeffrey R. Curtis, Barriersto Treatment Optimization
and Achievement ofPatients' Goals: Perspectivesfrom People Living with RheumatoidArthritis Enrolled in the ArthritisPower Registry, 22 ARTHRITIS RES. & THERAPY 7, 16 (2020) (noting that pa-

tients are relatively unlikely to change medication unless the change is initiated by a doctor, even if
they have high disease activity).
143.
Aaron S. Kesselheim, Joshua J. Gagne, Wesley Eddings, Jessica M. Franklin, Kathryn M.
Ross, Lisa A. Fulchino, & Eric G. Campbell, Prevalence and Predictors of Generic Drug Skepticism
Among Physicians: Results of a National Survey, 176 J. AM. MED. ASS'N INTERNAL MED. 845, 845-

46 (2016). However, this is better than in prior years. See William H. Shrank, Joshua N. Liberman,
Michael A. Fischer, Charmaine Girdish, Troyen A. Brennan, & Niteesh K. Choudhry, Physician
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"social desirability bias"-where an individual responds to a survey with
what they believe to be the socially desirable response instead of their actual belief. Unlike cognitive biases that modify thinking and perceptions,
social desirability bias masks what a person truly believes.1 44 This bias
may cause doctors to prescribe name brand drugs despite knowing that
there are rigorous studies showing that generics are not inferior. 45
An illogical bias against generics is reflected in the fact that virtually
all doctors agree that generics are safe and effective yet not as many prescribe them. The bias against generics could be due to availability bias
resulting from years of brand drug marketing, which is then perpetuated
through confirmation bias and loss aversion bias. As discussed earlier,
confirmation bias can lead individuals to discount information that is inconsistent with their views. For example, if an article states that randomized-controlled trials find no problem with a generic drug, yet nonetheless
mentions that some experts believe there is a problem, doctors with confirmation bias against generics are likely to focus on the brief mention of
the minority of experts who believe there is a problem (similar to the vaccination and autism study). Additionally, doctors swayed by confirmation
Perceptions About Generic Drugs, 45 ANNALS PHARMACOTHERAPY 31, 34 (2011) (finding that

roughly half of doctors surveyed had some concern about generic drug quality with about half reporting quality concerns and almost a quarter concerned about efficacy). The increased belief in generic
safety could be due to increased use because, at the time of the earlier study, generics were considered
underutilized. Id. at 31. There is worldwide physician bias against generics with approximately 30%
believing generics are less effective. E.g., Sarah Colgan, Kate Faasse, Leslie R. Martin, Melika H.
Stephens, Andrew Grey, & Keith J. Petrie, Perceptionsof Generic Medication in the General Population, Doctors and Pharmacists:A Systematic Review, BMJ OPEN, Nov. 2015, at 3; see also Suzanne
S. Dunne & Colum P. Dunne, What Do People Really Think of Generic Medicines? A Systematic

&

Review and CriticalAppraisal of Literature on Stakeholder Perceptions of Generic Drugs, 13 BMC
MED. 1, 2 (2015).
144.
E.g., Adrian Furnham, Response Bias, Social Desirability and Dissimulation, 7
PERSONALITY & INDIVIDUAL DIFFERENCES 385, 385 (1986). However, social desirability bias canbe
reduced by good survey design. See Roger Tourangeau, MaintainingRespondent Trust and Protecting
Their Data, in THE PALGRAVE HANDBOOK OF SURVEY RESEARCH, at 137-39 (David L. Vannette

Jon A. Krosnick, eds., 2018).
145.

E.g., LINDA L. BARRETT, PHYSICIAN ATTITUDES AND PRACTICES REGARDING GENERIC

&

DRUGS 19 (2005) (finding that although a third of doctors at least somewhat felt that "therapeutic
failures are a serious problem" with generics, studies do not support this difference); see also Rishi J.
Desai, Ameet Sarpatwari, Sara Dejene, Nazleen F. Khan, Joyce Lii, James R. Rogers, Sarah K.
Dutcher, Saeid Raofi, Justin Bohn, John G. Connolly, Michael A. Fisher, Aaron S. Kesselheim,
Joshua J. Gagne, ComparativeEffectiveness of Generic and Brand Name Medication Use: A Database
Study of US Health Insurance Claims, 16 PLOS MED, Mar. 2019, at 2 (finding equivalent clinical

outcomes among patients who used a generic versus the authorized generic product, which are manufactured by brand name producers); R.A. Hansen, J. Qian, R.L. Berg, J.G. Linneman, E. SeoaneVazquez, S. Dutcher, S. Raofi, C.D. Page, & P.L. Peissig, Comparison of Outcomes Following a
Switch From a Brand to an Authorized Versus Independent Generic Drug, 103 CLINICAL
PHARMACOLOGY & THERAPEUTICS 310, 313 (2018) (finding generics were not clinically worse than

authorized generics, which are made by brand name producers); Lamberto Manzoli, Maria Elena
Flacco, Sefania Boccia, Elvira D'Andrea, Nikola Panic, Carolina Marzuillo, Roberta Siliquini, Walter
Ricciardi, Paolo Villari, & John P. A. Ioannidis, Generic Versus Brand-Name Drugs Used in CardiovascularDiseases, 31 EUR. J. EPIDEMIOLOGY 351, 361 (2016); Aaron Kesselheim, Alexander S. Mis-

ono, Joy L. Lee, Margaret R. Stedman, M. Alan Brookhart, Niteesh K. Choudhry, & William H.
Shrank, ClinicalEquivalence of Generic and Brand Name Drugs Used in CardiovascularDisease:A
Systemic Review and Meta-Analysis, 21 J. AM. MED. ASS'N 2514, 2524 (2008) (finding brand name

drugs for cardiovascular disease are not better, contrary to substantial number of editorials opposing
substitution).
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bias may focus on patient reports of adverse reactions to generics of narrow therapeutic index drugs, which have a narrow range of effectiveness
and greater potential for toxicity. These doctors might conclude that the
patients' anecdotal reports are proof of problems with generics when the
patients' negative outcomes are unrelated to generic use.1 46 This focus on
negative anecdotal reports contrasts with the American Medical Association (AMA) position as well as repeated FDA assurances that all generics,
including those with narrow therapeutic indexes, are safe.1 47
2. Evidence of Patient Bias Against Generics
Given that doctors are highly educated yet still susceptible to biases,
it should not be surprising that studies also reveal patient bias against generics-especially because patient bias is likely tied to a broader consumer
bias favoring brand name products1 48 and expensive products.1 49 Patient
bias against generics is more explicit than doctor bias, as reflected by the
comment of one study participant who falsely asserted, "Generic medicine
is not as effective as ... the real medicine prescriptions."" 0 Other patients
are aware that generics are safe and effective yet nonetheless have implicit
biases against generics. This is evidenced by a 40% gap between those that
say generics are safe and effective with equivalent side effects versus those
that prefer generics in a 2016 study.' 5 ' This finding is similar to prior

146.
Consistent with cognitive bias that favors personal experience over data, doctors may needlessly assume a seizure is "evidence" that the generic is not effective when it could be due to disease
progression, as noted by the AMA. VISANTE, UNDERMINING GENERIC DRUG SUBSTITUTION: THE
COST OF GENERIC CARVE-OUT LEGISLATION 5 (2008); see also David G. Vossler, Gail D. Anderson,
& Jacquelyn Bainbridge, AES Position Statement on Generic Substitution andAntiepilepticDrugs, 16
EPILEPSY CURRENTS 209, 210 (2016) (reversing prior position to now favor generic drugs).
147.
VISANTE, supra note 146, at 5.

148.

See Paula Varela, Gaston Ares, Ana Gimenez, & Adriana Gambaro, Influence of Brand
&

Information on Consumers' Expectations and Liking of Powdered Drinks, 21 FOOD QUALITY

PREFERENCE 873, 880 (2010) (well-knownbrand products taste better only when the brand is visible);
Jeffrey S. Nevid, Effects of BrandLabelingon Ratings ofProduct Quality, 53 PERCEPTUAL & MOTOR
SKILLS 407, 409 (1981) (finding subjects rated Perrier as tasting superior to generically titled seltzer

only when label was shown).
149.
Liane Schmidt, Vasilisa Skvortsova, Claus Kullen, Bernd Weber, & Hilke Plassmann, How
ContextAlters Value: The Brain's Valuation and Affective Regulation System Link Price Cues to Experienced Taste Pleasantness, SCI. REP. Aug. 2017, at 2 (study participants rated wines as less tasty if

they were labeled as cheaper, even when the wines were in fact identical).
150.
Keri Sewell, Susan Andreae, Elizabeth Luke, & Monika M. Safford, Perceptionsof and
Barriersto Use of Generic Medications in a RuralAfrican American Population, Alabama, 2011,
PREVENTING CHRONIC DISEASE, Aug. 2012, at 2-3.

151.

Aaron S. Kesselheim, Joshua J. Gagne, Jessica M. Franklin, Wesley Eddings, Lisa A.

Fulchino, Jerry Avorn, & Eric G. Campbell, Variations in Patients'Perceptions and Use of Generic
Drugs:Results ofa NationalSurvey, 31 SOC'Y. GEN. INTERNAL MED. 609, 609 n.5, 611 (2016) (find-

ing that although 90% of patients considered generics effective and safe and 80% stated they had
comparable side effects, almost 40% of patients still preferred the brand name drugs).
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studies. 5 2 Further, bias against generics may be more prevalent concerning serious conditions. 53
Bias against generics could explain the well-documented physical
phenomena not tied to active ingredients. Numerous studies have found
that patients may experience placebo 5 4 or nocebo effects5 5 based on
whether they believe they are taking a brand drug or a generic drug. 5 6
Although researchers have long recognized that placebo and nocebo effects are tied to expectations and psychology, 57 these effects also provide
strong evidence of bias against generics.
Empirical studies demonstrate that placebo and nocebo effects are
associated with powerful biases against generics. In one study of subjects
who reported frequent headaches, brand-labeled drugs were always perceived as more effective and with fewer side effects than something labeled "generic"-even when the "brand" was inert and the "generic" had
the active ingredient (ibuprofen).1 58 This study shows a powerful placebo
effect with an inert substance and a nocebo effect with an active ingredient.
Similarly, in another experiment where subjects were initially given high
blood pressure medication and then told they were going to be switched to
either a brand or a generic, those receiving the labeled generic experienced
higher blood pressure and greater side effects despite receiving an inert
substance. 5 9 In addition, the same placebo and nocebo effects have been
152.

See William H. Shrank, Emily R. Cox, Michael A. Fischer, Jyotsna Mehta, & Niteesh K.

Chroudhry, Patients'Perceptionsof Generic Medications,28 HEALTH AFF. 546, 548-49 (2009) (find-

&

ing a third of patients believe that brand drugs are more effective and more than a quarter would
personally prefer the brand name drug); Amy J. Keenum, Jennifer E. DeVoe, Deena J. Chisolm,
Lorraine S. Wallace, Generic Medicationsfor You, but Brand-Name Medicationsfor Me, 8 RSCH.
SOC. & ADMIN. PHARMACY 574, 576 (2012) (finding among a sample of female Medicaid patients,

nearly two-thirds agreed generics were a better value, but the majority preferred the brand, and about
a quarter believed the brand was more effective).
153.
See, e.g., Maria Joao Figueiras, Maria Armanda Cortes, Dalia Marcelino, & John Weinman,
Lay Views About Medicines: The Influence of the Illness Label for the Use of Generic Versus Brand,

25 PSYCH. & HEALTH 1121, 1125-26 (2010) (finding subjects less likely to believe that generic use
was appropriate for more serious conditions).
154.
For example, it is well known that patients may experience an improvement of symptoms
when they expect that to happen, even if given an inert substance (i.e. the placebo effect).
155.
Along similar but opposite lines, the nocebo effect results in patients perceiving lack of
efficacy or side effects from a generic or even something labeled a generic. See, e.g., Victor Chavarria,
Joao Vian, Ciria Pereira, Joao Data-Franco, Brisa S. Fernandes, Michael Berk, & Seetal Dodd, The
Placebo and Nocebo Phenomena: Their ClinicalManagement and Impact on Treatment Outcomes,
39 CLINICAL THERAPEUTICS 477, 478 (2017).

156.
Somewhat analogously, studies show individuals perform better withbrand name consumer
goods that are actually identical. See Aaron M. Garvey, Frank Germann, & Lisa E. Bolton, Performance BrandPlacebos: How Brands Improve Performance and Consumers Take the Credit, 42 J
CONSUMER RSCH. 931, 945 (2016).

157.

Id.

158.
See Kate Fasse & Leslie R. Martin, Impact of Brand or Generic Labeling on Medication
Effectiveness and Side Effects, 35 HEALTH PSYCH. 187, 188-89 (2016) (finding that, among subjects

who report frequent headaches, subjects reported efficacy and fewer side effects with pills labeled
"Nurofen" over ones labeled "generic ibuprofen," whether or not it had an active or inert compound;
subjects who received unbranded drugs also reported less efficacy-even if given an active ingredient).
159.
Kate Faasse, Tim Cundy, Greg Gamble, & Keith J. Petrie, The Effect ofanApparent Change
to a Branded or Generic Medication on Drug Effectiveness and Side Effects, 75 PSYCHOSOMATIC
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observed with drugs not labeled as brand and generic but with similar characteristics, such as expensive versus cheap 60 or a simple versus complex
name, typical of scientific names used for generics.161 These studies show
a bias can not only impact perceptions, but can even manifest physically. 62
There are also real-life examples of the nocebo effect. For example,
there may be a nocebo effect with statins that are frequently prescribed to
patients with high blood cholesterol. About 30% of patients discontinue
statins due to alleged side effects. 63 However, when patients in clinical
trials are unaware of whether they are receiving a statin or an inert placebo,
side effects are indistinguishable.1 64 Accordingly, it appears that the 30%
of patients in the nonclinical setting are experiencing nocebo effects.

MED. 90, 94 (2013); see also Antonella Pollo, Martina Amanzio, Anna Arslanian, Caterina Casadio,
Giuliano Maggi, & Fabrizio Benedetti, Response Expectancies in PlaceboAnalgesia and Their Clinical Relevance, 93 PAIN 77, 82-83 (2001) (patients with postoperative pain who were told only that
they were given a powerful painkiller that was in fact a placebo needed about one-third less of a
stronger additional drug compared to those who knew they had a 50/50 chance of either receiving a
placebo or a powerful painkiller); Ulrike Bingel, Vishvarani Wanigasekera, Katja Wiech, Roisin Ni
Mhuircheartaigh, Michael C. Lee, Markus Ploner, & Irene Tracey, The Effect of Treatment Expectation on Drug Efficacy: Imagining the Analgesic Benefit of the Opioid Remifentanil, SCI.
TRANSLATIONAL MED., Feb. 2011, at 1, 4 (patients perceived a lack of efficacy when told that they

are no longer receiving a powerful pain relief medication compared to those not told anything, even
though all were receiving the same pain relief).
160.
Rebecca L. Waber, Baba Shiv, Ziv Carmon, & Dan Ariely, Commercial Features ofPlacebo and Therapeutic Efficacy, 299 J. AM. MED. ASS'N 1016, 1016-17 (2008) (finding that when
subjects were told that they were receiving a more expensive treatment, a pill that costs $2.50, they
experienced greater pain relief than when told they were receiving a heavily discounted treatment,
$.01 per pill, even though all subjects received the identical compound); Alberto J. Espay, Matthew
M. Norris, James C. Eliassen, Alok Dwivedi, Matthew S. Smith, Christi Banks, Jane B. Allendorfer,
Anthony E. Lang, David E. Fleck, Michael J. Linke, & Jerzy P. Szaflarski, PlaceboEffect ofMedication Cost in ParkinsonDisease:A Randomized Double-Blind Study, 84 NEUROLOGY 794, 794 (2015)
(patients with Parkinson's were given the same injection with no active ingredient, but perceived efficacy was dramatically different based on alleged cost).
161.
See Simone Dohle & Michael Siegrist, Fluency of PharmaceuticalDrug Names Predicts
PerceivedHazardousness,Assumed Side Effects and Willingness to Buy, 19 J. HEALTH PSYCH. 1241,
1248 (2014); Hyunjin Song & Norbert Schwarz, If it's Difficult to Pronounce it Must be Risky, 20

PSYCH SCI. 135, 138 (2009); A. Tinnermann, S. Geuter, C. Sprenger, J. Finsterbusch, & C. Bichel,
InteractionsBetween Brain and Spinal Cord Mediate Value Effects in Nocebo Hyperalgesia, 358 SCI.

&

105, 108 (2017) (finding that drugs with a simple name noted as a registered trademark resulted in
more pain relief than a product with a more complex name even with no price information disclosed).
162.
See supranotes 156-59 and accompanying text.
163.
See Corey K. Bradley, Tracy Y. Wang, Shuang Li, Jennifer G. Robinson, Veronique L.
Roger, Anne C. Goldberg, Salim S. Virani, Michael J. Louie, L. Veronica Lee, Eric D. Peterson,
Ann Marie Navar, Patient-ReportedReasonsfor Declining or DiscontinuingStatin Therapy: Insights
from the PALMRegistry, J. AM. HEART ASS'N, Mar. 2019, at 6-9; Kate Faasse & Leslie R. Martin,
The Power of Labeling in Nocebo Effects, 139 INT'L REV. NEUROBIOLOGY 379, 382 (2018).

164.
See Ajay Gupta, David Thompson, Andrew Whitehouse, Tim Collier, Bjorn Dahlof, Neil
Poulter, Rory Collins, & Peter Sever, Adverse EventsAssociatedwith Unblinded, but not with Blinded,
Statin Therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-LoweringArm (ASCOTLLA): A Randomized Double-BlindPlacebo-ControlledTrial andits Non-Randomized Non-Blind Ex-

tension Phase, 389 LANCET 2473, 2478 (2017); Judith A. Finegold, Charlotte H. Manisty, Ben Goldacre, Anthony J. Barron, & Darrel P. Francis, What Proportionof Symptomatic Side Effects in Patients
Taking Statins are Genuinely Caused by the Drug? Systematic Review ofRandomized Placebo-Controlled Trialsto AidIndividualPatient Choice, 21 EUR. J. PREVENTATIVE CARDIOLOGY 464, 467, 471

(2014).
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Perceived lack of efficacy could be a misattribution of a natural fluctuation
of the disorder or other causes, resulting in nocebo effects. 65
II. THE BIAS AGAINST BIOSIMILARS
This Part explains how biases concerning generics extend to biosimilars, making it more challenging for doctors and patients to accept the
latter. Although the biases are analogous, understanding the extent of the
problem is important in crafting effective solutions. This Part concludes
by explaining how originator biologics benefit from this bias, such that
they are financially motivated to perpetuate bias as discussed in more detail in Part III.
A. Evidence ofDoctors with Biases Against Biosimilars
Surveys of U.S. doctors indicate a bias against biosimilars despite a
majority of doctors now recognizing biosimilars as safe and effective.1 66
For example, a 2021 study of about 600 doctors showed that approximately three-quarters consider biosimilars to be at least as safe and effective as their counterpart biologic,1 67 but the number of doctors very likely
to start a new patient on a biosimilar was less than half.1 68 These doctors
were resistant to prescribe biosimilars even though a substantial number
thought that patient costs would be lower with a biosimilar.1 69 Another
study with a substantially larger sample size of doctors reported that almost a quarter were unwilling to start new patients on biosimilars even
though 83% knew biosimilars have no clinically meaningful difference

165.
See Chavarria et al., supranote 155, at 478.
166.
Studies from 2017 to 2021 indicate a trend towards an increasing number of doctors viewing
biosimilars as safe and effective, but the highest number is still not comparable with a 2016 survey of
around 90% of doctors considering generics safe and effective. See Kesselheim et al., supra note 151,
at 609-11 (survey of doctor views on generics). Whereas the first study of U.S. doctors prescribing
biologics found less than half of doctors believed biosimilars to be safe, a survey conducted in 2020
found three-quarters found biosimilars safe. Compare A. Teeple, L.A. Ellis, L. Huff, C. Reynolds, S.
Ginsburg, L. Howard, D. Walls, & J. R. Curtis, PhysicianAttitudes About Non-MedicalSwitching to
Biosimilars: Resultsfrom an Online Physician Survey in the United States, 35 CURRENT MED. RES.
& OPINION 611, 613 fig.2 (2019) (among nearly 300 doctors prescribing biologics, 44% considered
biosimilars safe and 42% considered them riskier than generics) with NORC, supranote 13, at 3 fig.1
(among 602 doctors prescribing biologics, roughly 75% consider them safe and effective). But see A.
Kolbe, A. Kearsley, L. Merchant, E. Temkin, A. Patel, J. Xu, & A. Jessup, Physician Understanding
and Willingness to PrescribeBiosimilars: Findingsfrom a US National Survey, 35 BIODRUGS 363,
369 (2021) (reporting that a study of 500 health-care professionals with varying prior biosimilar experience found that less than 50% expected biosimilars to perform the same clinically); see also Judith
M. Orvos, US HealthcareProviders(Reluctantly) PrescribeBiosimilars,MEDPAGE TODAY (June 14,
2021), https://www.medpagetoday.com/resource-centers/biosimilars-peer-to-peer/us-healthcare-providers-reluctantly-prescribe-biosimilars/3321 (discussing Kolbe study).
167.
Seventy-eight percent of doctors considered biosimilars just as safe and 75% considered
them just as effective, but more than 10% thought that biosimilars were safer or more effective than
the originator drugs. See NORC, supra note 13, at 3.
168.
Id. (showing that there were an additional 39% of physicians that were "somewhat comfortable" with prescribing biosimilars that had been approved by the FDA).
169.
Id. at 7 fig.7 (finding that 41% of doctors thought that biosimilars would be cheaper most
of the time and 44% thought this was true some of the time).
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from their related originator biologics. 7 0 In these studies, as well as older
ones, doctors were resistant to prescribing biosimilars despite knowing
that they were as safe and effective as the originator biologic.' 7' That doctors are most comfortable prescribing biosimilars to new patients (as opposed to patients stable on an originator biologic) suggests a bias against
biosimilars. This bias could be sustained by some unique aspects of U.S.
biosimilar law and financial coverage in addition to substantial advertising, as discussed in Part III.172 However, bias is not limited to U.S. doctors.
Similar evidence of doctor bias against biosimilars exists in other
countries. A 2018 study of European rheumatologists two years after the
first biosimilar was available in their specialty found that the vast majority
(over 70%) were satisfied with originator biologics, but less than 40%
were satisfied with biosimilars.1 73 Most strikingly, a 2014 study of Canadian rheumatologists conducted the same year a biosimilar of originator
biologic Remicade was approved in Canada found that only 11% of doctors would choose a biosimilar if cost were not an issue. 7 4 Familiarity with
biosimilars at that time was low-only one-third of surveyed doctors considered themselves familiar. 75 Nonetheless, it is notable that less than 30%
of doctors considered drug approval adequate to provide confidence in
drug safety and efficacy when regulatory approval demanded such
proof;1 76 in addition, existing literature showed no problems switching
170.
Allan Gibofsky & Dorothy McCabe, US Rheumatologists' Beliefs and Knowledge About
Biosimilars: A Survey, 60 RHEUMATOLOGY 896, 898 (2020) (reporting on a survey of over 9,000

rheumatologists); see also Kolbe et al., supra note 166, at 367 (noting that 86% would choose the
originator biologic over the biosimilar if both were covered).
171.
See Simani M. Price, Amie C. O'Donoghue, Lou Rizzo, Saloni Sapru, & Kathryn J. Aikin,
What Influences HealthcareProviders'PrescribingDecisions? Resultsfrom a National Survey, 17

RSCH. SOC. & ADMIN. PHARMACY 1770, 1777 (2021) (survey of 700 primary care physicians and 600
specialists found that less than 40% were at least moderately comfortable prescribing biosimilars, despite knowing what they are, although this does not distinguish between patients new to biologics);
Joshua Cohen, Will 2021 Be Another Break-Through Year for Biosimilars?, FORBES (Dec. 3, 2020,
9:21
AM),
https://www.forbes.com/sites/joshuacohen/2020/12/03/will-2021-be-another-breakthrough-year-for-biosimilars (noting a 2019 study that found that more than 60% of U.S. oncology
doctors prefer the brand over biosimilar).
172.
See discussion infra Part III. Indeed, doctors sometimes note that they would be more likely
to switch stable patients to a biosimilar if there were greater cost savings potential. See, e.g., Keith
Loria, Survey: Rheumatologists Still Reluctant to Switch Patients to Biosimilars, MANAGED
HEALTHCARE ExEC. (July 2, 2020), https://www.managedhealthcareexecutive.com/view/survey-

rheumatologist-still-reluctant-to-switch-patients-to-biosimilars (reporting that in a Cardinal Health
survey of 100 rheumatologists, only 11% were likely to prescribe a biosimilar to a stable patient; the
rheumatologists cited lack of significant cost benefit and 38% of those surveyed maintained concerns
about efficacy of biosimilars); see also Kyle Herndon, Jason Braithwaite, Brittany Berry, & Kathleen
Bourget, Biosimilar Perceptions Among Healthcare Professions and Commercial Medical Benefit
Policy Analysis in the United States, 35 BIODRUGS 103, 108-9 (2021).
173.
Casey Zhang, Denise Baldock, & Elizabeth Baynton, Physician Perceptionsof Biologics
Versus Their Biosimilar Counterpartsin Rheumatology: A Multicounty Study in Europe, 78 ANNALS
RHEUMATIC DISEASE 611, 611 (2019) (evaluating rheumatologists in United Kingdom, France, Italy,

Spain, and Germany concerning etanercept, infliximab, and rituximab).
174.
David Grabowski, Bradley Henderson, Dennis Lam, Edward C. Keystone, Carter Thorne,
Shahin Jamal, Janet Pope, Boulos Haraoui, Daming Lin, & Leigh Revers, Attitudes Towards Subsequent Entry Biologics/Biosimilars: A
RHEUMATOLOGY 1427, 1429 (2015).
175.
Id.

176.

Id. at 1431 tbl.3.

Survey of Canadian Rheumatologists, 34 CLINICAL
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patients from originator Remicade to biosimilar Remsima. 7 Moreover, a
2016 study of Belgian doctors found that even if the originator was more
expensive, 73% preferred it.l' 8 Notably, this preference was not due to a
lack of knowledge about biosimilars-the vast majority had good understanding of the definition of a biosimilar.1 79 The disproportionate preference for a more expensive originator biologic despite understanding that
biosimilars are highly similar is also consistent with a strong bias against
biosimilars.
Bias against biosimilars can also be seen in global studies showing
that doctors are generally not comfortable switching stable patients to biosimilars1 80 despite empirical studies indicating it is safe.' 8' In multiple
surveys of doctors, generally no more than 51% of surveyed doctors are
comfortable switching a patient to a biosimilar. 8 2 Cited concerns mirror
some of the general concerns about biosimilars, such as concerns that they
will be less effective and less safe, as well as that there is inadequate

177.
178.

Id. at 1431.
See Kati Sarnola, Merja Merikoski, Johanna Jyrkka, & Katri Hameen-Anttila, Physicians'
Perceptionsof the Uptake ofBiosimilars:A Systematic Review, 10 BMJ OPEN, Apr. 2020, at 12 tbl.2.
179.
Id. (noting that 95% of surveyed doctors self-reported a correct understanding that biosimilars are biologics similar, but not identical to, an originator).
180.

Id. at 17.

181.
See, e.g., Jer6me Avouac, Anna Molto, Vered Abitbol, Adrien Etcheto, Axelle Salcion, Loriane Gutermann, Caroline Klotz, Murial Elhai, Pascal Cohen, Pierre Antoine Soret, Florence Morin,
Ornella Conort, Francois Chast, Claire Goulvestre, Claire Le Jeunne, Stanislas Chaussade, Andre Kahan, Christian Roux, Yannick Allanore, & Maxime Dougados, Systematic Switch from InnovatorInfliximab to BiosimilarInfliximab in Inflammatory Chronic Diseases in Daily Clinical Practice:The
Experience of Cochin University Hospital Paris, France, 47 SEMIN. ARTHRITIS RHEUMATISM 741,

747 (2018); Edmond-Jean Bernard, Richard N. Fedorak, & Vipul Jairath, Systematic Review: NonMedicalSwitching oflnfliximab to CT-P13 in Inflammatory Bowel Disease, 65 DIGESTIVE DISEASES

& SC'. 2354, 2368-69 (2019); Kristin K. Jorgensen, Inge C. Olsen, Guro I. Goll, Merete Lorentzen,
Nils Bolstad, Espen A. Haavardsholm, Knut E.A. Lundin, Cato Mork, Jorgen Jahnsen, & Tore K
Kvien, Switchingfrom OriginatorInfliximab to BiosimilarCT-P13 Comparedwith Maintained Treatment with OriginatorInfliximab (NOR-SWITCH), 389 LANCET 2304, 2304 (2017); Andras Inotai,

Christiaan P. J. Prins, Marcell Csanadi, Dinko Vitezic, Catalin Codreanu, & Zoltan Kald, Is There a
Reasonfor Concern or is it Just Hype? -A Systematic LiteratureReview of the Clinical Consequences
of Switchingfrom OriginatorBiologics to Biosimilars, EXPERT OP. BIO. THERAPY 915, 915 (2016);

Liese Barbier, Hans C. Ebbers, Paul Declerck, Steven Simoens, Arnold G. Vulto, & Isabelle Huys,
The Efficacy, Safety and Immunogenicity of Reference Biopharmaceuticals and Biosimilars:A Systemic Review, 108 CLINICAL PHARMACOLOGY & THERAPEUTICS 734, 752 (2020); Silvana A. M. Urru,

Stefania Spila Alegiani, Anna Guella, Giuseppe Traversa, & Annalisa Campomori, Safety ofSwitching
Between Rituximab Biosimilarsin Onco-Hematology, SCI. REP, Mar. 2021, at 3; Paul Corens & Matti
Aapro, The Impact ofBiosimilarsin Supportive Care in Cancer, 14 SUPPORTIVE ONCOLOGY 20, 23-

27 (2018) (discussing various studies that show no problems with switching). Switching between biosimilars has also been suggested as safe. See Eduardo Mysler, Valderilio Feijb Azevedo, Silvio
Danese, Daniel Alvarez, Noriko Iikuni, Beverly Ingram, Markus Mueller, & Laurent Peyrin-Biroulet,
Biosimilar-to-BiosimilarSwitching: What is the Rationaleand CurrentExperience?, 81 DRUGS 1859,

1864-65.
182.
Sarnola et al., supra note 178, at 17. However, there are differences among specialties,
which could reflect lower use of certain biosimilars. See, e.g., Stephen R. Chapman, Raymond W.
Fitzpatrick, & Mohammed I. Aladul, Knowledge, Attitude and Practice of HealthcareProfessionals
Towards Infliximab and Insulin GlargineBiosimilars:Result of a UK Web-Based Survey, BMJ OPEN,

May 2017, at 6 fig.5 (noting differing level of concerns with safety and efficacy of switching to a
biosimilar among dermatologists, gastroenterologists, and rheumatologists in a survey of U.K. doctors,
with rheumatologists having major concerns for both issues, but no major concerns by gastroenterologists).
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clinical data.1 83 However, as will be discussed, these concerns also reflect
marketing by self-interested originator biologic manufacturers. In addition, doctor bias against biosimilars could reflect confirmation bias that
causes them to focus on studies that suggest problems with switching without considering that most of the studies that suggest a problem are observational studies versus the rigorous empirical studies that do not find a
problem.1 84 Further evidence of an illogical bias against biosimilars is anecdotal; many doctors have no express reason for preferring the originator
biologic.1 85 Lack of a principled reason is consistent with mental shortcuts
based on cognitive biases rather than logical reasoning.
Some doctor bias could be based on a lack of knowledge. For example, a 2019 survey found that the vast majority of U.S. oncologists-almost three-quarters-could not provide a correct definition for biosimilar.1 86 In addition, a 2018 survey found that a majority of doctors that prescribe biologics do not prescribe biosimilars because they are not familiar
with them.' 87 Inadequate knowledge sets the stage for cognitive biases to
proliferate to fill in knowledge gaps. 88 It is possible that doctors with existing bias against generics assume that because, unlike generics, biosimilars are not identical to a prior biologic, they should be especially hesitant
about prescribing them, resulting in a stronger bias against biosimilars than
generics. Bias could be exacerbated by the fact that doctors are not certain
that biosimilars would reduce patient out-of-pocket costs given that insurance coverage tends to not favor biosimilars and originator biologic manufacturers often provide discount coupons to patients.1 89 This is in stark
contrast to the fact that generics are well-known to often be dramatically
cheaper than the equivalent brand. Considering that some doctors do not
prescribe substantially cheaper generics, bias against prescribing biosimilars that may not be cheaper is not surprising.

183.

Amy Hemmington, Nicola Dalbeth, Paul Jarrett, Alan G. Fraser, Reuben Broom, Peter

Browett, & Keith J. Petrie, Medical Specialists' Attitudes to Prescribing Biosimilars, 26
PHARMACOEPIDEMIOLOGY & DRUG SAFETY 570, 570-71 (2017).

&

184.
See Inotai et al., supra note 181, at 915.
185.
See Interview by Matthew Gavidia with Robert Rifkin, M.D., FACP, Med. Oncologist
Hematologist, Rocky Mountain Cancer Ctrs. (Dec. 5, 2020), https://www.centerforbiosimilars.com/view/robert-rifkin-md-discusses-overcoming-lingering-biosimilar-education-gaps.
186.

Chad Pettit, The Casefor Optimism in the U.S. BiosimilarMarket, BIOSIMILAR DEV. (July

28, 2020), https://www.biosimilardevelopment.com/doc/the-case-for-optimism-in-the-u-s-biosimilarmarket-0001. Similarly, a 2018 survey of 442 clinicians found 55% were unfamiliar with biosimilars.
See

ALEX BRILL

&

CHRISTY

ROBINSON,

MATRIX

GLOB. ADVISORS,

BIOSIMILAR

SAVINGS

OPPORTUNITIES IN THE MEDICAL BENEFIT: A LARGE-EMPLOYER CASE STUDY 3 n.8 (2019).
187.
PWC HEALTH RESEARCH INSTITUTE, REGULATORY SPOTLIGHT: GENERIC DRUG PRICING 8

(2018) (reporting that in an April 2018 survey of doctors that already prescribe biologics, 55% said
they did not prescribe any biosimilars because they are not familiar with them).
188.
See Kendra Cherry, What is Cognitive Bias?, VERYWELL MIND (July 19, 2020),
https://www.verywellmind.com/what-is-a-cognitive-bias-2794963.
189.
NORC, supra note 13, at 7-8; see also Loria, supra note 172 (noting rheumatologists indicate lack of cost savings for patients as an issue for not switching patients to biosimilar).
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B. Evidence of PatientBias Against Biosimilars
Studies also indicate patient bias against biosimilars. For example, in
a 2013 survey of over 3,000 diabetes patients, almost 20% indicated they
would be unlikely to or definitely would not use a biosimilar when told it
was a lower cost version akin to a generic. 90 Moreover, statements by the
subjects seem to reflect bias. For example, some noted that they considered a brand to indicate quality, effectiveness, and trustworthiness, with
one noting that because manufacturers spend money on research, that must
indicate it is the "best, safest, and fastest" product.191 One respondent
stated, "I would be concerned about quality" for a hypothetical insulin biosimilar.1 92
Although biosimilars are new to the United States, studies of patients
in Europe, where biosimilars have been available since 2006, also show
patient bias against biosimilars. For example, one study found that that the
vast majority of German patients treated with an originator biologic for
gastrointestinal issues were satisfied while a lower number of patients receiving a biosimilar were satisfied, including differing perceived control
of symptoms. 93 As with studies of doctors, patients were biased against
biosimilars even if they were more cost-effective.1 94 A study of French
rheumatology patients revealed that although 99% considered themselves
sensitive to medication cost, the vast majority (almost 80%) had some hesitancy to use biosimilars to reduce cost, often due to a misconception that
the lower cost meant lower quality. 95
Express bias against biosimilars seems to align with patients' willingness to switch from a brand to a biosimilar. In one study, a majority of
patients were concerned about quality and roughly 40% were concerned
about efficacy, safety, or both if they switched to a biosimilar.1 96 A subsequent study found that patients who refused to switch to a biosimilar to

190.

Alasdair R. Wilkins, Manu V. Venkat, Adam S. Brown, Jessica P. Dong, Nina A. Ran,
&

James S. Hirsch, & Kelly L. Close, Patient Perspectives on BiosimilarInsulin, 8 J. DIABETES SCI.
TECH. 23, 24 (2014). These numbers may undercount bias because biosimilars cannot be identical,

unlike generics.
191.
Id.
192.
Id. at 25. Another stated that "you get what you pay for .... " Id.
193.
See Emma Sullivan, James Piercy, John Waller, Christopher M. Black, & Sumesh Kachroo,
Assessing Gastroenterologistand PatientAcceptance of Biosimilarsin Colitis and Crohn'sDisease
Across Germany, PLOS ONE, Apr. 2017, at 7.

194.

See Ira Jacobs, Ena Singh, K. Lea Sewell, Ahmad AL-Sabbagh, & Lesley G. Shane, Patient

Attitudes and UnderstandingAbout Biosimilars: An Internal Cross-Sectional Survey, 10 PATIENT
PREFERENCE & ADHERENCE 937, 943-44 (2016).

195.
Lea Frantzen, Jean-David Cohen, Sonia Trope, Morgane Beck, Audrey Munos, Marie-Annick Sittler, Rita Diebolt, Isabelle Metzler, & Christelle Sordet, Patients'Information and Perspectives on Biosimilars in Rheumatology: A French Nation-Wide Survey, 86 JOINT BONE SPINE 491, 495

(2019).
196.

Id.
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treat their rheumatic disease all admitted a negative opinion of biosimilars.1 97
The nocebo effect is also present with biosimilars.1 98 There are a
number of studies that report patient discontinuation after switching to a
biosimilar based on purported lack of efficacy or vague side effects such
as fatigue and headache without observable changes in disease state, consistent with the nocebo effect.1 99 A systematic review found that the discontinuation rates were twice as high among patients who knew they were
switched to a biosimilar versus double-blinded studies where patients did
not know what treatment they were receiving. 200 This establishes a nocebo
effect even though studies do not always use this term.201 Patients switched
197.

Marc Scherlinger, Emmanuel Langlois, Vincent Germain, & Thierry Schaeverbeke, Ac-

ceptance Rate and SociologicalFactorsInvolved in the Switch from Originatorto BiosimilarEtanercept, 48 SEMINARS ARTHRITIS & RHEUMATISM 927, 929 (2019). In contrast, among patients willing

to switch, only 11% had a negative view of generics. Id.
198.
Not all agree that there is a documented nocebo effect. E.g., Roy Fleischmann, Vipul Jairath,
Eduardo Mysler, Dave Nicholls, & Paul Declerck, Nonmedical Switchingfrom Originatorsto Biosimilars: Does the Nocebo Effect Explain Treatment Failuresand Adverse Events in Rheumatology and
Gastroenterology?, 7 RHEUMATOLOGY THERAPEUTICS 35, 37 (2020) (concluding that although there

could be a nocebo effect, the studies to date are not rigorous enough to establish this conclusively).
Admittedly, biologics are scientifically complicated, such that there could potentially be more differences for individual patients and some of the diseases treated by biologics may be measured by arguably subjective criteria such as joint pain. See id. at 40. Nonetheless, given that the nocebo effect has
been well-documented to exist even with inert components, it seems logical that it would also exist
with biologics.
199.
See Avouac et al., supra note 181, at 747 (noting that more than 20% discontinued the
biosimilar and the majority of these asserted inefficacy even though there was no independently verifiable issue); M. Chaparro, A. Garre, M.R. Guerra Veloz, J. M. Vazquez Moron, M.L. De Castro, E.
Leo, E. Rodriguez, A. Y. Carbajo, S. Riestra, I Jimenez, X. Calvet, L. Bujanda, M. Rivero, F. Gomollon, J.M. Benitez, F. Bermejo, N. Alcaide, A. Guitierrez, M. Manosa, M. Iborra, R. Lorente, M.
Rojas-Feria, M. Barreiro-de Acosta, L. Kolle, M. Va Domselaar, V. Amo, F. Arguelles, E. Ramirez,
A. Morell, D. Bernardo, & J. P. Gisbert, Effectiveness and Safety of the Switch from Remicade to CTP13 in Patientswith Inflammatory Bowel Disease, 13 J. CROHN'S COLITIS 1380, 1384 (2019) (finding
a higher rate of relapse among IBS patients switched to a biosimilar even though there were no noted
medical differences between the groups, such that the researchers concluded the relapse was likely
due to nocebo effect); E.M.H. Schmitz, P.J. Boekema, J.W.A Straathof, D.C. van Renswouw, L.
Brunsveld, V. Scharnhorst, M.E.C. van de Poll, M.A.C. Broeren, & L.J.J. Derijks, Switchingfrom
Infliximab Innovator to Biosimilar in Patients with Inflammatory Bowel Disease, 47 ALIMENTARY
PHARMACOLOGY THERAPEUTICS 356, 359 (2017) (noting that one-quarter discontinued primarily due

&

to subjective higher disease activity or adverse events); Lieke Tweehuysen, Bart J.F. Van den Bemt,
Iris L. van Ingen, Alphons J.L. de Jong, Willemijn H. van der Laan, Frank H.J. van den Hoogen,
Alfons A. den Broeder, Subjective Complaints as Main Reason for BiosimilarDiscontinuationafter
Open Label Transitioningfrom Originatorto BiosimilarInfliximab, 70 ARTHRITIS RHEUMATOLOGY

60, 65-67 (2018) (finding no objective differences for those switched to an infliximab biosimilar, but
some subjective differences such as reported tenderness); see also Mourad F. Rezek & Burkhard Pieper, Treatment Outcomes with Biosimilars: Be Aware of the Nocebo Effect, 4 RHEUMATOLOGY
THERAPY 209, 212 (2017) (suggesting multiple study results indicate a nocebo effect).
200.
See Johlee S. Odinet, Chelsea E. Day, Jennifer L. Cruz, & Gregory A. Heindel, The Biosimilar Nocebo Effect? A Systematic Review of Double-Blinded Versus Open-Label Studies, 24 J.
MANAGED CARE & SPECIALTY PHARMACY 952, 952 (2018) (finding that discontinuation for any rea-

son was 14.3% for open-label studies versus 6.95% for double-blinded studies, and discontinuation
for adverse effects was 5.6% in open-label studies versus 3.1% in double-blinded studies for multiple
types of biosimilars).
201.
E.g., Christopher J. Edwards, Jana Hercogova, Helene Albrand, & Aurelian Amiot, Switching to Biosimilars: CurrentPerspectivesin Immune-MediatedInflammatory Diseases, 19 EXPERT OP.
BIOLOGICAL THERAPY 1001, 1003 (2019); Anna La Noce & Marcin Ernst, Switching from Reference
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back to original therapy "improved," consistent with removal of the
nocebo effect. 202 Along similar lines, new patients started on a biosimilar
have similar discontinuation rates as those started on an originator biologic, suggesting that the nocebo effect explains the observational studies
finding more discontinuation and alleged subjective problems with biosimilars. 20 3 Indeed, after reviewing the literature, a group of European clinicians from multiple fields concluded that the nocebo effect is underrecognized. 20 4
The nocebo effect is particularly likely in switching cases (from originator biologic to biosimilar) as opposed to patients new to biologics. First,
some patients may be opposed to switching based on a past negative experience with generics. 205 In addition, patients often desire to remain on a
familiar medication, consistent with loss aversion, which requires the potential benefit of switching to be two times greater; this is impossible because a biosimilar should simply provide the same benefit as the corresponding originator biologic. 206 The nocebo effect is especially likely with
biologics that treat serious conditions where it is common for patients to
have tried several different previous treatments that did not work or had
severe side effects. 207 In one survey, a substantial number of patients noted
that if switched to a biosimilar, they would be more attentive to changes
concerning safety and efficacy.208 This increased attention might prompt a

to BiosimilarProducts:An Overview of the EuropeanApproach and Real-World Experience So Far,

3 EUR. MED. J., 74, 79 (2018) (discussing several studies yielding discontinuation and suggesting the
nocebo effect may be at play); Mourad F. Rezk & Burkhard Pieper, To See or NOsee: The Debate on
the Nocebo Effect and Optimizingthe Use ofBiosimilars,35 ADVANCES THERAPY 749, 750-51 (2018)

(discussing the various studies that have explored the phenomenon).
202.
See Avouac et al., supra note 181, at 747; Fleischmann et al., supranote 198, at 56.
203.
See Hans C. Ebbers & Huub Schellekens, Are We Ready to Close the Discussion on the
InterchangeabilityofBiosimilars?,24 DRUG DISCOVERY TODAY 1963, 1966 (2019).

204.
205.

See Pouillon et al., supranote 26, at 1181.
See Vincent Haghnejad, Catherine Le Berre, Yoann Dominique, Camille Zallot, Francis
Guillemin, & Laurent Peyrin-Biroulet, Impact of a MedicalInterview on the Decision to Switch from
OriginatorInfliximab to its Biosimilarin Patientswith Inflammatory Bowel Disease, 52 DIGESTIVE

& LIVER DISEASE 281, 286-87 (2019) (finding patients who objected to switching reported lower
overall satisfaction with past generics).
206.
See Chiara Gasteiger, Maria Lobo, Nicola Dalbeth, & Keith J. Petrie, Patients'Beliefs and
Behaviours are Associated with Perceptions of Safety and Concerns in a Hypothetical Biosimilar
Switch, 41 RHEUMATOLOGY INT'L 163, 164 (2020) (a patient who has been using a brand medicine

may be reluctant to switch as opposed to a patient who is new to a treatment); see also sources cited
supra notes 135, 138 and accompanying text (discussing loss aversion).
207.

E.g.,

GLOB. HEALTHY LIVING

FOUND., PATIENT PERSPSECTIVES

ON

MEDICATION

SWITCHING FOR NON-MEDICAL REASONS 3 (2015), https://www.SOstatenetwork.org/wp-content/up-

loads/2015/04/GHLF-Switching-Stable-Patients-SurveySummary.pdf (finding some patients are reluctant to try any new treatment for fear that their condition could worsen, even if existing treatment
is not ideal); Yomei Shaw, Illinca D. Metes, Kaleb Michaud, Julie M. Donohue, Mark S. Roberts,
Marc C. Levesque, & Judy C. Chang, Rheumatoid Arthritis Patients'Motivationsfor Accepting or
Resisting Disease-Modifying Antirheumatic Drug Treatment Regimens, ARTHRITIS CARE & RSCH.

June 2018, at 7-8.
208.
See Frantzen, supra note 195, at 495 (providing results of French study surveying patients
who suffer from rheumatoid arthritis).
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nocebo effect. 209 Moreover, to the extent that a patient must switch to a
biosimilar due to insurance coverage reasons, the nocebo effect is particularly likely to be triggered. Studies find patients indicate more adverse
effects and allege diminished efficacy when switched to a biosimilar for
cost as opposed to when they are switched for clinical reasons.21 0
C. How OriginatorBiologics Benefitfrom the Biosimilars Bias
This Section evaluates the extent to which originator biologic manufacturers economically benefit from a bias against biosimilars, explaining
their interest in perpetuating the bias. The U.S. biologics market is valued
at $211 billion 21' and constitutes 60% of global biologic sales.21 2 Originator biologics account for most of these sales because only 19% of originator biologics face biosimilar competition in the United States. 213 Moreover, the market for biologics is rapidly expanding, increasing over 14%
annually since 2014.214
The U.S. pharmaceutical market is of particular interest to originator
biologic manufacturers because it is the largest.21 5 Strong profits in the
United States exist because, unlike other countries, the United States does
not control prices and the federal government is barred from negotiating

209.
See supra notes 154-57 and accompanying text (discussing nocebo effect when patients
believe they are taking the nonbrand drug); see also Fabrizio Cantini, Laura Niccoli, Giulia Franchi,
Arianna Damiani, & Maurizio Benucci, The Nocebo Effect in Rheumatology: An Unexplored Issue,

22 ISR. MED. ASS'N J. 185, 188-89 (2020) (concluding that the nocebo effect could cause treatment
failures in patients switched to biosimilars to treat inflammatory rheumatic diseases).
210.
See Elaine Nguyen, Erin R. Weeda, Diana M. Sobieraj, Brahim K. Bookhart, Catherine Tak
Piech, & Craig I. Coleman, Impact of Non-Medical Switching on Clinical and Economic Outcomes,
Resource Utilization andMedication-TakingBehavior: A Systematic LiteratureReview, 32 CURRENT
MED. RSCH. & OP. 1281, 1283 (2016) (finding almost 70% experienced negative outcomes); see also

Douglas Wolf, Martha Skup, Hongbo Yang, Anna P. Fang, Andrew Kageleity, Jingdong Chao, Manish Mittal, & Mark Lebwohl, Clinical Outcomes Associated with Switching or Discontinuationfrom
Anti-TNF Inhibitorsfor Nonmedical Reasons, 39 CLINICAL THERAPEUTICS 849, 853 (2017) (finding

that the majority of stable patients treated with anti-TNF who were switched for economic reasons had
problems with disease control while the vast majority of those unswitched had well-controlled symptoms); Avouac et al., supranote 181, at 747 (finding that among patients at a French hospital switched
to a biosimilar of infliximab, there were no differences in objective measurements, although some
patients asserted differences, consistent with the nocebo effect); Richard H. Parrish II, BiosimilarInterchangeabilityand Emerging Treatment Strategiesfor Inflammatory Bowel Diseases: A Commentary, GASTROENTEROLOGY INSIGHTS 293, 296 (2021) (noting studies showing higher discontinuation

rates for patients switched to biosimilars for nonmedical reasons).
211.
See IQVIA, supra note 1, at 3.
212.

DENIS KENT,

SARAH RICKWOOD,

& STEFANO DI BIASE, IQVIA, DISRUPTION AND

MATURITY: THE NEXT PHASE OF BIOLOGICS 21 (2017).

213.
214.

See IQVIA, supra note 1, at 4, 9.
Id. at 3; see also Ying Chen, Alex Monnard, & Jorge Santos da Silva, An Inflection Point
for Biosimilars, MCKINSEY & CO. (June 7, 2021), https://www.mckinsey.com/industries/life-sciences/our-insights/an-inflection-point-for-biosimilars (noting that the global market is estimated to
continue double-digit growth to double in size by 2025).
215.

E.g., Matej Mikulic, Distribution of the Total Global PharmaceuticalMarket, STATISTA

(Mar. 9, 2021), https://www.statista.com/statistics/266547/total-value-of-world-pharmaceutical-market-by-submarket-since-2006 (noting that the United States accounts for 48% of total global pharmaceutical sales).
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lower prices for Medicare. 216 Recent proposed legislation to permit Medicare to engage in price negotiations for biologics has stalled. 217 It is not
surprising that the biosimilar market is currently underdeveloped given
that structural incentives in U.S. law do not promote the use of lower cost
biosimilars. In addition, originator biologic manufacturers have entered
into anticompetitive agreements with biosimilar manufacturers to prevent
FDA-approved biosimilars from entering the market218 and have entered
contracts with insurance companies that mandate patients "fail first" on
the originator biologic before biosimilar use can be authorized. 219
The lucrative market in the United States works as a major incentive
for companies to advance biases through marketing in the United States.
As a result, U.S. doctors and consumers may be especially vulnerable to
being exposed to marketing that exacerbates bias against biosimilars. The
next Part explains how originator biologics capitalize on structural differences in the United States.
III. FACTORS PERPETUATING BIAS AGAINST BIOSIMILARS

This Part turns to factors that perpetuate bias against biosimilars and
explains why bias is more problematic for biosimilar uptake than for
216.
See 42 U.S.C. § 1395w-111(h)(i)(1) (barring government interference in negotiation between drug manufacturers and pharmacies on prices under Medicare Part D, which covers drugs dispensed from pharmacies); see also Rena M. Conti, Francis J. Crosson, Allan Coukell, & Richard G.
Frank, Reform Medicare PartB to Improve Affordability and Equity, HEALTH AFFS. (June 25, 2021),
https://www.healthaffairs.org/do/10.1377/hblog20210622.349716/full (noting no price controls in the
United States and recommending that Medicare be permitted to negotiate prices because negotiation
estimated to save $456 billion over a decade).
217.
The House passed legislation that includes Medicare price negotiation for biologics. See
Build Back Better Act, H.R. 5376, 117th Cong. § 139001I (2021) (as passed by the U.S. House of
Representatives on Nov. 19, 2021); Juliette Cubanski, Tricia Neumann, & Meredith Freed, Explaining
the PrescriptionDrug Provisionsin the Build Back Better Act, KAISER FAM. FOUND. (Nov. 23, 2021),
https://www.kff.org/medicare/issue-brief/explaining-the-prescription-drug-provisions-in-the-buildback-better-act (noting that the pending legislation would create an exception to current law regarding
Medicare Part D that would permit the government to negotiate prices for a small number of the most
expensive drugs starting in 2025 and for Part B starting in 2027). Some have criticized this provision
as permitting not price negotiation, but mandatory price reduction. See Jonathan Weisman & Emily
Cochrane, Democrats Add Drug Cost Curbs to Social Policy Plan, Pushingfor Vote, N.Y. TIMES

(Nov. 6, 2021), https://www.nytimes.com/2021/11/02/us/politics/prescription-drug-prices-medicare.html; see also Elizabeth Bauer, The PrescriptionDrug PriceNegotiation Plan in the Biden BBB
Bill
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FORBES
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6,

2021,

6:18

PM),

https://www.forbes.com/sites/ebauer/2021/ 11/06/the-prescription-drug-price-negotiation-plan-in-thebiden-bbb-bill-is-not-what-its-claimed-to-be. However, the biggest issue is whether this bill will pass.
Alexander Bolton, Biden 's Build Back Better Suddenly In Serious Danger, THE HILL (Dec. 16, 2021,

1:34 PM), https://thehill.com/homenews/senate/586147-bidens-build-back-better-bill-suddenly-in-serious-danger.
218.
Eric Grannon & Adam M. Acosta, FTC and FDA Announce Plansto CombatAnticompetitive Practicesin the "Biologic Marketplace," WHITE & CASE (Feb. 12, 2020), https://www.white-

case.com/publications/alert/ftc-and-fda-announce-plans-combat-anticompetitive-practices-biologicmarketplace.
219.
See Van de Wiele et al., supra note 6, at 1202 (noting settlements from litigation); see also
Tony Hagen, PfizerResolves Antitrust Lawsuit with J&J OverRemicade, CTR. FOR BIOSIMILARS (July

22, 2021), https://www.centerforbiosimilars.com/view/pfizer-resolves-antitrust-lawsuit-with-j -j-overremicade; Stanton Mehr, Contracting 'Schemes' to Prevent BiosimilarInfliximab Access: Let's Drop
the

Feigned

Outrage, BIOSIMILARS

REV.

&

REP.

(July

larsrr.com/2018/07/18/contracting-prevent-biosimilar-infliximab-access.

18,

2018),

https://biosimi-
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generic uptake given legal and structural differences. This Part begins by
explaining the contribution of U.S. regulatory laws and policies to bias and
then turns to direct actions by companies,220 in conjunction with patient
groups, that improperly emphasize differences and perpetuates bias. Finally, this Part highlights current financial disincentives against biosimilars as well as how cognitive biases exacerbate mismarketing efforts to
sustain an unnecessary bias against biosimilars.
A. U.S. Law
There are several aspects of U.S. law that may promote unnecessary
bias against biosimilars. As discussed earlier, the United States is the only
country that: (1) requires an additional regulatory designation of interchangeability to permit pharmacy substitution of biologics and (2) requires
that a biosimilar have a different nonproprietary name than its related originator biologic. 22' These differences make it challenging to substitute a biosimilar for an originator biologic, challenges not faced by generics. The
differences can also be improperly utilized to promote the perception that
biosimilars are inferior.
1. Interchangeability Designation and State Laws
The existence of an interchangeability designation inherently promotes a bias against biosimilars not designated as interchangeable. Because generics do not need such a designation to be substituted, doctors
and patients may mistakenly believe that only interchangeable biosimilars
can be safely used-as highlighted in the discussion about doctor and patient bias against biosimilars. 2 2 A separate interchangeable designation
was proposed in initial U.S. legislation concerning a biosimilar pathway
and likely reflects scientific differences between biologic and traditional
drugs. 223 The designation was in part due to hesitancy concerning whether
biosimilars should be substituted without doctor intervention.224
220.
This Part treats patients and doctors as broad groupings although there are of course differences within each of these groups. See Sarnola et al., supranote 178, at 17 (noting that men and those
more familiar with brand name drugs were less likely to use biosimilars).
221.
See supra note 66 and accompanying text (U.S. interchangeability designation is unique);
Zachary Brennan, CanadaSteersAway From UsingSuffixes in Biologics'Names,REGUL. AFFS. PROS.

SOC'Y (Feb. 18, 2019) https://www.raps.org/news-and-articles/news-articles/2019/2/canada-steersaway-from-using-suffixes-in-biosimil (noting U.S. naming convention is unique in the world); see
also Brad Jordan, U.S. Biologics andBiosimilarsNeedDistinguishableNames, STAT (Apr. 23, 2019),

https://www.statnews.com/2019/04/23/biologics-biosimilars-distinguishable-names (comparing U.S.
approach to other countries' approaches as well as justification for different views).
222.
See discussion supra Sections IIA-B (discussing the bias against biosimilars).
223.
See Krista Hessler Carver, Jeffrey Elikan, & Erika Lietzan, An Unofficial Legislative History of Biologics Price Competition and InnovationAct of 2009, 65 FOOD & DRUG L. J. 671, 700-01,
720 (2010) (discussing legislative history of interchangeability bills and noting the Center for Drug
Evaluation & Research's 2003 concern questioning absolute therapeutic interchangeability between
originator drugs and their subsequent biologics).
224.
Id. at 733-34 (noting that there were competing views concerning whether interchangeability was appropriate including that the EU had noted that biosimilars were different than generics).
Even in 2017 when the FDA considered standards for how to demonstrate interchangeability, some
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However, today, global practice indicates no need to be cautious in
using biosimilars not labeled as interchangeable. There have been over
14,000 successful switches from an originator biologic to a biosimilar
without this designation,2 5 in addition to a plethora of rigorous double-blinded studies showing no problems with switching patients to biosimilars.22 6 Based on strong indications of biosimilar safety, Australia relaxed the considerations required to recommend substitution of a biosimilar.227 Also, beyond laws to promote automatic substitution, based on current science, some have suggested that all EU-approved biosimilars should
be considered clinically interchangeable after a decade of unproblematic
use. 228 Even in the United States, some have suggested that at least for
insulin, the interchangeability standard should be waived because typical
concerns with biologics, such as immunogenicity, have not been an issue.229

In contrast to the global trend towards promoting biosimilar use and
despite the interchangeable designation that allows for biosimilar substitution, U.S. state laws make substitution more difficult-dissimilar to state
laws that promote generic use. 230 Most states have laws limiting substitution to only biosimilars deemed interchangeable, which requires substantially more clinical data beyond that required for a biosimilar not classified
as interchangeable. 23' These laws make substitution less likely by requiring notice to doctors and patients and by sometimes permitting objection
to substitution. 232 Beyond notification requirements, some state laws impose burdensome record keeping requirements that may further disincentivize substitution of a biosimilar. 233 Notably, these requirements were
physicians remained concerned about interchangeability. See Jackie Syrop, PhysiciansExpress Concerns About Biosimilar Interchangeability to FDA, AM. J. MANGAGED CARE (June 30, 2017),

https://www.centerforbiosimilars.com/view/physicians-express-concerns-about-biosimilar-interchangeability-to-fda; see also GaBI J. Ed., PhysicianAssociations Comment on FDA 's interchangeability Guidance, 6 GENERICS & BIOSIMILARS INITIATIVE J., June 2017, at 120-21 (summarizing physician comments to FDA concerning interchangeability guidance).
225.
BIOSIMILARS FORUM, supra note 81, at 8.
226.
See supranote 181 and accompanying text.
227.

See AUSTL. GOV'T DEP'T OF HEALTH, PUBLIC SUMMARY DOCUMENT-MARCH 2018 PBAC

MEETING, Mar. 2018, at 3 (noting no safety issues in EU since first biosimilar registration in 2006 as
well as published studies showing no issues with switching patients to biosimilar).
228.
See Kurki, supra note 66, at 84; MEDICINES FOR EUROPE, POSITIONING STATEMENTS ON
PHYSICIAN-LED SWITCHING FOR BIOSIMILAR MEDICINES, Sept. 2020, at 4; Ebbers & Schellekens,
supra note 203, at 1963.
229.
Mariana P. Socal & Jeremy A. Greene, InterchangeableInsulins- New PathwaysforSafe,
Effective, Affordable DiabetesTherapy, 382 NEW ENG. J. MED. 981, 981-82 (2020).
230.
E.g., Aaron Hakim & Joseph S. Ross, Obstacles to the Adoption ofBiosimilarsfor Chronic
Diseases, 317 J. AM. MED. ASS'N 2163-64 (2017); Katherine Macfarlane, Camouflaging State BiosimilarLaws as Pro-PatientLegislation, 26 ANNALS HEALTH L. 52, 58-59 (2017).
231.
See Richard Cauchi, State Laws and LegislationRelatedto Biologic Medications and Substitution of Biosimilars, NAT'L CONF. OF STATE LEG. (May 3, 2019), http://www.ncsl.org/re-

search/health/state-laws-and-legislation-related-to-biologic-medications-and-substitution-of-biosimilars.aspx.
232.

Id.

233.
See id. The first state-level biosimilar legislation making substitution complicated was opposed by pharmacists concerned about "too much red tape for substitution." See Macfarlane, supra
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generally imposed not because of scientific concerns, but because of extensive lobbying by self-interested brand companies. 234
2. Nonproprietary Naming
The United States has a distinct naming regulation for biosimilars that
may further suggest to doctors and patients that biosimilars are different
and suspect. Unlike generic drugs, which share the exact nonproprietary
(i.e., not trademarked) name as the related brand drug, biosimilars do not
share an identical nonproprietary name with the originator biologic. For
example, the brand drug Nexium, commonly used to treat heartburn, has
the identical nonproprietary name, esomeprazole, as all generic versions
of the drug. 23s In contrast, the United States requires that biosimilars use a
four-letter random suffix unrelated to the manufacturer name.236 For example, the originator biologic Remicade has the nonproprietary name "infliximab," whereas biosimilars include "infliximab-dyyb" and "infliximab-abda." 237
Different names for biosimilars and their corollary originator biologics suggests caution and skepticism concerning biosimilars. Indeed, the
FTC previously cautioned this could result in unnecessary costs by improperly signaling a false distinction to doctors and patients. 238 Moreover,
given that there remains some bias against generics despite identical
nonproprietary names, those with an existing bias against generics are especially likely to be biased against biosimilars named differently than originator biologics. 239
The FDA's rationale for using distinct names does not align with promoting biosimilar use. The FDA has stated that different names were
needed to track adverse events, prevent inadvertent substitution by
note 230, at 66; see also Norman V. Carroll, Jack E. Fincham, & Fred M. Cox, The Effects of Differences in State Drug Product Selection Laws on Pharmacists'Substitution Behavior, 25 MED. CARE

1069, 1069 (1987) (finding more substitution in states that did not require additional record keeping
and did not require patient consent).
234.
See Macfarlane, supra note 230, at 66-67.
235.

Generic Nexium Availability, DRUGS.COM, (Jan. 12, 2022), https://www.drugs.com/availa-

bility/generic-nexium.html.
236.
HHS, FDA, CDER, & CBER, NONPROPRIETARY NAMING OF BIOLOGICAL PRODUCTS:
GUIDANCE FOR INDUSTRY 5-6 (2019) (draft guidance document) [hereinafter 2019 DRAFT NAMING
GUIDANCE]. In the 2019 draft guidance document, the agencies reversed their prior guidance that
originator biologics should be given suffixes retroactively upon approval. Id. at 5.
237.
Infliximab (Rx), MEDSCAPE, https://reference.medscape.com/drug/remicade-inflectra-infliximab-343202 (last visited Mar. 21, 2022); see also Nancy J. Globus, Alphabet Soup: The Story
BehindBiosimilarName Suffixes, AM. J. MANAGED CARE (Aug. 8, 2020), https://www.centerforbiosimilars.com/view/alphabet-soup-the-story-behind-biosimilar-nonproprietary-name-suffixes (explaining naming for biosimilars).
238.
Fed. Trade Comm'n, Comment onHHS and FDA's Guidance for Industry onthe "Nonproprietary Naming of Biologic Products; Draft Guidance for Industry; Availability," at 2-3 (Oct. 27,
2015); see also Suffix v. Non Suffix: Naming Biosimilars, AAM: BIOSIMILARS COUNCIL (Oct. 21,

2019), https://biosimilarscouncil.org/resource/naming-biosimilars-suffix (stating that different naming may improperly suggest biosimilars are not as safe and effective as originators and thus, negatively
impact biosimilar use).
239.
See discussion supra Section IC; Gasteiger et al., supranote 206, at 163 (noting that biosimilar naming affects patients' perceptions of whether biosimilars are appropriate).
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pharmacists, and ensure doctors do not inadvertently assume biosimilars
are interchangeable. 240 However, adverse event tracking does not require
distinct nonproprietary names; in reality, virtually all adverse event reports
involving biologics use brand names. 24' Indeed, Europe has a much longer
and more extensive use of biosimilars with identical nonproprietary names
and uses brand names for all biologics, including biosimilars, without negative health outcomes. 242 In addition, pharmacists are unlikely to make inadvertent substitutions given that they already rely on the FDA-published
Orange Book to see if a generic can be safely substituted, and there is no
basis for assuming they would make improper assumptions for biolog2.43
*
ics.24

B. Beyond Regulatory Issues
1. Advertising and Promotion Exacerbate Bias Against Biosimilars
This Section explores how marketing and social media campaigns
capitalize on U.S. regulatory oddities and other issues to establish and perpetuate bias against biosimilars. This Section focuses on three issues that
perpetuate bias against biosimilars by activating the availability bias that
all individuals are susceptible to. The first misleading issue is that biosimilars are not scientifically identical. The second misleading issue involves
aspects of U.S. law where biosimilars are treated differently than generics.
The third misleading issue concerns overhyped dangers of switching to a
biosimilar. The power of these messages has been underscored by similar
messages from patient advocate groups, 244 many of which are funded by
pharmaceutical companies.24s

240.
HHS, FDA, CDER & CBER, NONPROPRIETARY NAMING OF BIOLOGICAL PRODUCTS:
GUIDANCE FOR THE INDUSTRY 4-5 (2017) [hereinafter 2017 DRAFT NAMING GUIDANCE].

241.

Fed. Trade Comm'n, supra note 238, at 13.

242.

EMA & EUR. COMM'N, supra note 67, at 24-26; see also AUSTL. GOV'T DEP'T OF HEALTH,

supra note 227227, at 2-3 (noting Australia's use of the same name without suffix).
243.
Fed. Trade Comm'n, supra note 238, at 14. Moreover, a different name for interchangeable
biosimilars could prevent pharmacists from substituting it for the equivalent biologic due to state laws
that require the identical name for automatic substitution. Id. at 14 n.52.
Patient groups have a history of advancing pharmaceutical industry interests. See Emily
244.
Kopp & Rachel Bluth, Nonprofit Linked to PhRAL4 Rolls Out Campaign to Block Drug Imports,
KAISER HEALTH NEWS (Apr. 19, 2017), https://khn.org/news/non-profit-linked-to-phrma-rolls-out-

campaign-to-block-drug-imports (noting a patient group's opposition to drug importation legislation
in sync with pharmaceutical lobbying group PhRMA); see also Susannah L. Rose, PatientAdvocacy
Organizations:InstitutionalConflicts ofInterest, Trust and Trustworthiness, 41 J. L. MED. & ETHICS
680, 682 (2013) (noting a nonprofit group for mental health promoted use of antidepressants and
downplayed risk of suicide consistent with industry). At the extreme, a drug company succeeded in
using a seemingly grassroots campaign to promote a drug previously rejected to treat low desire in
women that had been deemed dangerous. Ray Moynihan, Commentary: The Voice of the People,
FundedNow by Your FriendlyPharmaceuticalCompany, 17 BIOETHICAL INQ. 61, 61 (2020).

245.
E.g., Alice Fabbri, Lisa Parker, Paola Mosconi, Giussy Barbara, Maria Pina Frattaruolo,
Edith Lau, Cynthia M. Kroeger, Carole Lunny, Douglas M. Salzwedel, & Barbara Mintzes, Industry
FundingofPatientand Health Consumer Organisations:Systematic Review with Meta-Analysis, 368

BRIT. MED. J., Dec. 2020, at 9, 11 (finding industry funding of patient advocacy groups is common,
yet fewer than 30% of these groups typically disclose this funding on their websites); Rose, supra note
244, at 681 (noting conflict of interest problems); Emily Kopp, Sydney Lupkin, & Elizabeth Lucas,
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a. Capitalizing on the Nonidentical Nature of Biosimilars
Manufacturers of originator biologics repeatedly highlight scientific
differences when promoting a bias against biosimilars. For example,
Genentech's website states that the FDA requires a biosimilar to be "very
similar to the original medicine, but not identical [to the reference product]." 246 Additionally, there is substantial discussion of how biosimilars
are not generics, which can play upon the existing bias against generics. 247
For example, an article posted on Genentech's website highlights a quote
in large font: "[E]ven with the most advanced technologies, scientists can't
make exact copies of biologics. That's why they're called biosimilars." 248
These statements are correct, yet misleading. It is of course true that
biosimilars are not identical copies. 249 However, the FDA and other agencies approve these highly similar, albeit not identical, drugs because they
are considered just as safe and effective as their comparable biologics.s0
What marketing suggests is a flaw is in fact the intended goal of the system. As explained earlier, even different batches of biologics from the
originator company are not identical such that focusing on identity is inappropriate. Moreover, some doctors, scientists, and policymakers outside
the United States do consider biosimilars to be medically interchangeable
with the originator biologics.2 s' Nonetheless, these misleading statements
are likely believed by patients who have an existing bias against generics,
leading them to be especially suspicious of biosimilars that are not identical, unlike generics. 2 Even for those without an existing bias against generics, hearing these distorted truths frequently repeated by drug companies and patient advocacy groups establishes an availability bias. 2s3
b. Capitalizing on Legal Distinctions of Interchangeability and
Different Names
A related issue is a repeated yet misleading suggestion that a biosimilar is unsafe if it is not interchangeable. For example, Janssen, maker of
originator biologic Remicade, issued a brochure in 2017, two years before
the FDA set requirements for what would be interchangeable, that

PatientAdvocacy Groups Take in Millionsfrom Drug Makers. Is there a payback?, KAISER HEALTH

NEWS (Apr. 6, 2018), https://khn.org/news/patient-advocacy-groups-take-in-millions-from-drugmakers-is-there-a-payback (noting that in 2015, donations to these groups were slight compared to the
amount that companies spent on federal lobbying).
246.
UnderstandingBiosimilars, GENENTECH (June 1, 2017), https://www.gene.com/stories/understanding-biosimilars.
247.
See discussion supra Section IC.
248.

Myriam Mendila, Similar, Not the Same; The Road Ahead for Biosimilars, GENENTECH

(June 2, 2016), https://www.gene.com/stories/similar-not-the-same-the-road-ahead-for-biosimilars.
249.
See, e.g., sources cited supra note 55.
250.
See, e.g., sources cited supra note 38-39.
251.
E.g., Ebbers & Schellekens, supra note 203, at 1963-64; Afzali et al., supra note 66, at
2080-81 tbl.2.
252.
See discussion supra Section I.C.2.
253.
See discussion supra Section IIB.i.
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emphasized that no biosimilar has met the requirements for interchangeability. 5 4 The current Remicade website still states that no Remicade biosimilar is interchangeable. 5 5 Although legally true, it improperly suggests
a problem with biosimilars to Remicade.2 s6 This is especially disingenuous
because all biosimilars to Remicade are administered by infusion257 such
that it could not be dispensed at a pharmacy-the only setting where interchangeability is relevant. 258 Discussion of interchangeability to Remicade is a red herring.
Another misleading marketing document suggests that only interchangeable biosimilars are safe with the heading "high standards should
be non-negotiable" before the discussion of interchangeability. 2 s9 This
section is misleading as it states, "substitution of a biosimilar in place of
an original biologic medicine should only occur ifthe biosimilar is deemed
interchangeable by the FDA," 26° which suggests that interchangeability is
always an issue. However, only a minority of current biosimilars could be
interchangeable because the majority are not sold in pharmacies. 261 Interestingly, companies do not mention that scientific studies to date have
found no problems resulting from the same type of multiple switching between a biosimilar and its biologic that would be used to seek interchangeable status for such biosimilars. 262
Statements by associations may also suggest that interchangeability
is important based on statements made by individuals that are associated
with originator biologics. For example, when the FDA approved the first
biosimilar to Remicade, the Spondylitis Association for America, which
advocates for patients, 263 issued a statement that included a quote from
Johnson & Johnson that the newly approved biosimilar, Inflectra, was not
254.
See Pfizer, Citizen Petition to Request that the FDA Issue Guidance to Ensure Truthful and
Non-Misleading Communications by Sponsors Concerning the Safety and Effectiveness of Biosimilars, Including Interchangeable Biologics, Relative to Reference Product(s), at 8 (Aug. 22, 2018),
https://www.regulations.gov/document/FDA-2018-P-3281-0001 (noting that biosimilar Inflectra is
not interchangeable, and no biosimilar to Remicade has established interchangeability).
255.
BiosimilarsFAQ, REMICADE, https://www.remicade.com/additional-resources.html#biosimilar (last visited Feb. 6, 2022).
256.
Pfizer, supra note 254, at 8.
257.
E.g., Infliximab, CROHN'S & COLITIS UK, at 8 (2021), http://s3-eu-west-1.amazonaws.com/files.crohnsandcolitis.org.uk/Infliximab_Ed_8b_Nov_2021_.pdf (explaining that all versions of infliximab are administered by infusion or injection).
258.
See supra notes 59-60 and accompanying text (explaining that interchangeability only applies to biosimilars dispensed by pharmacies).
259.
Mendila, supra note 248.
260. Id.
261.
See discussion supra Section I.A.2.
262.
See A. Blauvelt, J.-P. Lacour, J.F. Fowler Jr., J.M. Weinberg, D. Gospodinov, E. Schuck,
J. Jauch-Lembach, A. Balfour, & C.L. Leonardi, Phase III Randomized Study of the ProposedAdalimumab Biosimilar GP2017 in Psoriasis:Impact of Multiple Switches, 179 BRIT. J. DERMATOLOGY
623, 623 (2018); see also Hiroaki Matsuno & Tsukasa Matsubara, A Randomized Double-BlindParallel-Group PhaseIII Study to Compare the Efficacy and Safety ofNI-071 and Infliximab Reference
Product in Japanese Patients with Active Rheumatoid Arthritis Refractory to Methotrexate, 29
MODERN RHEUMATOLOGY 919, 924 (2018).
263.
Our Mission & Vision, SPONDYLITIS ASS'N OF AMERICA, https://spondylitis.org/about-

saa/our-mission-vision (last visited Mar. 21, 2022).
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approved as interchangeable. 264 The press release also quoted a doctor stating that the approval does not have any language or data "that would allow
forced change from Remicade use." However, the FDA only has authority
to approve drugs and cannot force patients to change drugs.
There is some evidence that doctors are responding to this marketing.
A 2020 study found that the vast majority (86%) of U.S. rheumatologists
already prescribing biologics thought that it was very important for a label
to indicate whether a biosimilar is interchangeable despite the designation
only applying to biosimilars dispensed at a pharmacy. 26s Notably, unlike
some prior studies, most of these doctors (83%) asserted that they were
very or extremely familiar with the fact that biosimilars have no clinically
meaningful differences. 266 Although the study suggested that doctors may
not truly understand the biosimilar definition they allege to be familiar
with, an alternative theory is that they are influenced by marketing. Importantly, the doctors surveyed prescribed a type of biologic not available
to patients for purchase at a pharmacy, making the interchangeability designation irrelevant.267 Marketing that suggests that interchangeability is
important, even for biologics that are not available at a pharmacy, could
be misleading these doctors.
Companies have also suggested that different nonproprietary names
between an originator and biosimilar suggest key differences, reinforcing
biosimilar bias. A 2018 tweet by Amgen stated, "While #biosimilars may
be highly similar to their #biologic reference products, there's still a
chance that patients may react differently. See what you 're missing without
the suffix[.]" 268 Technically, even with generic drugs that, by definition,
have identical active ingredients, patients may react differently because of
inactive ingredients, the approved range of bioequivalence, or both. 269
Nonetheless, a patient seeing the tweet could easily assume that a lack of
a suffix or a different suffix is very important.270 Indeed, one study
264.

FDA Approves the First Biosimilar Medication for Ankylosing Spondylitis and Psoriatic

Arthritis, SPONDYLITIS ASS'N OF AM., https://spondylitis.org/research-new/fda-approves-the-first-biosimilar-medication-for-ankylosing-spondylitis-and-psoriatic-arthritis (last visited Mar. 21, 2022).
265.
Allan Gibofksy & Dorothy McCabe, US Rheumatologists' Beliefs and Knowledge about
Biosimilars: A Survey, 60 RHEUMATOLOGY 896, 898 (2020) ("86% [of study respondents] felt it im-

portant/very important for interchangeable approval to be on the label.").
266.
Id. About three-quarters of these doctors considered effectiveness to be either the most important or second most important factor in considering whether to use a biosimilar, although this
seemed only a considerationfor patients starting biologic treatment, as opposed to those already doing
well on the reference product. Id. at 898-900.
267.
Id. at 896 (noting surveyed doctors prescribed TNF inhibitors).
268.
See Ned Pagliarulo, Pfizer Calls Out Pharma Peers for 'Scare Tactics' on Biosimilars,
BIOPHARMADIVE (Aug. 29, 2018) (emphasis added) (reporting on the April 13, 2018 tweet).
269.
See Jacinthe Leclerc, Claudia Blais, Louis Rochette, Denis Hamel, Line Gudnette, & Paul
Poirier, Impact of the Connercbization of Three Generic Angotensin II Receptor Blockers on Adverse Evns in Quebec, Canada:
Population-Based Time Series nalysis, 10 CIRCULATION:
CARDIOVASCULAR QUALITY & OUTCOMES, Oct. 2017, at 7.

270.
See Association for Accessible Medicines, Comments of the Association for Accessible
Medicines and the Biosimilars Council onBehalfof Our Member Companies: Nonproprietary Naming
of Biological Products, at 4 (May 7, 2019) (noting FDA's concernthat suffixes could be misinterpreted
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indicates individuals shown a print advertisement for a fictitious biosimilar with a nonproprietary name that included a suffix were less likely to
use the biosimilar compared to the originator with no suffix. 27' Although
study participants were told that the biosimilar had no meaningful differences in terms of efficacy, safety, and purity, the suffix distinction nonetheless created bias. 272
c. Overhyping Dangers of Switching to Biosimilars
In addition to the foregoing issues, companies have made statements
to discourage switching from the originator biologic to its biosimilar by
framing it as risky despite the robust regulatory approval process that contemplates such a switch. For example, an alliance of companies warned
biosimilars could "put you in the emergency room" even though biosimilars are only approved if they have no clinically meaningful differences
from the originator biologics. 273 Even worse, the chairman of Biotechnology Innovation Organization's (BIO) international advisory board suggested that moving patients to biosimilars should be approached cautiously "so we don't end up with another thalidomide." 274 Referencing a
drug that caused many birth defects in the 1960s conjures serious concern,
yet is inapplicable. After all, modern drug regulation developed as a result
of this tragedy, and the United States never approved thalidomide at the
time it was causing birth defects. 25
These statements vastly overstate potential problems and promote an
unnecessary bias against biosimilars. In Europe, where biosimilars have
been marketed since 2006, patients in multiple drug classes who have
switched to a biosimilar from an originator biologic have not encountered
safety or efficacy problems. 276 Similarly, scientific studies have found no
problems with switching to biosimilars such as infliximab, adalimumab,
etanercept, and rituximab. 277 Some countries have been adequately
as indicating that biosimilars are clinically different or inferior); FTC, Statement of the Federal Trade
Commissionto the Department of Health and Human Services Regarding the HHS Blueprint to Lower
Drug Prices and Reduce Out-of-Pocket Costs, at 16 (July 16, 2018).
271.
See Mariana P. Socal, Jace B. Garrett, William B. Tayler, Ge Bai, & Gerard F. Anderson,
Naming Convention, Interchangeabilityand PatientInterest in Biosimilars,33 DIABETESSPECTRUM

273, 273, 275 (2020). But see Kolbe et al., supra note 166, at 369 (asserting that biosimilar names did
not impact willingness to prescribe drugs, although this study relied on self-reporting).
272.
Socal et al., supra note 271, at 273, 275.
273.
E.g., Christopher Rowland, MarketersAre Having a Field Day: PatientsStuck in Corporate
Fight against Generic Drugs, WASH. POST (Jan. 9, 2019), https://www.washingtonpost.com/busi-

ness/economy/drugmakers-alleged-scare-tactics-may-hold-back-competition/2019/01/09/612ac994046d-11e9-9122-82e98f91ee6f stoy.html; see also Pfizer, supra note 254, at 7-9.
274.
Rowland, supra note 273.
275.
See Bara Fintel, Athena T. Samaras, & Edson Carias, The Thalidomide Tragedy: Lessons
for Drug Safety and Regulation, HELIX (July 28, 2009) https://www.helix.northwest-

ern.edu/2009/07/28/the-thalidomide-tragedy-lessons-for-drug-safety-and-regulation.
276.
See EUR. MEDS. AGENCY & EUR. COMM'N, supra note 66, at 24.
277.
See Hillel P. Cohen, Andrew Blauvelt, Robert M. Rifkin, Silvio Danese, Sameer B. Gokhale, & Gillian Woollett, Switching Reference Medicines to Biosimilars: A Systematic Literature
Review of Clinical Outcomes, 78 DRUGS 463 476 (2018) (summarizing review of various studies
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persuaded by the existing evidence and now mandate that patients use biosimilars 278 or at least strongly encourage switching through incentives. 279
A related issue is that companies and patient groups have argued
against so-called "non-medical switching" 280 to biosimilars when insurance coverage requires stable patients on an originator biologic to switch
to its biosimilar. 281For example, the Patient Access Collaborative has videos and fact sheets suggesting a problem with titles such as "non-medical
switching hurts patients." 282 Similarly, the National Infusion Center Association states that "[n]on-medical switching is a strategy that health insurers use to control their costs by forcing stable patients to switch .. . to
drugs that may not be as effective." 283 It asserts, without citation, that
"when a patient switches off a medication and later switches back onto the
same medication after failing other medication(s), that once effective treatment may lose its effectiveness .... "284
These arguments might be persuasive to those that are already skeptical of biosimilars but are inconsistent with other facts. For example, in
countries where the payor is the government, the government would have
no interest in an action that results in higher costs-assuming that governments are engaging in logical cost-saving action, they would prefer the
equally-effective, lower-cost biosimilar. In addition, over time, more governments that pay for drugs are strongly recommending, or even requiring,

concerning infliximab, epoetin, filgrastim, etanercept, and adalimumab that found great majority of
studies surveyed concluded no differences in efficacy or immunogenicity compared to remaining on
an existing reference biologic, including three large multiple switch studies showing no problems after
multiple switches); see also Inotai, supra note 181, at 915; Edwards et al., supranote 201, at 1004.
278.
E.g., Kelly Davio, RegulatorExplains How DenmarkHas Achieved Its BiosimilarSuccess,
CTR. FOR BIOSIMILARS (Mar. 21, 2019), https://www.centerforbiosimilars.com/view/regulator-ex-

plains-how-denmark-has-achieved-its-biosimilar-success (noting that Denmark requires that patients
use biosimilars); Skylar Jeremias, Rising Costs Explain Why Canadais Switching to Biosimilars,CTR.
FOR BIOSIMILARS (June 15, 2020), https://www.centerforbiosimilars.com/view /rising-costs-explain-

why-canada-is-switching-to-biosimilars (noting Canadian provinces that require biosimilar use).
279.
E.g., INESSS, supra note 69, at 36.
280.
Although "non-medical switching" has been used broadly to refer to any coverage-based
switch to a biosimilar, some have suggested that this term is overbroad and imprecise. See Kayt Sukel,
The Fight to End Misleading Info on Biosimilars, MANAGED HEALTHCARE EXEC. (April 1, 2019),

https://www.managedhealthcareexecutive.com/view/fight-end-misleading-info-biosimilars
("[T]erms ... like 'non-medical switching' are deliberately misleading-and may scare providers and
patients away from using equally effective but less expensive treatment drugs.").
281.

See Non-Medical Switching, PATIENT ACCESS COLLABORATIVE, https://www.patientac-

cesscollaborative.org/nms (last visited Mar. 21, 2022); Patient Access Collaborative, Barriersto Pa-

tient Access:

Non-Medical Switching, YOUTUBE (June 15, 2020), https://youtu.be/Hrh3Ma_u5Uo;
How Non-MedicalSwitching Hurts Patients,ALLIANCE FOR PATIENT ACCESS, https://admin.alliance-

forpatientaccess.org/wp-content/uploads/2020/01/AfPA-How-NMS-Hurts-Patients.pdf ("A national
study shows that [non-medical switching] can hurt nearly every aspect of patients' lives .... "); Alliance for Patient Access, Non-Medical Switching Hurts Patients, FACEBOOK (Jan. 8, 2020),

https://www.facebook.com/patientaccess/videos/non-medical-switching-hurts-patients/4630818413
10061 (asserting that among those who switched, many needed additional care including hospitalization); What is Non-Medical Switching, NAT'L INFUSION CTR. ASS'N ("NICA"), https://infusion-

center.org/education/non-medical-switching (last visited Mar. 21, 2022) [hereinafter NICA].
282.
283.
284.

See sources cited supra note 283.
NICA, supra note 283.
Id.
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patients to switch to biosimilars to expand patient coverage, reflecting an
understanding that switching is safe and cost-effective.ss
Nonetheless, advocacy against non-medical switching may be effective for some doctors and patients. In one survey of EU physicians, 60%
were comfortable switching stable patients to biosimilars, but when the
same physicians were asked the same question using the term "non-medical switching," only 42% were comfortable. 286 A study of U.S. patients
found that the vast majority tried to avoid switching and were willing to
pay more to avoid the switch; almost 20% were willing to pay $200 or
more per visit, which would result in additional out-of-pocket costs of
more than $2,000 in many cases. 287 In addition, over 40% of switched patients claimed they experienced more side effects with the new biologic 288
consistent with prior observational (not blinded) studies where patients
had negative outcomes after they knew they were switched to a biosimilar
due to payor request. 289 These results are consistent with a nocebo effect
caused by the highly available statements by companies and patient advocates alike against switching, which prompts the cognitive bias of loss
aversion that makes patients highly averse to change.
2. Financial Disincentives
Bias against biosimilars is influenced by payor preferences, as well
as laws governing Medicare reimbursement that typically disincentivize
biosimilar use. Although originator biologic companies have a role in
skewing financial disincentives with rebates to pharmacy benefit managers (who negotiate drug benefits for insurance companies) to promote use
of originator biologics, this Section will first focus on Medicare given that
it often has a major influence on private insurers and doctors.290
Before addressing Medicare coverage, it is important to remember
that distribution of biologics is different than generic drugs. Currently, the
vast majority of biologics are administered at doctor offices and
285.
286.

287.

E.g., INESSS, supra note 69, at 35-37.
INDUS. STANDARD RSCH., ASBM EUROPEAN PRESCRIBERS SURVEY 90 (2019).
A. Teeple, S. Ginsburg, L. Howard, L. Huff, C. Reynolds, D. Walls, L.A. Ellis, & J.R.

Curtis, PatientAttitudesAboutNon-Medical Switching to Biosimilars:ResultsFrom an Online Patient
Survey in the UnitedStates, 35 CURRENT MED. RSCH. & OP. 603, 606 (2019).

288.
Id. at 606, 607 fig.4. However, a roughly equal percentage asserted that the new biologic
did a better job treating their disease. Id. at 607 fig.4.
289.
Elaine Nguyen, Erin R. Weeda, Diana M. Sobieraj, Brahim K. Bookhart, Catherine Tak
Piech, & Craig I. Coleman, Impact of Non-Medical Switching on Clinical and Economic Outcomes,
Resource Utilization andMedication-TakingBehavior: A Systematic LiteratureReview, 32 CURRENT

MED. RSCH. & OP. 1281, 1283 (2016) (finding that patients whose conditions were stable had negative
or neutral outcomes in terms of resource utilization or drug costs); Erin R. Weeda, Elaine Nguyen,
Silas Martin, Michael Ingham, Diana M. Sobieraj, Brahim K. Bookhart, & Craig I. Coleman, The
Impact ofNon-Medical Switching ofAmbulatory Patients:An UpdatedSystematic LiteratureReview,
7 J. MKT. ACCESS & HEALTH POL'Y, Oct. 2019, at 11-14; Olivia S. Costa, Tabassum Salam, Amy

Duhig, Arati A. Patel, Ann Cameron, Jennifer Voelker, Brahim Bookhart, & Craig I. Coleman, Specialist Physician Perspectives on Non-Medical Switching of PrescriptionMedications, 8 J. MKT.
ACCESS & HEAL TH POL'Y, Mar. 9, 2020, at 8 (finding negative or neutral patient outcomes).
290.
Jinoos Yazdany, Failure to Launch: BiosimilarSales Continue to FallFlat in the United
States, 72 ARTHRITIS & RHEUMATOLOGY 870, 871 (2020).
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hospitals. 291For any treatment dispensed at a doctor office, there is no potential for automatic substitution by a pharmacist because no pharmacist
is involved. 292 So, the usual structural mechanism of automatic pharmacy
substitution of a generic for reducing costs simply does not exist. Moreover, health-care providers tend to purchase biologics in bulk and only later
obtain reimbursement for actual use, which provides an incentive to maintain the status quo of continuing to use the originator biologic that they
have already purchased. 293 Even though a doctor could theoretically purchase biosimilars in the next bulk purchase, financial incentives work
against doing so because doctors are reimbursed based on the drug's average sales price plus a percentage. However, the average sales price does
not account for frequent discounts only provided by originator biologics,
such that doctors are compensated more for originator biologics.2 94 In addition, logistical issues favor continuing with the status quo; doctors have
stated that it is not convenient to keep both the originator and biosimilar
on hand especially given that biologics, unlike traditional drugs, may have
unique storage needs like specific temperatures. 29s Also, even if a doctor
wanted to switch all patients to a biosimilar, it would require unreimbursed
time to explain the change to the patient. 296
The Medicare pricing scheme for biologics sold from pharmacies
also disincentives use of biosimilars in a manner different than generics.
First, for biosimilars distributed in health-care settings, there are separate
reimbursement codes and prices, unlike generics that share the same codes
291.

E.g., BRILL, supra note 6, at 5; Makurvet, supra note 6, at 4-5.

292.
See Afzali et al., supra note 66, at 2078 tbl.1 ("Auto-substitution [is the] practice of replacing one product for another at the pharmacy-level without notifying or seeking the approval of the
prescriber.").
293.
See, e.g., NITZAN ARAD, MARIANNE HAMILTON LOPEZ, REBECCA RAY, SUSAN DENTZER,
ADAM KROETSCH, MARK MCCLELLAN, & MARTA WOSINSKA, DUKE MARGOLIS CTR. FOR HEALTH
POL'Y, REALIZING THE BENEFITS OF BIOSIMILARS: WHAT THE

U.S.

CAN LEARN FROM EUROPE 8-9;

see also Cole Werble, Medicare Part B, HEALTH AFFS. Aug. 2017, at 2 (discussing "buy-and-bill"

practice). Contrary to this "buy-and-bill" practice, some health-care providers engage in "white bag"
practice where they are reimbursed solely for administering the product whereas a pharmacy handles
acquisition and thus has different incentive structures; however, providers could still opt for the more
familiar brand biologic. E.g., SAYANTAN NIYOGI, NICHOLAS ADOLPH, & ARTEM PASHCHINSKIY,
IQVIA, BIOSIMILARS IN THE U.S.: REIMBURSEMENT AND IMPACTS TO UPTAKE 3-4, 7 (2021).
294.

See HENRY A. WAXMAN, BILL CORR, JEREMY SHARP, RUTH MCDONALD, & KAHAARI

KENYATTA, THE COMMONWEALTH FUND, GETTING TO LOWER PRESCRIPTION DRUG PRICES: THE
KEY DRIVERS OF COSTS AND WHAT POLICYMAKERS CAN DO TO ADDRESS THEM 9 (Maggie Van

-

Dyke ed., 2020); see also Paul B. Ginsburg & Stephen M. Lieberman, Medicare Paymentfor Physician-Administered (PartB) Drugs: The Interim Final Rule and a Better Way Forward, USCBROOKINGS SCHAEFFER ON HEALTH POL'Y (Feb 10, 2021), https://www.brookings.edu/blog/uscbrookings-schaeffer-on-health-policy/2021/02/10/medicare-payment-for-physician-administeredpart-b-drugs/ (noting a problem with the current system and suggesting possible solutions). In addition, the majority of outpatient clinics that administer biologics are eligible for discounts through the
340 B program, but this system does not require that discounts be passed to payers or patients, such
that there is an incentive to continue using the more expensive drug, such as originator biologics. Conti
et al., supra note 216.
295.
See Teeple, supra note 166, at 613 (finding over 72% of doctors already prescribing biologics note logistical problems); see also OMAR HAFEZ, MCKESSON LIFE SCIENCES, BIOSIMILARS
OVERCOMING PHYSICIAN BARRIERS TO ADOPTION IN CLINICS 1 (2019) (noting that doctors may resist
biosimilars depending on if it creates more hassle for their practice and/or the patient).
296.
See Yazdany, supra note 290, at 872.
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as their related drug to drive price competition. 297 As noted in one study,
the current Medicare reimbursement policy does not provide the same
magnitude of price competition for biosimilars as for traditional drugs, resulting in excess payments of $1.6 billion over four years. 298 Not only is
there precedent in the United States based on traditional drugs, but other
countries have found a similar approach successful in promoting greater
use of lower cost biosimilars. 299
Another issue that disincentivizes biosimilar use is that Medicare Part
D plan sponsors transition from complete to minimal responsibility once
individuals on Medicare reach a threshold of spending. When a patient
spends enough on pharmacy drugs each year to reach the catastrophic
phase, the primary financial burden (80%) switches to the federal government. 300 More expensive drugs, such as originator biologics, result in a
patient reaching the catastrophic phase more quickly, at which point the
Medicare Part D plan sponsors pay less. 301 This practice raises Medicare
costs for the government and disincentivizes biosimilar use. 302 An increasing number of patients are entering the catastrophic phase with Medicare
spending tripling from 2010 to 2019.303

297.
Ginsburg & Lieberman, supra note 294. It is currently unknown whether interchangeable
biosimilars will share the same reimbursement code as the brand biologic.
298.
Sean R. Dickson & Tyler Kent, Association of Generic Competition with PriceDecreases
in Physician-AdministeredDrugs and EstimatedPriceDecreasesfor Biosimilar Competition,4 J. AM.
MED. ASSOC. NETWORK OPEN, Nov. 2021, at 6.
299.
Id. at 7 (citing JC Robinson & Q. Jarrion, Competitionfrom BiosimilarsDrives PriceReductions for Biologics in the French Single Payer Health System, 40 HEALTH AFFS. 1190, 1192
(2021)).
300.
WAXvIAN ET AL., supra note 294, at 11. However, patients still pay 5%. BIOSIMILARS
COUNCIL, INCREASING PATIENT ACCESS TO BIOSIMILARS IN MEDICARE PART D 1 (2020).

301.

Stacie B. Dusetzina, Rena M. Conti, Nancy L. Yu, & Peter B. Bach, Association of Pre-

scriptionDrug Price Rebates in Medicare PartD with Patient Out-of-Pocket and FederalSpending,
177 JAMA INT'L MED. 1185, 1186 (2017) (noting that at this point, the plan pays 15% and patients
pay 5%).
302.
See id.
303.
E.g., Juliette Cubanski & Tricia Neuman, Millions ofMedicarePartDEnrolleesHave Had
Out-of-Pocket Drug SpendingAbove the CatastrophicThreshold Over Time, KAISER FAMILY FOUND.

fig.3 (July 23, 2021), https://www.kff.org/medicare/issue-brief/millions-of-medicare-part-d-enrollees-have-had-out-of-pocket-drug-spending-above-the-catastrophic-threshold-over-time.
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Private insurance companies also tend to favor originator biologics
over biosimilars,30 4 contrary to their current practices with generics. 305 Insurance companies typically give preference to lower cost generics by offering a lower co-pay or, where there is no generic, by imposing a requirement that patients "fail first" on a particular brand that has negotiated with
the insurer for preference. 30 6 However, in the biologics context, insurance
companies have often preferred the originator over a biosimilar and even
required patients to first fail on the originator before being given the biosimilar. 307 This could be due to rebates that sway formulary decisions. As
of 2019, only 14% of the largest private insurance plans prefer biosimilars
and more than 30% prefer the originator. 308 This is likely caused by self-interested originator biologic manufacturers using rebates to incentivize

304.
One caveat is that some insurance companies may prefer cancer biosimilars, which are some
of the most expensive biosimilars. See Yang et al., supra note 89, at 80 (stating that qualitative interviews suggest that the majority of payors prefer biosimilars for patients new to monoclonal antibodies
to treat cancer and that few of these were available at the time of the Chambers et al. study, infra note
305); Laura Joszt, AMCP Nexus Survey: Two Thirds ofPayers Use Biosimilars to Manage Oncology

Drug Costs, AJMC (Nov. 23, 2021), https://www.ajmc.com/view/amcp-nexus-survey-two-thirds-ofpayers-use-biosimilars-to-manage-oncology-drug-costs (finding that among eleven payors covering
238 million patients, 67% preferred oncology biosimilars, generally due to the increasing cost of cancer care). But see Alice J. Chen, Priya Bhanot, Laura Gascue, Rocio Ribero, Rita Shane, & Karen Van
Nuys, InsurerFormulariesComplicate the Adoption ofBiosimilar Cancer Therapies,HEALTH AFFS.

(Apr. 8, 2021), https://www.healthaffairs.org/do/10.1377/forefront.20210405.345071/abs (finding
that for five major insurance providers that provide coverage for 40% of U.S. cancer patients, although
biosimilars were interchangeable, there was no consensus on preferring the biologic or biosimilarversion).
305.
James Chambers, Rachel C. Lai, Nikoletta M. Margaretos, Ari D. Panzer, Joshua T. Cohen,
& Peter J. Neumann, Coveragefor Biosimilarsvs. Reference ProductsAmong US CommercialHealth
Plans, 323 J. AM. MED. ASS'N 1972, 1972 tbl.1 (2020). But see Mariana Socal, Ge Bai, & Gerard F.
Anderson, FavorableFormularyPlacement of BrandedDrugs in Medicare PrescriptionDrug Plans
When GenericsAre Available, 179 JAMA INTERNAL MED. 832, 832 (2019) (finding that over 70% of

formularies placed the brand product in a lower-cost sharing tier than at least one generic); James
Schneider, UnitedHealthcare,Cigna, Aetna, All Unveil New Policies RestrictingBiologics Use, FYNE

FETTLE (July 29, 2021) (noting that some insurance companies are now requiring patients to switch
to a biosimilar), https://fynefettle.com/unitedhealthcare-cigna-aetna-all-unveil-new-policies-restricting-biologics-use.
306.
See Charles Ornstein & Katie Thomas, Take the Generic Drug, PatientsAre Told- Unless
InsurersSay No, PROPUBLICA (Aug. 6, 2017, 6:00 PM) https://www.propublica.org/article/take-the-

generic-drug-patients-are-told-unless-insurers-say-no.
307.

E.g., AVALERE HEALTH, USE OF STEP THROUGH POLICIES FOR COMPETITIVE BIOLOGICS

AMONG COMMERCIAL US INSURERS 8 (2018) (finding that more than half of plans with publicly available information require use of brand biologic Remicade first); WAYNE WINEGARDEN, INCENTING
COMPETITION TO REDUCE DRUG SPENDING: THE BIOSIMILAR OPPORTUNITY 17 (2019) (noting that

UnitedHealthcare prefers originator Neulasta rather than biosimilars); see also Laura Karas, The Ongoing Step Therapy Debate, BILL OF HEALTH (Apr. 19, 2021), https://blog.petrieflom.law.har-

vard.edu/2021/04/19/step-therapy-pharma-biosimilars (noting that the reintroduction of proposed federal legislation has revived debate about counterintuitive step therapy to mandate use of more expensive brand biologic first which can not only increase health-care costs, but may also lower medication
adherence). Some of these requirements could be due to anticompetitive activity. See generally Van
de Wiele et al., supra note 6 (discussing antitrust dispute regarding Remicade).
308.
Chambers et al., supra note 305, at 1972 tbl.1; see also Chen et al., supra note 304 (finding
that for five insurance providers that provide coverage for 40% of cancer patients, one preferred the
brand biologic, one preferred biosimilars, and two covered both equally, although also noting that
plans can and do change coverage preferences); Sean McGowan, Five Years on, BiosimilarsNeed
Support from

All

Health

Care

Players,

STAT

(Mar.

6,

2020),

https://www.stat-

news.com/2020/03/06/biosimilars-in-us-turn-five (noting that UnitedHealthcare favors only some
brand biologics likely due to rebates).
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payors to prefer their biologic. 30 9 Given that the rebates can be 50% of the
list price, it may be cheaper for the payor to prefer the originator rather
than a biosimilar. 310 As some have noted, unless a substantial number of
patients switch to a biosimilar, the rebates make it less profitable for
payors to promote a biosimilar. 31' This practice seems less common for
nonbiologic drugs, potentially because the larger price differential for generics disincentivizes remaining with the brand.
C. How Cognitive Biases Promote Bias Against Biosimilars
This Section explains why marketing has been successful in establishing and perpetuating bias against biosimilars due to common cognitive
biases, such as loss aversion bias, availability bias, and confirmation bias.
Moreover, given inherent ambiguity with regulatory approval of biosimilars, these biases are especially likely to proliferate to address the ambiguity. Understanding how these individual biases make doctors and patients
gullible to marketing is important to gauge the strength of existing biases
and to determine appropriate solutions.
1. Loss Aversion Bias and Availability Bias
The marketing previously discussed could easily cause availability
bias in favor of originator biologics and trigger loss aversion bias. For example, consider that originator biologics are marketed for a minimum of
twelve years before a biosimilar can be approved. 312 During this time, only
the originator biologic is available and marketed. 313 So, for example, the
originator biologic Remicade was advertised and used by patients for more
than a dozen years before the first biosimilar started to be marketed. 31 4

309. See Hakim & Ross, supra note 230, at 2163; see also Karas, supra note 307; Benjamin
Hayes, Cats at the Christening: Bundled Rebates, DoctrinalBlind Spots, and the Risks ofAntitrust
Under-Enforcement in the Biologic PharmaceuticalMarket, 51 U. MEMPHIS L. REV. 917, 931-32,

950 (2021); FTC, REPORT ON REBATE WALLS 2-5 (2021) (discussing how rebates incentivize higher
priced drugs and antitrust implications), https://www.ftc.gov/system/files/documents/reports/federaltrade-commission-report-rebate-walls/federaltradecommissionreporton_rebate_walls_.pdf;
Joanna Shepherd, Pharmacy Benefit Managers, Rebates and Drug Prices: Conflicts of Interest in the
Marketfor PrescriptionDrugs, 38 YALE L. & POL'Y REV. 357, 391-94 (2019) (discussing different

ways to tackle rebates including eliminating them altogether as well as requiring partial pass through
of benefits).
310. See Hakim & Ross, supranote 230, at 2163. Moreover, rebates increased by over 50% from
2012 to 2016. PEW CHARITABLE TRUSTS, THE PRESCRIPTION DRUG LANDSCAPE EXPLORED: A LOOK

AT RETAIL PHARMACEUTICAL SPENDING FROM 2012 TO 2016 40 (2019).

311.
See Hakim & Ross, supra note 230, at 2163. This has been referred to as a "rebate trap"
given insurers prefer the brand biologic with a higher list price because it is cheaper for the insurer to
do so. Id. Some companies enter into multiyear rebate agreements immediately before a biosimilar
launch. See Yazdany, supranote 290, at 871.
312. See 42 U.S.C. § 262(k)(7)(A).
313.

See id.

314.

Remicade was first approved in the United States in 1998. See REMICADE (INFLIXIMAB)

LABEL, JANSSEN BIOTECH, INC. 1 (2013), https://www.janssenlabels.com/package-insert/product-

&

monograph/prescribing-infonnation/REMICADE-pi.pdf. Although the FDA approved a biosimilar in
2016, it was not marketed until 2017. E.g., Stacy Elder Dalpoas, Mariana Socal, Celia Proctor,
Kenneth M. Shermock, Barriers to Biosimilar Utilization in the United States, 77 AM. J. HEALTH-
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When availability bias is combined with loss aversion bias, serious
resistance to change likely results. After all, loss aversion bias disproportionately overvalues possible loss. 315 A patient who has been taking
Humira for more than a decade might assume there would be worse outcomes from a biosimilar after seeing advertisements that suggest switching to a biosimilar is unsafe. Even an advertisement that stated the scientifically accurate fact that biosimilars are not identical could exacerbate
loss aversion bias; this is especially true if the patient is already biased
against generics, as many are. 316 These implications are consistent with
studies indicating patients are more reluctant to switch to biosimilars if
they were treated longer with the originator biologic. 317
Moreover, those with a bias against biosimilars may, through confirmation bias, improperly interpret evidence and then further propagate bias
by spreading incorrect information to others. For example, Andrew Spiegel, the leader of the Global Colon Cancer Association, is a noted patient
advocate who has made repeated statements questioning the safety of biosimilars in Europe, 318 contrary to actual findings of scientists concerning
their safety. 319 Because patients are likely to encounter views of patient
advocates such as Spiegel on patient-oriented websites, his inaccurate
views are highly available to existing patients. 320 Moreover, a patient who
has been taking an originator biologic for a decade is likely to view the
false statements from Spiegel as true due to loss aversion bias.
2. High Ambiguity Promotes Confirmation Bias
Existing bias against biosimilars may be exacerbated by confirmation
bias occurring in situations of high ambiguity such as biosimilar science
and regulatory approval. 321Although there are multiple systematic reviews
supporting the safety and efficacy of switching to a biosimilar, some with
SYS. PHARMACISTS 2006, 2007 tbl.1(2020); see also AMGEN BIOSIMILARS, 2021 BIOSIMILAR TRENDS
REPORT
11
fig.3
(2021),
https://www.amgenbiosimilars.com/commitment/-/media/Themes/Amgen/amgenbiosimilars-com/Amgenbiosimilars-com/pdf/USA-CBU-80962_Amgen2021-Biosimilar-Trends-Report.pdf#page=ll (showing timeline of FDA approval versus launch of
biosimilars).
315. See supranotes 137-40 and accompanying text (discussing loss aversion).
316. See discussion supra Section J.C.2 (describing patient bias against generics).
317. See Scherlinger et al., supra note 197, at 929 (finding that the majority of those who refused
to switch to a biosimilar had been treated with the originator for seven versus four years on average).
318. See PublicHearing on FacilitatingCompetition and Innovation in the BiologicalProducts
Marketplace, Part 15: HearingBefore the Food & Drug Admin. 193-94, 197-99 (2018) (statement

of Andrew Spiegel, Global Colon Cancer Ass'n). Spiegel also cofounded Alliance for Safe Biologic
Medicines, which often raises concerns about switching biosimilars due to cost. See id. at 194; see
also Patients, PhysiciansRaise Concerns with BC Biosimilar Non-Medical Switching Policy, ALL.
FOR SAFE BIOLOGIC MEDS. (June 6, 2019) https://safebiologics.org/2019/06/patients-physicians-raise-

concerns-with-bc-biosimilar-non-medical-switching-policy.
319.
E.g., BIOSIMILARS FORUM, supra note 81, at 8; EUR. MEDS. AGENCY & EUR. COMM'N,
supra note 66, at 24; Eduardo Cazap, Ira Jacobs, Ali McBride, Robert Popovian, & Karol Sikora,
GlobalAcceptance ofBiosimilars, 23 ONCOLOGIST 1188, 1194 (2018).
320.

See, e.g., Andrew Spiegel, Patient Safety is Essentialfor New Cancer Meds, PENNLIVE

(Mar. 23, 2019, 4:16 PM), https://www.pennlive.com/editorials/2011/08/patient safetyisessentialfo.html (discussing the safety of biosimilars in a skeptical fashion).
321.
E.g., Dangerous Concoction, supra note 119, at 805.
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a bias against biosimilars might focus on arguable ambiguity to perpetuate
that bias. 322 For example, although the vast majority of studies support
switching to biosimilars, there are two out of ninety studies that found possible safety issues that could provide enough ambiguity for those with confirmation bias to view as proof of safety problems. 323 Some reviews have
noted that studies to date do not provide robust evidence, again creating
ambiguity that could promote confirmation bias against biosimilars. 324
Sometimes even a systematic review that finds no statistical differences
on safety or efficacy will nonetheless suggest that the studies do not provide robust evidence because there is inadequate long-term data. 325 This
suggestion could simply be a cautious statement by a scientist. However,
someone with an existing bias against biosimilars may view this as evidence confirming that biosimilars are not safe. Similarly, someone biased
against biosimilars that reads a conclusion that studies show safety and
efficacy concerns are a "low risk" in the "great majority" of switching
studies may remain skeptical based on confirmation bias, especially if
there are limited studies. 326
Confirmation bias also likely plays a role in the interpretation of studies of, and policies regarding, the switching of patients to biosimilars.

322. See sources cited supra note 279. There are some studies that conclude that switching for
nonmedical reasons such as cost is generally safe and effective. E.g., Bernard et al., supra note 181,
at 2355, 2359; see also Ahmad Zainal Abidin, Centaine L. Snoswell, Leila Shafiee Hanjani, Gavin
Callaghan, & Michelle Edmonds, Infliximab Switching from Reference Product to Biosimilar:A Review of Evidence Regarding the Clinical Efficacy, Safety Profile and Immunogenicity, 51 J.
PHARMACY PRAC. & RSCH. 358, 371 (2021) (review establishing ever-increasing evidence of safety

in switching).
323. See Cohen et al., supra note 277, at 464, 471, 475; see also Stanton Mehr, More Clinical
Evidence that Biosimilar Switching Carries Low Risk, BIOSIMILARS REV. & REP. (Mar. 6, 2018),

https://biosimilarsrr.com/2018/03/06/clinical-study-evidence-biosimilar-switching-carries-low-risk
(discussing Cohen et al. article and findings).
324. See Brian G. Feagan, Gordon Lam, Christopher Ma, & Gary R. Lichtenstein, Systematic
Review: Efficacy and Safety of Switching PatientsBetween Reference and BiosimilarInfliximab, 49
ALIMENTARY PHARMACOLOGY THERAPEUTICS 31, 37 (2019) (concluding that evidence is weak with

only the NOR-SWITCH study reporting on the noninferiority of switching and that different patient
groups may also have different responses); see also Brian G. Feagan, Mona Marabani, Jashin J. Wu,
Freddy Faccin, Claire Spronk, & Gilberto Castaneda-Hernandez, The Challenges of Switching Therapies in an Evolving Multiple Biosimilars Landscape: A Narrative Review of Current Evidence, 37
ADVANCES THERAPY 4491, 4509 (2020) (concluding that evidence is inadequate because it is mostly
based on real-world studies that are not empirically robust); Ross A. McKinnon, Matthew Cook, Winston Liauw, Mona Marabani, Ian C. Marschner, Nicolle H. Packer, & Johannes B. Prins, Biosimilarity
and Interchangeability:Principles & Evidence: A Systematic Review, 32 BIODRUGS 27, 45 (2018)
(reviewing fifty-seven switching studies and finding that the majority reported nonstatistically significant differences on efficacy, although noting that there is a lack of robustness of evidence and limited
long-term data because only eight studies evaluated beyond one year). In addition, although there are
extensive studies of switching to biosimilar infliximab, given fewer studies available for areas such as
oncology, this could be viewed as a point of ambiguity. See Ebbers & Schellekens, supra note 203, at
1964 (noting that data is mostly available for infliximab switching and not for other products, such as
those used in oncology).
325.
See McKinnon et al., supra note 324, at 27 (focusing on observational studies that lack
information on immunogenicity and inadequate powering within all diagnostic groups as revealing
evidence gaps); Zoltan Szekanecz, Biosimilars: To Switch or Not to Switch-That is the Question, 58
REUMATOLOGIA, Jan. 2020, at 1-2 (suggesting that there is no medical reason to switch and that there

remains inadequate real-world data on nonmedical switching).
326.
See Cohen et al., supra note 277, at 464 (citing Keypoints discussion).
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There is real-world evidence, including more than a decade of biosimilar
use in Europe and multiple medical society and domestic health agency
recommendations, in favor of switching. 327 Also, a number of medical societies have modified their positions over time in favor of switching. 328
Nonetheless, because there is not complete agreement in favor of switching, the ambiguity prompts confirmation bias in those with existing bias
against biosimilars, directing focus on the minority of statements that do
not recommend switching.
Additional ambiguity exists around the regulatory approval process
for biosimilars that could unduly promote skepticism and bias against biosimilars. For example, the regulatory approval standard of highly similar
for biosimilars is more ambiguous than an identical active ingredient that
is bioequivalent (for generics), even if deemed to be as safe and effective
as the originator. 329 The approval process for biosimilars can also be characterized as ambiguous. In particular, whereas every generic application
involves the same standard process, the FDA review of biosimilars is individually tailored in terms of what type of evidence is required. 330 Although the biosimilar review process is intended to provide flexibility
given inherent scientific complexities with biologics that do not exist with
traditional drugs, this flexibility injects ambiguity that promotes bias. An
additional layer of ambiguity promoting confirmation bias is the FDA policy to permit a biosimilar manufacturer to gain approval for some indications based on extrapolation from evidence of one indication. 33i Indeed,
some doctors have expressed concern about biosimilars approved for

327. E.g., Edwards et al., supra note 201, at 1008 ("The European Crohn's and Colitis Organisation, various national rheumatology societies and the British Association of Dermatology have all
expressed support for prescriber-initiated switching."); CADTH, INTERNATIONAL POLICIES ON THE
APPROPRIATE USE OF BIOSIMILAR DRUGS 7-8 (2018) (noting that the UK, Germany, France, Nether-

lands, Norway, Finland, Australia, and New Zealand health agencies all consider it safe to switch to
biosimilars); Jonathan Kay, Monika M. Schoels, Thomas Ddrner, Paul Emery, Tore K. Kvien, Josef
S. Smolen, & Ferdinand C. Breedveld, Consensus-BasedRecommendationsfor the Use ofBiosimilars
to Treat RheumatologicalDiseases, 77 ANNALS RHEUMATIC DISEASES 165, 165 (2018) (citing con-

sensus of an international panel of rheumatologists around the safety of switching).
328.
Several groups changed their position within just a few years to favor biosimilars from either prior opposition or waiting for more information. See MEDICINES FOR EUROPE, supra note 228,
at 19-21 (noting the positions of several groups and potential changes they endorse).
329.
See discussion supra Section I.A.2 (discussing biosimilar regulatory standard); see also
John R.P. Tesser, Daniel E. Furst, & Ira Jacobs, Biosimilars and the Extrapolationof Indicationsfor
Inflammatory Conditions, 11 BIOLOGICS: TARGETS & THERAPY 5, 8 (2017) (noting that regulatory

approval ofbiosimilars is based ontotality of evidence, suchthat there is a great deal of interpretation).
330.

See BiosimilarDevelopment, Review and Approval, FDA, https://www.fda.gov/drugs/bio-

similars/biosimilar-development-review-and-approval#types (last visited Mar. 21, 2022).
331.
See HHS, FDA, CDER, & CBER4, SCIENTIFIC CONSIDERATIONS IN DEMONSTRATING
BIOSIMILARITY TO A REFERENCE PRODUCT: GUIDANCE FOR INDUSTRY 21 (2015). The EU also fol-

lows the same practice. EMA COMM. FOR MED. PRODS. FOR HUMAN USE, GUIDELINE ON SIMILAR
BIOLOGICAL MEDICINAL PRODUCTS CONTAINING BIOTECHNOLOGY-DERIVED PROTEINS AS ACTIVE

SUBSTANCE: NONCLINICAL AND CLINICAL ISSUES, 12 (2015). The ambiguity inherent with extrapola-

tion is underscored by the fact that agencies can come to different conclusions based on the same
evidence. E.g., Tesser et al., supra note 329, at 8 (noting that regulatory agencies in fact have come to
different conclusions); see also Andriy Krendyukov & Martin Schiestl, Extrapolation Concept at
Work with Biosimilar:A Decade of Experience in Oncology, 3 ESMO OPEN 1, 1 (2018) (noting that
extrapolation is "most commonly misunderstood").
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indications based on extrapolations, rather than affirmative data, 332 with a
significant number believing that it should never be appropriate.333 However, extrapolation is consistent with legal and scientific principles, 334 essential to making biosimilar regulatory approval cost-effective, 33 and ethically supported to ensure that patients are not subjected to unnecessary
tests. 336 Nonetheless, the term extrapolation itself may have improper connotations.337
Due to confirmation bias, somewhat ambiguous, neutral statements
by health-care professionals may be negatively perceived by a patient that
has an existing bias against biosimilars. For example, consider a likely
scenario where a patient is told that a biosimilar "may" help, which is true
of all medications. A patient who is already biased against biosimilars will
inappropriately assume the biosimilar is less effective due to the bias
against biosimilars compounded by confirmation bias which causes the
patient to interpret all facts consistent with biased beliefs. Of course, even
if a patient is told that the biosimilar "is likely" to help, a patient who has
a strong bias against biosimilars may cling to the fact that there is no guarantee that the biosimilar will help. In either event, statements by healthcare professionals can unintentionally prompt nocebo effects, which will
result in further confirmation bias against biosimilars. 338
IV. ADDRESSING BIAS AGAINST BIOSIMILARS

A. The Challenge of Changing Beliefs
Identifying that there is a problem is only the first step to a solution.
This Section briefly explains why biases against biosimilars can be difficult to overcome. Nonetheless, there is reason for optimism. While changing beliefs is challenging, sometimes desired behavior can be nudged
332. E.g., Hemmington et al., supra note 183, at 574 (finding that 32% of surveyed New Zealand
doctors in specialties that prescribe biologics were not confident about the indications of extrapolation); Sarnola et al., supra note 178, at 16-17 (noting extrapolation is an issue noted in studies concerning biosimilar disadvantages). But see Yang et al., supra note 89, at 10 (noting that among surveyed oncologists who had previously prescribed biologics, most were comfortable with extrapolated
indications).
333. See Eline van Overbeeke, Birgit De Beleyr, Jan de Hoon, Rene Westhovens, & Isabelle
Huys, Perceptionof OriginatorBiologics and Biosimilars:A SurveyAmongBelgian RheumatoidArthritis PatientsandRheumatologists, 31 BIODRUGS 447, 452-53 (2017) (39% of Belgian rheumatologists surveyed suggested it was never appropriate to extrapolate indications).
334.

E.g., Ryan Abbott & Ian Ayres, Evidence and Extrapolation:Mechanisms for Regulating

Off-Label Uses of Drugs and Devices, 64 DUKE L. J. 377, 379-80 (2014) (discussing use of extrapolation not only for biosimilars, but also for off-label uses, new subpopulations of patients, and new
doses); Krendyukov & Schiestl, supra note 331, at 1.
335.
Gareth P. Gregory, Christine Carrington, Chan Y. Cheah, Eliza A. Hawkes, Ian M. Ivring,
Jim Siderov, & Stephen Opat, A Consensus Statement on the Use ofBiosimilarMedicine in Hematology in Australia, 16 ASIA-PAC. J. CLINICAL ONCOLOGY 211, 218 (2020).
336.
Id.
337. See Krendyukov & Schiestl, supra note 331, at 1. In fact, Canada removed use of this term
in its guidance document and instead uses the term "authorization of indications" of the biosimilar.
GUIDANCE DOCUMENT: INFORMATION AND SUBMISSION REQUIREMENTS FOR
BIOSIMILAR BIOLOGIC DRUGS 19-20 (2016).
HEALTH CAN.,

338.

Rezk & Pieper, supra note 201, at 212; Luana Colloca & Damien Finniss, Nocebo Effects,

Patient-ClinicianCommunication and Therapeutic Outcomes, 307 JAMA 567, 567 (2012).
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through structural changes. This Section documents eventual successful
use of generics in the United States as well as some successful biosimilar
use in the United States despite biases.
1. Why Biases Are Hard to Change
A major issue with addressing bias against biosimilars is that biases
can be difficult to change. Studies show attempts to correct misinformation
may actually result in people incorrectly remembering the discredited information as truth. 339 This could be because the correction repeats the prior
wrong information and makes that information more available than the
new information. 340 Even when a correction has some success, it tends to
be partial; for example, after false advertisements that Listerine "prevents
colds," corrective advertising only slightly reduced beliefs concerning this
inaccurate information. 34' Moreover, studies show that attempts to correct
misperceptions can backfire and instead strengthen initial beliefs. 342 This
result is consistent with the previously discussed concept of confirmation
bias, which reinforces existing views.
Although correcting biases can be challenging, there is reason for
hope in addressing bias against biosimilars. First, studies indicate that corrections are more likely to be successful concerning issues of health than
other issues like politics. 343 Of course, this is only true if the health issue
is not associated with partisan identities, such as a predominant view
among some conservatives that masks are ineffective in protecting against
COVID-19 infections, contrary to scientific data. 344 However, not all public health issues are tied to politics and views on drugs can change-doctors and patients alike have an increasingly accurate perception of generic
drugs. 345 Second, corrections are more likely to succeed if an alternative
and coherent explanation is provided, including potentially a reason for
the original bias. 346 For example, simply stating that vaccines are safe is

339.

E.g., John M. Carey, Victoria Chi, D. J. Flynn, Brendan Nyhan, & Thomas Zeitzoff, The

Effects of Corrective Information About DiseaseEpidemics and Outbreaks:Evidence from Zika and
Yellow Fever in Brazil, 6 SCI. ADVANCES, Jan. 2020, at 8 (finding that corrected information disap-

peared after a delay).
340. See supranotes 120-26 and accompanying text (discussing availability bias).
341.
Lewandowsky et al., supra note 15, at 107.
342. See, e.g., id. at 119. As one example, campaigns to reduce smoking may potentially lead to
an increase in smoking. Id.
343.
Nathan Walter & Sheila T. Murphy, How to Unring the Bell: A Meta-Analytic Approach to
CorrectionofMisinformation, 85 COMMC'N MONOGRAPHS 423, 436 (2018). This likely helps explain

why some conservatives continue to believe President Obama is not a U.S. citizen; the debunked information is political. Brendan Nyhan & Jason Reifler, When Corrections Fail: The Persistence of
PoliticalMisperceptions,32 POL. BEHAV. 303, 323 (2010).
344.
See, e.g., Toni G.L.A. van der Meer & Yan Jin, Seeking FormulaforMisinformatonTreatment in Public Health Crises: The Effects of Corrective Information Type and Source, 35 HEALTH
COMMC'N 560, 568-69 (2020); RyanLizza & Daniel Lippman, Wearing aMaskisfor Smug Liberals.
Refusing for Reckless Republicans, POLITICO (May 5, 2020, 4:30 AM), https://www.politico.com/news/2020/05/0 1/masks-politics-coronavirus-227765.

345. See, e.g., supra note 141 and accompanying text (noting change in perspectives from 2011
to 2016).
346.
Lewandowsky et al., supra note 15, at 117.
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not as helpful as explaining how the misconception that they cause autism
began. 347 However, providing an alternative story is tricky because studies
show that individuals tend to believe simple and persuasive stories, which
reflects pharmaceutical marketing that focuses on simple, albeit inaccurate, stories. 348 Nonetheless, given that consumers broadly recognize that
generics are safe and a better value, it is possible to recognize the value of
lower cost, high quality drugs, even if there might be some lingering bias
against them.
Researchers have proposed guidelines to directly address misinformation. First, education with correct information needs to avoid repetition
of misinformation (i.e., the common myth versus fact formula is not helpful because it may simply reinforce the misinformation). 349 Second, the
correct information needs a strong narrative because compelling stories
are better remembered. 35 0 Also, presenting the correct information in a
way that affirms an individual's world view is ideal; this can be tricky with
biosimilars because patients often assume more expensive products are
better.35' However, unlike generics that are usually much cheaper than the
brand version, biosimilars are still typically quite expensive. 3s2 In addition,
some researchers have suggested moving beyond direct refutation of misinformation to include peer pressure and structural nudges. 35 3 For example, opposition to climate change does not matter if there are structural
nudges to incentivize climate-friendly behavior, such as tax credits for
electric cars. And, as discussed next, the dominant use of generics in the
United States is likely a function of structural nudges in the form of laws
as well as private payor policies.35 4
2. Structural Changes Can Nudge Desired Action Despite
Lingering Biases
This Section provides examples of how structural changes can successfully improve desired usage and dissipate biases. It shows how U.S.
generic use has dramatically increased despite some continued bias. It also
provides examples of how structural changes in Europe and in some limited situations in the United States have successfully promoted biosimilar
use.

347. See id. (providing example that suspected weapons of mass destruction (WMD) sites in Iraq
were actually grain silos would be ineffective since it would not explain why initial reports suspected
the sites housed WMDs).
348.
349.
350.

See id.
Id. at 122-23.
See, e.g., Drugged Out, supra note 116, at 445-46.

351.

Lewandowsky et al., supra note 15, at 123; Schmidt et al., supra note 149, at 1.

352.
See, e.g., Beth Snyder Bulik, Biosimilars Versus Biologics: Is MarketingMadness on the
Way as Biosimilar Approvals Balloon?, FIERCE PHARMA (Aug. 16, 2021, 4:17 PM),

https://www.fiercepharma.com/marketing/biosimilar-or-biologic-marketing-madness-way-as-biosimilar-approvals-balloon.
353.
Lewandowsky et al., supra note 15, at 124.
354.
See discussion infra Section IV.A.2
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a. History of Generics in the United States
The history of generic drug use in the United States shows that structural changes to laws and policies can increase generic use and change
personal views. Widespread generic use that happens promptly after generics enter the market is often attributed to state laws that permit or even
require generic substitution.355 However, in an earlier era, most states had
laws banning generic substitution because of a massive misinformation
campaign initiated by pharmaceutical companies. 35 6 The dramatic change
from banning generic substitution to actively encouraging it was prompted
in large part by newly enacted Medicare and Medicaid laws that created a
financial incentive to reduce costs. 357 In addition, anti-substitution laws
created practical and economic burdens in terms of keeping all brand drugs
in stock. 358 By 1971, the national lobbying group for pharmacists, in conjunction with AARP and organized labor, took a firm stand against
anti-substitution laws that included efforts to educate patients and change
state laws. 35 9 In 1973, Medicaid reimbursements for drugs were set to the
price of generics unless there was a demonstrated difference in therapeutic
effect. 360 The Medicaid reimbursement policy is consistent with hospitals'
prior successful use of formularies (lists of covered drugs) to promote use
of cheaper generics-even during the era of anti-substitution laws that
could override doctor preferences because doctors were required to consent to the formulary as a condition of treating patients at the hospital. 361
By 1984, anti-substitution laws were successfully repealed. 362
However, repealing anti-substitution laws was only the first step toward increasing generic use because views of doctors and patients still
needed to change. Initially, doctors resisted substitution with generics; the
American Medical Association (AMA) passed a resolution in 1975 urging
doctors to consistently bar pharmacy dispensation of generics by indicating that the prescription should be dispensed as written, apparently at the
suggestion of drug companies appealing to doctors valuing their autonomy. 363 Around the same time, some grocery stores advertised drug prices

355.
Typically, within a month of generic market entry the generic will account for 90% of dispensed prescriptions. See, e.g., Marta Wosinska & Robert S. Huckman, Generic Dispensing and Substitution in Mail and Retail Pharmacies, 23 HEALTH AFF. 409, 413 (2004).
356.

JEREMY A. GREENE, GENERIC: THE UNBRANDING OF MODERN MEDICINE 139-40 (2014);

see also Neil J. Facchinetti & W. Michael Dickson, Access to Generic Drugs in the 1950s: The Politics

of a Social Problem, 72 AM. J. PUB. HEALTH 468, 473-74 (1982) (discussing the need to bar generic
substitution as an engineered social crisis).
357. GREENE, supra note 356, at 151.
358.
Id. at 141 (discussing substitution bars as creating challenges for pharmacists).
359.
Id. at 147-49. Pharmacists had previously supported bars for substitution of drugs but
changed their stance once more stringent federal laws made counterfeit drugs no longer a problem.
See, e.g., Hossein Salehi & Stuart
CARE FIN. REV. 59, 59-60 (1985).

360.
361.
362.
363.

O.

Schweitzer, Economic Aspects of Drug Substitution, 6 HEALTH

GREENE, supra note 356, at 152.
Id. at 151 (noting that generics helped reduce costs and manage inventory).
Id. at 155.
Id. at 195.
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and even took out ads promoting generics. 364 Despite these efforts, most
patients in 1980 did not request generics, and doctors and pharmacists
were still reluctant to prescribe and dispense them. 36 A survey in the mid1980s found that most patients were familiar with the term generic and
20% erroneously believed that generics were lower quality than brand
drugs. 366
Generic use has increased over the decades, 367 likely due to increased
knowledge oftheir equivalent safety and efficacy, as well as several financial incentives. 368 First, a 1984 change to regulatory laws expedited approval of generics, which lowered the cost of generic entry and substantially increased the number of generics in the market3 69 with increased
competition resulting in lower prices. Lower priced generics promoted
substitution by pharmacists because their profit margin was higher with
generics than brand name drugs. 370 In addition, although some doctors and
patients may retain illogical biases against generics, today only about 5%
of prescriptions are written as "do not substitute," which contrasts sharply
with the 1975 AMA position urging doctors to oppose all generics. 371
Some of this could be due to payor pressure to use generics; starting in the
early 1990s, insurers began using formularies to exclude coverage of expensive brands. 372 By the 2000s, private insurers further promoted generics with tiered formularies that included greater cost differentials between
generics and brands, which could result in a twofold difference in price. 373
b. How the United States Can Learn from Other Countries and
Contexts
There is also direct evidence of how existing structures can promote
biosimilar use. Europe is an obvious place to consider because it accounts

364.
365.
366.

Id. at 198.
Id. at 203.
Id. at 206.

367.

See, e.g., Scott Gottlieb, Don't Give Up on Biosimilars-CongressCan Give Them a Boost,

WALL ST. J. (Aug. 25, 2019), https://www.wsj.com/articles/I-give-up-on-biosimilarscongress-cangive-them-a-boost-11566755042 (noting that generics were only 36% of drugs in 1994, then about
75% in 2009, and 87% in 2015).
368.
As discussed earlier, the vast majority of patients now agree that generics are safe and effective, whereas in the mid-1980s, about 20% believed that generics were lower quality. GREENE,
supra note 356, at 206.
369.
21 U.S.C. § 355(); CBO, HOW INCREASED GENERIC COMPETITION HAS AFFECTED DRUG
PRICES AND RETURNS IN THE PHARMACEUTICAL INDUSTRY 27-28 (1998).

370.
See Elyse Tanouye, PriceMarkups on Generics Can Top Brand-Name Drugs, WALL ST. J.
(Dec. 31, 1998, 12:01 AM), https://www.wsj.com/articles/SB915062993167849000.
371.
William H. Shrank, Joshua N. Liberman, Michael A. Fischer, Jerry Avorn, Elaine Kilabuk,
Andrew Chang, Aaron S. Kesselheim, Troyen A. Brennan, & Niteesh K. Choudhry, The Consequences ofRequesting "Dispense as Written," 124 AM. J. MED. 309, 313 (2011). A 2005 study revealed that three-quarters of physicians permit generic substitution. BARRETT, supra note 143, at 7.
372.
GREENE, supra note 356, at 232.
373.
Teresa B. Gibson, Ronald J. Ozminkowski, & Ron Z. Goetzel, The Effects of Prescription
Drug Coverage:A Review of the Evidence, 11 AM. J. MANAGED CARE 730, 730 (2005) (noting that
in 2005, a review of the literature indicated that most payors had moved from two-tier plans to threetier plans).
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for 90% of global biosimilar sales. 374 However, many structural policies
used in Europe to promote biosimilars such as mandating that biosimilars
have lower prices, nationwide purchasing of lower cost biosimilars, quotas
on individual doctors, and sometimes mandating biosimilar use are anathema to U.S. practices. 375 Accordingly, this Section focuses on aspects of
European structures that promote biosimilar use, as well as a couple of
niche U.S. situations with very strong biosimilar use.
i. European Structural Policies that Promote Biosimilar
Use
Studies in Europe suggest that ideally biosimilar use is promoted by
multiple incentives. Germany, which has the most policies favoring biosimilars, has the highest biosimilar usage. 376 Although some policies such
as prescription quotas and penalties would not apply to the United States,
there are nonetheless other structural policies that could be adopted, including financial incentives and gentle nudges such as prescription guidelines and education.
One structural nudge used in Europe involves policies directed at patients that create a financial incentive to choose biosimilars. In several European countries, cost-effective biosimilars are promoted by requiring patients to pay the difference between the brand and biosimilar. 377 This
somewhat mirrors what U.S. insurers already do with coverage of generics
in terms of lower co-pays. 378 However, even in Europe, this strategy alone
was not entirely successful because the originator biologic manufacturers
sometimes reduced their prices immediately before biosimilar entry. 379
This highlights the problem of relying on a single strategy to promote biosimilar use.

374. BIOSIMILARS FORUM, supra note 81, at 6. The authors note that Europe admittedly has
fewer patent and anticompetitive barriers than the United States. Id. at 3. However, that is true for all
countries other than the United States but Europe still had more than 80% of global use of biosimilars
and thus is still an important example of how to incentivize biosimilar use. Id.
375. See, e.g., Moorkens et al., supra note 67, at 5, 8-9; Remuzat, Supply Side, supra note 67, at
6-7 (noting financial penalties for doctors who do not meet quotas or alternatively financial rewards
for those who meet targets); Thomas Bo Jensen, Seoyoung C. Kim, Espen Jimenez-Solem, Dorthe
Bartels, Hanne Rolighed Christensen, & Jon Trrup Anderson, Shift from Adalimumab Originatorto
Biosimilars in Denmark, 180 JAMA INTERNAL MED. 902, 902-03 (2020) (noting that Denmark

bought biosimilars of brand biologic Humira through national tenders and achieved price cuts of onefifth); see also Alan Cassels, Why BiosimilarsShould be Interchangeable,PHARM. J. (Jan. 9, 2017),
https://pharmaceutical-journal.com/article/opinion/why-biosimilars-should-be-interchangeable-withbiologics (noting that drug company lobbying is more successful in the U.S. than in Europe and thus
operates to restrain biosimilar use).
376.
Cecile Remuzat, Julie Dorey, Olivier Cristeau, Dan Ionescu, Guerric Radiere, & Mondher
Toumi, Key Driversfor Market Penetrationof Biosimilarsin Europe, 5 J. MKT. ACCESS & HEALTH

POL'Y 1, 7-9 (2017).
377.

Remuzat, Supply Side, supra note 67, at 9.

378. See GREENE, supra note 356, at 152 (discussing formularies that promote generics with
lower co-pays).
379.
Remuzat et al., supra note 379, at 3; see also Frank et al., Working Paper 2021, supra note
97, at 18-19 (noting that in the United States, sometimes the originator will reduce its price with
bio similar entry).
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A different type of financial incentive targets patients and doctors.
For example, at one UK hospital, all stakeholders, including patients who
were to be treated with a biosimilar for inflammatory bowel disease, were
involved in designing a successful switching program to biosimilar infliximab, which has been the basis for broader policy recommendations for
benefit sharing. 380 The program involved patient education on biosimilars
and investing savings gained from lower cost biosimilars in new patient
services, such as dietician support and specialist nurses. 381 All patients
treated at the hospital were offered the opportunity to switch and 99% of
patients accepted. 382 The researchers concluded this was likely due to improved patient understanding ofthe science and regulatory process, as well
as benefits in terms of new services. 383 As will be discussed, Medicare
could be modified to promote a semblance of cost sharing for doctors and
patients that could be expected to have positive results based on this example.384
A recurring theme in studies of successful biosimilar use is the importance of education. Even in countries with financial incentives favoring
biosimilars, studies note that it is important to combat limited knowledge
of biosimilars among doctors and patients. 385 One study noted prescribers'
"positive attitude and trust in biosimilar medicines should be the priority." 386 These comments would equally apply to the United States given
that a 2020 study of U.S. patients indicated more than 80% trust doctors a
great deal to make the right decisions and 70% would accept a biosimilar
if their doctor prescribed it. 387 Although the importance of education has
been repeatedly noted and even underscored by a 2021 federal law (mandating the Secretary of Health and Human Services to provide web-based
380.

IMPROVING

HEALTHCARE DELIVERY IN HOSPITALS BY OPTIMIZED UTILIZATION OF

MEDICINES: A STUDY INTO 8 EUROPEAN COUNTRIES, COMMISSIONED BY MEDICINES FOR EUROPE,

KPMG 119 (2019); ARAD ET AL., supra note 293, at 9 (noting cost sharing not only in the UK, but
also in France and Germany); James C. Robinson & Quentin Jarrion, Competitionfrom Biosimilars
Drives PriceReductionsfor Biologics in the French Single Payer Health System, 40 HEALTH AFFS.

1190, 1196 (2021) (noting that although France has a single payer health-care system, permitting hospitals to retain half of savings from biosimilars encouraged their use); see also Liese Barbier, Steven
Simoens, Arnold G. Vulto, & Isabelle Huys, EuropeanStakeholder LearningsRegardingBiosimilars:
Part II-Improving Biosimilar Use in Clinical Practice, 34 BIODRUGS 797, 805 (2020) (noting sur-

veyed doctors, nurses, and some regulators believed financial incentive would help incentivize switching to biosimilar especially since a switch requires significant planning and time).
381.
Violeta Razanskaite, MarionBettey, Louise Downey, Julia Wright, James Callaghan, Miles
Rush, Simon Whiteoak, Sarah Ker, Kim Perry, Caron Underhill, Eren Efrem, Iftikar Ahmed, & Fraser
Cummings, BiosimilarInfliximab in Inflammatory Bowel Disease: Outcomes of a Managed Switching
Programme, 11 J. CROHNS & COLITIS 690, 691 (2017).

Id. at 692.
Id. at 695.
See infra Section IV.B.3.b. (discussing Medicare cost sharing).
See, e.g., Moorkens et al., supra note 67, at 10; Jorge Mestre-Ferrandiz, Adrian Towse,

&

382.
383.
384.
385.

Mikel Berdud, Biosimilars: How Can Payers Get Long-Term Savings?, 34 PHARMACOECONOMICS

609, 613 (2016); Laurence Greene, Rubina M. Singh, Mary Jo Carden, Caroline

O.

Pardo, & Gary R.

Lichtenstein, Strategiesfor Overcoming Barriersto AdoptingBiosimilars and Achieving Goals of the
Biologics Price Competition and Innovation Act: A Survey ofManaged Care and Specialty Pharmacy
Professionals,25 J. MANAGED CARE & SPECIALTY PHARMACY 904, 908-09 (2019).

386.
387.

Remuzat, Supply Side, supra note 67, at 10.
NORC, supra note 13, at 4.
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educational materials for doctors and patients), exactly what that education
includes to minimize existing biases is an important yet nuanced issue that
this Article aims to shed light on.388
ii. Models of Effective Biosimilar Use in the United
States
The best example of how biosimilar usage can be promoted in the
United States comes from Kaiser Permanente. Although Kaiser is an unusual integrated health-care company that is a payor as well as employer of
doctors, its strong biosimilar usage compared to the rest of the U.S. market
makes it a case study for consideration. 389 There are a couple factors that
may contribute to its successful biosimilar use. First, doctors do not have
a financial incentive to use the originator biologic because doctors are not
paid for services such as providing infusions, 390 and Kaiser also does not
accept any rebates from originator biologic companies. 39' So, contrary to
most U.S. insurers, there is no financial incentive for Kaiser doctors to
choose originator biologics. 392 In addition, Kaiser incorporates doctor input in deciding what drugs to cover and only covers one biosimilar per
drug class to strongly promote use of that biosimilar. Moreover, Kaiser is
not swayed by unfounded safety concerns and instead evaluates its own
patient use. Once Kaiser decides that biosimilars are safe and effective, it
educates doctors, 393 utilizing a team of research pharmacists to disseminate
information and answer questions. 394
Although an integrated approach that includes both financial incentives and education is ideal, there is some evidence that improved education alone can result in successful switching to biosimilars. In the United
388.
Advancing Education on Biosimilars Act of 2021, Pub. L. No. 117-8, 135 Stat. 254.
389. See, e.g., Sameer Awsare, Anthony Barrueta, Amy Gutierrez, & Polly F. Webster, The Case
for Letting Biosimilars Compete, HEALTH AFFS. (Dec. 19, 2019), https://www.healthaffairs.org/do/10.1377/forefront.201912 12.286621/full/ (noting Kaiser use of Zarxio is 95% compared
to 31.7% for the rest of the market and use of biosimilar Inflectra is 80% versus under 4% for rest of
market); In addition, Kaiser has had rapid adoption of biosimilars that included 97% biosimilar adoption of an oncology drug within a mere month of launch Stanton Mehr, How Did KaiserPermanente
Reach 95%+ Utilization of BiosimilarHerceptin andAvastin so Quickly?, BIOSIMILAR REV. & REP.

(Nov. 7, 2019), https://biosimilarsrr.com/2019/11/07/how-did-kaiser-permanente-reach-95-utilization-of-biosimilar-herceptin-and-avastin-so-quickly/.
390.
E.g., Awsare et al., supra note 392.
391.
See Mehr, supra note 392. Rebates by brand companies have been noted as a problem in
incentivizing payors to use the brand and financially benefiting, but not passing on their cost savings
to consumers. Shepherd, supra note 309, at 376; Katie Thomas, Meet the Rebate, the New Villain of
High Drug Prices,N.Y. TIMES (July 27, 2018), https://www.nytimes.com/2018/07/27/health/rebateshigh-drug-prices-trump.html.
392.
See Richard Brasington & Vibeke Strand, New Treatments in Rheumatology: Biosimilars,
6 CURRENT TREATMENT OPS. RHEUMATOLOGy 325, 330, 333 (2020) (explaining that in the United

States there is a financial incentive to use brand biologics based on reimbursements and rebates, but
Kaiser's refusal to accept rebates limits the financial incentive to use brand biologics and favors the
use of biosimilars).
393.
Mehr, supra note 392.
394.
Letter from Kaiser Permanente to Alex. M. Azar, U.S. Dep't Health & Human Servs., Feb.
12, 2019, at 2. Kaiser also has a registry to address concerns for patients switched to a biosimilar,
although there does not seem to be any evidence of difference regarding safety and efficacy forpatients
switched to the biosimilar. Brasington & Strand, supra note 392, at 333.
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States, 97% of patients at an academic medical center whose insurance
permitted coverage of a biosimilar were successfully switched from Remicade to a biosimilar to treat inflammatory bowel disease. 395 The patients
experienced no significant clinical differences, yet recognized a total cost
savings of $500,000 per year for 150 patients. 396 This required involvement of key stakeholders to approve a formulary change to prefer the biosimilar, as well as education of doctors that included clinical evidence
from the United States and the EU, and education of individual patients. 397
In addition to educating patients about the appropriateness of biosimilars,
patients were told that because biosimilars cost less for insurers to cover
than originator biologics, use of biosimilars over time could lower insurance premiums and out-of-pocket costs. 398
B. PromotingBiosimilar Use in the UnitedStates Despite Biases
Because this Article has demonstrated that the hesitancy to use biosimilars is likely due to an illogical bias, this Section focuses on modifying
existing structures to nudge individuals to adopt biosimilars despite this
bias. As discussed in the last Section, structural changes can result in desired behavior. Accordingly, this Section proposes changes to structural
impediments, including existing laws that are perpetuating the bias, in conjunction with appropriate education and incentives.
This Section begins by suggesting reversal of the most significant
structural changes, including unique aspects of U.S. law that perpetuate
bias by suggesting skepticism against biosimilars. Even if this is not possible immediately, a critical component to minimize bias against biosimilars and increase usage is appropriate education of doctors to reduce illogical biases against biosimilars that in turn can help to reduce bias in patients. Lastly, this Section recommends financial incentives to promote biosimilar usage. Although financial incentives have had a major impact
with promoting generic use, this is considered last because the nocebo effects are likely stronger with biologics than with generics. Financial incentives alone will not necessarily have desired outcomes without educating
doctors on the existence of nocebo effects and how to reduce them.
1. Removing Structural Biases and Barriers in Existing Laws
Two unusual structural impediments to biosimilar use lie with unique
U.S. regulatory approaches to biosimilars. First, the United States has
taken a different approach from all other nations by creating a separate
designation to permit biosimilars to be automatically substituted by

395.

Shuba Bhat, Sarah Altajar, Divya Shankar, Toni Zahorian, Regine Robert, Taha Qazi,

Bhavesh Shah, & Francis A. Farraye, Process and Clinical Outcomes of a BiosimilarAdoption Program with Infliximab-Dyyb, 26 J. MANAGED CARE & SPECIALTY PHARMACY 410, 413-14 (2020).

396.
397.
398.

Id.
Id. at 411-13.
Id. at 412.
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pharmacists. 399 Second, the United States also requires that biosimilars
have a different nonproprietary name than their corollary biologic, which
may result in an improper misperception of a significant difference because generic versions of traditional drugs lack such distinctions.400 Given
that European countries have broader acceptance and adoption of biosimilars and do not have either of these requirements, removing these impediments seems like a helpful first step.4t This Section acknowledges that
changing the status quo is challenging, especially because pharmaceutical
manufacturers are a key stakeholder in negotiating the current laws and
have shown substantial lobbying power in creating restrictive state laws
limiting substitution. 40 2 Nonetheless, understanding what would be ideal
can still be valuable in recognizing that the current structure is promoting
bias and could be harnessed in education efforts as discussed in the next
Section.
a. Addressing Interchangeability
It is important to ensure the interchangeability designation functions
as it was originally intended, to promote biosimilar use, rather than propagate misperceptions that any biosimilar that is not interchangeable is suspect. Although there are few countries that have laws to promote pharmacy
substitution of lower cost biosimilars, most other countries have more effective mechanisms to promote biosimilar use. 403 For example, some
countries impose quotas on doctors to promote biosimilar and generic
use. 4 4 Other countries may require biosimilar use because the national
health-care system elected to purchase the cheaper biosimilar or at least
may encourage biosimilar use through national mandates that require that
biosimilars cost less. 4 5 Given these other levers, pharmacy substitution
may not be as important in other countries, but it is important in the United
States where these levers do not and are unlikely to exist.40 6
There are two possible ways to address systemic barriers to use of
interchangeable biosimilars, one of which would be faster although more
399. See supra text accompanying note 66 (discussing interchangeability requirement in U.S.
law being unique).
400. See supra text accompanying note 219 (discussing how the United States has different
nonproprietary names).
401. WAXMAN ET AL., supra note 294, at 16 (noting that naming and labeling rules may make
doctors uncertain about biosimilars).
402. See Macfarlane, supra note 230, at 66-67 (discussing corporate lobbying to enact state antisubstitution laws for biosimilars).
403. See supra notes 377-91 and accompanying text (discussing efforts in other countries to
promote biosimilar use).
404. E.g., Remuzat, Supply Side, supra note 67, at 6-7 (noting quotas in eight European countries); Moorkens et al., supra note 67, at 8-9, 12 (discussing strategies aimed at doctors).
405. E.g., Brasington & Strand, supra note 392, at 333 (noting Denmark required patients to
switchto biosimilars in 2016 as a cost-saving measure); Moorkens etal., supra note 67, at 5-8 (providing overview of pricing issues); see also ARAD ET AL., supra note 293, at 11 (noting that countries are

moving away from a contract with a single biosimilar manufacturer to promote competition among
biosimilar suppliers).
406.
E.g., ARAD ET AL., supra note 293, at 8 (noting differences between U.S. and European
systems concerning degree of government involvement in pricing of drugs and price negotiation).
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challenging to implement. The ideal way to dismantle current barriers to
biosimilar substitution is to create a federal mechanism for permitting substitution of biosimilars that would supersede state laws. This could include
rules that would promote rather than limit usage, such as barring patients
from objecting to substitution. 40 7 A federal system for substitution would
not replace the existing scheme for evaluating what is interchangeable at
the pharmacy level. However, importantly, it would avoid the current hurdles in state laws that originator biologic companies have successfully lobbied for states to enact. Such companies are likely to object to anything
that would dismantle laws they created with substantial and expensive lobbying. 408 Accordingly, the second approach is a piecemeal one. As the history of generic state substitution laws shows, it is also possible to change
laws over time on a piecemeal basis. 40 9 Notably, that history indicates that
a strong coalition of competing forces, along with financial imperative,
may be necessary to prompt change. 4 0 A financial imperative should be
obvious given that biologics comprise a disproportionate part of expenses
while constituting a minority of drugs-especially because more biologics
are likely to enter the market and further increase financial strains. 4"' Perhaps with appropriate education of doctors and advocacy from consumer
groups with aligned interests, state laws to better promote substitution of
interchangeable biosimilars would be possible.
b. Addressing Suffixes for Biosimilars
Whereas the interchangeability designation is difficult to change, it
should be easier to modify existing U.S. regulations concerning distinct
suffixes for the nonproprietary names of biosimilars given that there is no
need for congressional action and no robust reason for the rule. The origin
of distinct names is tied to industry lobbying asserting that distinct naming
ensure safety. 4 2 FDA guidance similarly alleges suffixes could improve
pharmacovigilance. 413 However, this is contrary to real-life data. The EU,
for example, does not use suffixes and has not had any trouble with

407.
E.g., Daniel Kadin, Note, Taking Biosimilarsto the Next Level: Why Federalizingthe Substitution of Biosimilars Promotes Innovation, Competition, and PatientSafety, 45 SW. L. REV. 405,

422-27 (2015).
408. E.g., Macfarlane, supra note 230, at 66-67 (noting company lobbying to create state legislation limiting biosimilar substitution); Andrew Pollack, Biotech Firms, Billions atRisk, Lobby States
to Limit Generics, N.Y. TIMES (Jan. 28, 2013), https://www.nytimes.com/2013/01/29/business/battle-

in-states-on-generic-copies-of-biotech-drugs.html.
409. See supra notes 358-65 and accompanying text (discussing history of U.S. structural
changes to law and policy).
410. See supranotes 333-36 and accompanying text.
411. E.g., supra notes 1-2 and accompanying text (noting that biologics constitutes 40% of drug
costs although they are only about 2% of drugs used).
412.
BIO, EBE, EFPIA, EuROPABIO, IFPMA, & PHRMA, POLICY POSITION ON NAMING OF
BIOTECHNOLOGY-DERIVED THERAPEUTIC PROTEINS 3-4 (Oct. 31, 2006); Mendila, supra note 248

(Genentech argued "distinct" names are essential to avoid unintended substitution even though that
does not seem to be a problem with generics that share the same name).
413.

2017 DRAFT NAMING GUIDANCE, supra note 240, at 4-6; see also 2019 DRAFT NAMING

GUIDANCE, supra note 236, at 5-6 (revising guidance to not require suffixes for biologics approved
without an FDA suffix).
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tracking biosimilars by using brand names in conjunction with other identifiers, such as batch numbers. 414 Moreover, despite the FDA claim that
unique suffixes help with tracking adverse reactions, less than 1% of reported adverse reactions actually use the suffix; rather, virtually all reports
are based on the brand name, as is the case in Europe. 45 The FDA seemed
to see the fallacy of different names when it briefly suggested suffixes for
all biologics, including retroactively applying them to originator biologics.41 6 However, current FDA guidance now reflects brand manufacturer
claims that retroactive suffixes cause undue burden. 417 This argument is
not compelling. Even if there is a financial cost to changing suffixes, the
overall economic cost of bias against biosimilars should be given greater
weight. The annual savings of $2-$7 billion resulting from increased use
of biosimilars would make the onetime cost of changing product names
insignificant. 418
Jettisoning use of suffixes for all biologics is ideal. If this is not possible, having suffixes associated with the manufacturer would better parallel the system with generics where the generic has the same nonproprietary name, but pharmacists can distinguish between different manufacturers. Indeed, pharmacists currently have trouble associating the random
suffixes that the FDA requires with specific biosimilars, which is likely
because the meaningless suffix makes it hard to remember. 419
At a minimum, it is desirable for at least interchangeable biosimilars
to share the same proprietary name, including the suffix. 420 The FDA only
grants an interchangeable designation to a biosimilar that can be substituted by a pharmacist when it is supported by extensive data on the safety
of multiple switches. Sharing the same name would underscore that such
biosimilars can be substituted in the same manner as generics. Admittedly,
this would require that a biosimilar's nonproprietary name change once
the biosimilar is deemed interchangeable. The FDA asserts that it might
cause unnecessary confusion if a biosimilar was later deemed interchangeable and needed a name change. 42 ' However, this ignores the fact that
414. EUR. MEDS. AGENCY & EUR. COMM'N, supra note 66, at 25-26; Niels S. Vermeer, Thijs J.
Giezen, Sofia Zastavnik, Elena Wolff-Holz, & Ana Hidalgo-Simon, Identifiability of Biologicals in
&

Adverse Drug Reports Received from European ClinicalPractice, 105 CLINICAL PHARMACOLOGY

THERAPEUTICS 962, 964, 967-8 (2018).
415.
Stanton Mehr, More from GRx+ Biosims on Four-Letter Suffixes and BiosimilarInterchangeability,
BIOSIMILARS
REV.
&
REP.
(Sept.
20,
2018),
https://biosimi-

larsrr.com/2018/09/20/more-from-grxbiosims-on-interchangeability/.
416. 2017 DRAFT NAMING GUIDANCE, supra note 240, at 7.
417.
2019 DRAFT NAMING GUIDANCE, supra note 236, at 5-6; see also Stanton Mehr, If Four
Letter Suffixes Aren't Used in Biosimilar Tracking, What Use are They?, BIOSIMILAR DEV. (Nov. 6,

2018), https://www.biosimilardevelopment.com/doc/if-four-letter-suffixes-aren-t-used-in-biosimilartracking-what-use-are-they-000 (arguing that changing suffixes for currently marketed biologics
would involve forty hours per product).
418.
WINEGARDEN, supra note 102, at 5.
419.
Stephen Barlas, FDA Pleases No One with Final Guidance on Naming of Biologics and
Biosimilars,42 PHARMACY & THERAPEUTICS 222, 222 (2017).

420.
The FDA did contemplate this as a possible option. See FDA, Nonproprietary Naming of
Biological Products: Draft Guidance for Industry, 80 Fed. Reg. 52,296 (Aug. 2015).
421.
2019 DRAFT NAMING GUIDANCE, supranote 236, at 6.
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distinct nonproprietary names already cause confusion and bias against biosimilars. 4aa Moreover, a name change for an interchangeable biosimilar
would serve an important signaling function as to its changed status.
2. Enlightened Education in View of Bias and Nocebo Effect
Even if existing U.S. structural barriers to biosimilar use are not eliminated, biosimilars can nonetheless be promoted with appropriate education that is cognizant of bias against biosimilars. Notably, although many
have suggested that education of doctors and patients is important, the type
of education is critical. 423 As discussed earlier, accurate facts do not necessarily change views because cognitive biases can distort how facts are
perceived. 42 4 Moreover, biosimilar bias adds an additional layer of complication. Considering that biosimilars treat more serious conditions, patients who are switched to a biosimilar could likely experience a nocebo
effect. 4 5 So, patient education must be carefully tailored to reduce this
effect.
Doctors are the starting place for improving knowledge about biosimilars to reduce illogical bias because they can influence patients and
payors. Many patients are willing to switch from a brand to biosimilar if
advised by a physician. 42 6 Even payors are sensitive to doctor preferences;
some have suggested that insurers thus far have been resistant to preferring
biosimilars because of strong doctor aversion to switching stable patients. 427 In addition, once doctors are familiar with biosimilars, they may
adopt subsequent ones more easily. 42 8
The first thing to educate doctors on is that all biosimilars-even if
not designated as interchangeable-are safe and effective. It may be helpful to educate doctors on the long history of biosimilar use in Europe as
well as the rigorous clinical trials establishing safety and efficacy. Moreover, doctors should be informed that the interchangeable designation is a
unique U.S. designation to promote greater use of biosimilars rather than
a signal of a problem, and that a similar designation does not exist in other
countries because they have other levers to promote biosimilar use inapplicable to the United States, such as government purchasing of lower cost

422.
Socal et al., supra note 271, at 278; see also Kolbe et al., supra note 166, at 368 (noting that
46% of doctors said that suffixes make prescribing confusing).
423. See generally supra notes 385-88 and accompanying text (discussing need for education).
424. See supranotes 112-15 and accompanying text.
425. See, e.g., supra notes 197-206 and accompanying text (discussing likely nocebo effect with
biosimilars); Wolfe & Michaud, supra note 140, at 2135 (finding that RA patients not entirely satisfied
with existing therapy are reluctant to try new treatment for fear that it could be worse).
426.
Scherlinger et al., supra note 197, at 930 (noting that 70% of patients willing to switch to a
biosimilar for rhematic disease involved a situation where the doctor had a good opinion ofbiosimilars
and patient trust in doctor opinion was considered important whereas only 30% were persuaded by
cost).
427.
428.

Hakim & Ross, supra note 230, at 2164.
BIOSIMILARS FORUM, supra note 81, at 11.
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biosimilars for all. Essentially, education should seek to counter misinformation about the importance of the interchangeability designation.
Another important component is to educate doctors that it is safe to
switch patients currently on an originator biologic to a biosimilar. Studies
have repeatedly noted that it is impossible to substantially reduce overall
costs if only new patients, who are the minority of total patients, are
switched to biosimilars; existing patients must also be switched. 429 However, current bias against biosimilars coupled with advertisements that repeatedly caution against "non-medical switching" can promote the cognitive bias of loss aversion, which creates an unnecessary hesitance to
change medication. 430 Indeed, one study revealed that including the term
non-medical switching in a survey question changed doctor willingness to
switch patients.431 This is not surprising because the term suggests that a
biosimilar would be used when it is not medically appropriate, as opposed
to using a biosimilar that is just as medically appropriate but more cost
effective than the originator biologic. 43 2 In addition, although marketing
and materials from some patient advocate groups emphasize a list of problems that could result from switching to a biosimilar, those same problems
could happen without any switch because each batch of biologics, even if
from the same manufacturer, is not identical. 433 Moreover, there is both
empirical evidence and real-life data from other countries showing that
switching is safe, which has persuaded some countries to mandate switching to biosimilars to maximize access to expensive biologics. 434 This fact
needs to be impressed on doctors, along with recent guidance from many
doctor groups in Europe promoting greater biosimilar use even for patients
who are currently stable on a biologic. In addition, perhaps a different term
should be used-such as "safe switching"-to promote the idea that
switching is safe, or at least neutrally referring to it simply as "switching,"
which some academic articles do. 435
A critical component that has not been acknowledged by the FDA or
most commentators is that doctors need to be educated on the nocebo effect to minimize it.43 6 Most fundamentally, doctors need to know that this
429. E.g., Hakim & Ross, supra note 230, at 2164. This is likely due to the fact that most biologics do not cure diseases and rather are long-term maintenance drugs, such that existing patients
make up a big part of biologic use.
430.
See supra notes 134-39 and accompanying text (discussing loss aversion).
431.
INDUS. STANDARD RSCH., supra note 288 and accompanying text.
432.
E.g., Anna Rose Welch, Amgen, Sandoz Biosimilar FDA AdComs: 5 Takeaways,
BIOSIMILAR DEV. (July 18, 2016), https://www.biosimilardevelopment.com/doc/amgen-sandoz-biosimilar-fda-adcoms-takeaways-0001 (noting that the term "non-medical switching" causes unnecessary concern and confusion).
433.
Rahman Kabir et al., supra note 34 (noting that different batches of originatorbiologics are
also not identical).
434. E.g., Davio, supra note 280; Jeremias, supra note 280.
435.
See generally Kurki et al., supra note 66, at 88.
436.
See Ferdinando D'Amico, Lieven Pouillon, Marjorie Argollo, Ailsa Hart, Gionata Fiorino,
Elena Vegni, Simona Radice, Daniela Gilardi, Maria Fazio, Salvo Leone, Stefanos Bonovas, Fernando
Magro, Silvio Danese, & LaurentPeyrin-Biroulet, MultidisciplinaryManagement ofthe NoceboEffect
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phenomenon takes place and how doctor-patient communications, including nonverbal gestures, can prompt a nocebo effect. Importantly, even just
one occasion of negative information can have long-lasting effects in
terms of nocebo effects. 437 Of course, informing doctors about the nocebo
effect and how to eliminate it will only be effective if doctors do not have
a bias against biosimilars themselves. 438 Even assuming no bias, doctors
should still be informed of specific strategies that can help generally reduce the nocebo effect, and specifically reduce the nocebo effect with biosimilars. 43 9
How information is disclosed or not disclosed to patients can have an
important impact on perceptions and subsequent nocebo effects. One
Dutch study indicated that improved communication, including clearly informing patients about the reason for a switch to a biosimilar, together
with "soft skills" such as training to address patient concerns and openly
discussing possible nocebo effects, resulted in higher patient acceptance
and persistence. 440 Beyond the nascent biosimilar context, there is evidence showing that negative framing may prompt nocebo effect 441
whereas positive framing can have positive effects. A balanced approach
focuses on a positive framing rather than just listing the adverse effects. 442
Positive framing would focus on similarities in safety and efficacy rather
than simply lower cost; this is important because patients sometimes improperly assume lower costs are associated with inferior products. 443

in Biosimilar-TreatedIBD Patients:Results of a Workshop from the NOCE-BIO Consensus Group,
52 DIGESTIVE & LIVER DISEASE 138, 140 (2020) (noting that patient-health-care-provider relationship

is a key driver in accepting biosimilars and limiting the risk of nocebo effect).
437.
Rea Rodriguez-Raecke, Beril Doganci, Markus Breimhorst, Anne Stankewitz, Christian
Bichel, Frank Birklein, & Arne May, Insular Cortex Activity is Associatedwith Effects of Negative
Expectation on Nociceptive Long-Term Habituation,30 J. NEUROSCIENCE 11363, 11366 (2010).
438. See supranotes 14-15 and accompanying text.
439.
Greene et al., supranote 388, at 905 tbl.1. These are generally applicable strategies although
those inclined to nocebo effects may share some characteristics. See Gasteiger et al., supra note 206,
at 169 (finding that women that engage in more information-seeking behavior have more negative
perceptions towards generics).
440.
L. Tweehuysen, V.J.B. Huiskes, B.J.F. van den Bemt, F.H.J. van den Hoogan, & A.A. den
Broeder, Higher Acceptance and Persistence Rates After Biosimilar Transitioning in Patients with
Rhematic Disease After Employing an Enhanced Communication Strategy, 17 ANNALS RHEUMATIC

DISEASE 557, 557 (2017) (the improved communication included first informing patients by letter and
then contacting by phone to see if they agreed, together with enhanced communication after the transition that explained that the transition would result in lower costs and fewer injection site reactions).
441.
Ted J. Kaptchuk, William B. Stason, Roger B. Davis, Anna T. R. Legedza, Rosa N. Schnyer,
Catherine E. Kerr, David A. Stone, Bong HyunNam, Irving Kirsch, & Rose H. Goldman, Sham Device
v. Inert Pill: Randomised Controlled Trial of Two Placebo Treatments, 332 BRIT. MED. J. 1, 5-6
(2006) (subjects told of possible adverse effects experienced them even when given sham treatments);
see also Luana Colloca, Leonardo Lopiano, Michele Lanotte, & Fabrizio Benedetti, Overt Versus
Covert TreatmentforPain, Anxiety, and Parkinsons, 3 LANCET NEUROLOGY 679, 681 (2004) (telling

patients when an infusion of morphine for postoperative pain would be interrupted resulted in more
pain than patients who knew the infusion would eventually stop, but not the exact time).
442.
Colloca & Finniss, supra note 338, at 568; Yannick Vandenplas, Steven Simoens, Philippe
Van Wilder, Arnold G. Vulto, & Isabelle Huys, Informing PatientsAbout BiosimilarMedicines: The
Role of EuropeanPatientAssociations, 14 PHARMS. 1, 6 (2021).

443.
D'Amico et al., supra note 436, at 140-41; Frantzen et al., supra note 195, at 495 (noting
that safety and efficacy data was the best incentive to convert patients to biosimilars and that doctors
are the most persuasive source of information).
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Indeed, one study found those in a positive framing group were more than
two times more likely to switch to a biosimilar and were more likely to
believe that the biosimilar would be effective. 444 In addition, educating patients on the fact that the differences between a biologic and a biosimilar
are similar to those between different batches of originator biologics is
also suggested as helpful to promoting patient acceptance. 445 Moreover,
providing education both orally and in writing is recommended. 446 All of
these considerations are particularly important for switching stable patients to a biosimilar to combat rampant negative messaging, the loss aversion cognitive bias, and the nocebo effect. 447
In terms of how to educate doctors, a broad effort is important. To
address the availability bias that has been promoting originator biologic
views, the education effort must be substantial enough to make it equally
available. This would require far more than just FDA guidance, which is
not as available as advertisements. However, the same techniques that
work to promote brand name drugs can be used to properly educate doctors. For example, studies have shown success with so-called academic
detailing of generic drugs where doctors are visited and provided information on generics to counteract advertising of brand drugs. 448 In addition,
just as European groups of doctors in particular areas have adopted consensus statements promoting use of biosimilars, so too U.S. doctors could
establish similar statements and-before those statements take effectpromote existing statements from their European peers with more experience.449
In addition, just as a coalition of interest groups helped to promote
generic usage, incorporating groups beyond the FDA interested in promoting biosimilar use would also be valuable. It would be ideal if patient advocacy groups could provide similar education. Not only could patient advocacy groups make information promoting biosimilars more available to
counteract marketing from brand biosimilars, but these groups are often
especially trusted by patients. 40 Studies focused on debunking
444.

Chiara Gasteiger, Annie S. K. Jones, Maria Kleinstauber, Maria Lobo, Rob Horne, Nicola

Dalbeth, & Keith J. Petrie, Effect of Message Framing on Patients'Perceptions and Willingness to
Change to a Biosimilarin a HypotheticalDrugSwitch, 72 ARTHRITIS CARE & RES.1323, 1327 (2020).

445.
Scherlinger et al., supra note 197, at 930. However, the level of detail to provide is difficult
to determine because more information might prompt patients to assume that there is a problem. E.g.,
Barbier et al., supra note 181, at 734 (noting no consensus on this issue among doctors and nurses).
446.
Scherlinger et al., supra note 197, at 931.
447.
This is particularly important given a recent study indicating that doctor and patient perceptions about whether adequate information was provided regarding switching to a biosimilar differed,
with less than half of patients believing their cancer would be treated effectively with a biosimilar
versus 79% of oncologists, and also the majority of oncologists believing the switch was a minor
change, but only 37% of patients seeing it as minor. E.g., Tony Hagen, Patient-ProviderSurveys Elucidate Biosimilar Switching Process in Oncology, CTR. FOR BIOSIMILARS (Dec. 13, 2021),

https://www.centerforbiosimilars.com/view/patient-provider-surveys-elucidate-biosimilar-switchingprocess-in-oncology.
448.
See Jerry Avorn, Academic Detailing: "Marketing"the Best Evidence to Clinicians,317 J.
AM. MED. ASS'N 361, 361 (2017).
449.

See generally MEDICINES FOR EUROPE, supranote 2268, passim.

450.

E.g., Vandenplas et al., supra note 442, at 10.
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misinformation indicate more success when information is presented in a
way that aligns with personal beliefs or partisan identities. 45 ' Patients may
feel such groups represent their interests and thus, be more amenable to
their positions like partisan identity. 42 Admittedly, it may be challenging
to persuade patient advocacy groups to promote biosimilars because many
of them are aligned with originator biologic interests. 453 Even if patient
advocacy groups are not readily amenable, there could be other entities
with an interest in promoting biosimilars such as AARP, which also helped
to promote generic use. 45 4
Another mechanism to promote availability of positive messages
concerning biosimilar use would be to simultaneously reduce availability
of inaccurate messages from originator biologic manufacturers. Beyond
the FDA taking more direct action to immediately correct messages, additional steps could be taken to further eliminate some current structural oddities that incentivize corporate mismarketing. For example, Congress
could remove tax deductions that currently apply to direct-to-consumer
advertising and instead, apply taxes on "spending on direct-to-consumer
broadcast advertising." 45
3. Financial Incentives
Last, but not least, financial incentives should promote biosimilar use
in a manner similar to what has worked with generics, rather than the current situation that promotes the originator.456 Of course, how to do so is
much more complex than with generic drugs given that biologics are primarily provided by doctors rather than pharmacists. However, there are
different and complementary ways to realign incentives that include disincentivizing rebates that favor the originator biologic and financial incentives to doctors and patients to use biosimilars.
a. Incentivize Biosimilar Coverage
One of the most obvious steps is to prevent payors from requiring
patients to fail first on the originator biologic before giving access to a

451. E.g., Lewandowsky et al., supra note 15, at 118.
452. See, e.g., Vandenplas et al., supranote 442, at 10.
453.
See supranotes 241-42 and accompanying text; see also supra Section III.B.2 (noting that
companies and patient advocacy groups both discourage switching to biosimilars).
454. See supranote 362 and accompanying text.
455. WAXMAN ET AL., supranote 294, at 19.
456.
Although other countries have mandated biosimilar use, this is inconsistent with U.S. history. See supra Section IILA. Moreover, mandatory use could increase overall health-care costs, possibly due to a nocebo effect. However, Denmark has successfully required patients switch to biosimilars without an increase in health-care service costs. See, e.g., Bente Glintborg, Rikke Ibsen, Rebecca
Elisabeth Qwist Bilbo, Merete Lund Hetland, & Jakob Kjellberg, Does a Mandatory Non-Medical
Switch from Originatorto BiosimilarEtanercept Lead to Increase in Healthcare Use and Costs? A
Danish Register-Based Study of Patients with Inflammatory Arthritis, RMD OPEN 1, 6, 8 (2019);
Bente Glintborg, Jan Sorensen, & Merete Lund Hetland, Does a Mandatory Non-Medical Switchfrom
Originator to BiosimilarInfliximab Lead to Increased Use of Outpatient HealthcareResources? A
Register-BasedStudy in Patientswith Inflammatory Arthritis,RMD OPEN 1, 4 (2018).
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biosimilar.4 7 Just as generic drug use has been promoted with tiered formularies that provide substantially reduced or zero co-pays for generics, a
similar framework would be helpful to promote use of biosimilars.458 At a
minimum, it would be desirable to bar preference for originator biologics
in formularies. While contrary to most existing practices in the United
States, one proposed state bill aims to do this. 45 9 In addition, some insurers
may already be doing so with use of biosimilars for patients new to expensive oncology treatments. 460
There is also a need to address the rebate trap that results in insurers
preferring brands to increase their profits. Addressing rebates is complex.
A Trump Administration rule, currently on hold, 46' proposed to bar rebates
for Medicare drugs under Part D that covers some common biologics, such
as insulin. 462 Although barring rebates for Medicare might promote biosimilar use, some suggested that it would increase premiums because insurers allegedly provide lower premiums due to the rebates. 463 Although
exploring the details of how to minimize rebate use without increasing
Medicare premiums is beyond the scope of this Article, this Article agrees
that anticompetitive rebates should be avoided. 464
Given the diversity of private payors, starting with Medicare reform
makes sense because private insurers often take cues concerning coverage
from Medicare. 465 The need to amend Medicare to better align incentives
is something that is already recognized by some policy makers as helpful; 466 indeed, Congress has already modified some Medicare benefits to
promote biosimilars dispensed at pharmacies. 467 However, Medicare can
and should also promote biosimilar administration in doctor offices, such
as by covering biosimilars and their corollary originator biologic under the
same billing code so that reimbursement is based on an average price that
includes both and provides an incentive for true price competition. 468 In
457.

E.g., AVALERE HEALTH, supra note 309, at 8.

458. See supra notes 375-76 and accompanying text (discussing tiered formularies incentivizing
use of generics).
459.
S. 990, 2021 Leg., 92d Sess. (Minn. 2021).
460. See supranote 307 and accompanying text.
461.
Pharm. Care Mgmt. Ass'n v. U.S. Dept. Health & Human Sevs., No. 21-95 (JDB), 2021
U.S Dist. LEXIS 30884, at *2 (D.D.C. Jan. 30, 2021).
462.
42 C.F.R. § 1001.952(h).
463.

Jeff Lagasse, Trump-Era Rebate Rule for Medicare Part D on Hold Until 2023,
1, 2021), https://www.healthcarefinancenews.com/news/biden-admin-
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istration-puts-hold-trump-era-rebate-rule-medicare-part-d.
464.
For some specific suggestions to address anticompetitive practices, see WAXMAN ET AL.,
supra note 294, at 19.
465.
E.g., Yazdany, supra note 290, at 871.
466.

E.g., BRILL, supra note 6, at 6-7; ARAD ET AL., supranote 293, at 9.

467.
Medicare benefits for biosimilars distributed at pharmacies have been modified to correct a
prior situation where there was a discount for brand biologic manufacturer, but not biosimilars for the
"gap phase" of Medicare Part 2. See Bipartisan Budget Act of 2018, Pub. L. No. 115-123, § § 5032325, 132 Stat. 64, 169.
468.
E.g., Benjamin N. Rome & Ameet Sarpatwari, PromotingBiosimilar Competition by Revising Medicare Reimbursement Rules, JAMA NETWORK OPEN, Nov. 15, 2021, at 1, 1 (explaining

that this is the situation for traditional drugs and the result is direct price competition between brand
name and generics that incentivizes doctors to purchase and administer the least expensive option).
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addition, even without amendment of Medicare rules, it is possible to use
different strategies through the Center for Medicare and Medicaid Innovation, which is designed to test innovative payment and service delivery
models to reduce costs like the suggestions below or, alternatively, like the
models that have worked for Kaiser and in Europe. 469
b. Promoting Biosimilars Through Medicare Modification

'

Biosimilars could be promoted by modifying Part B of Medicare,
which addresses the many biologics administered in health-care provider
offices. There are currently proposals to modify the law. 470 Based on structural changes that have been effective globally, permitting a shared savings model for physicians whereby they receive a portion of the difference
between the average sales price ofthe originator biologic and biosimilarin addition to standard payments-could be effective. After all, shared
savings have been effective in other countries. 47
Medicare Part D could also be modified to promote biosimilars. Just
as formulary tiers helped promote usage of generics, a formulary tier could
financially prefer a biosimilar over a corresponding originator biologic. 472
In addition, requiring plans to add biosimilars to formularies as soon as
they come on the market and removing step therapy requirements would
also promote biosimilar use. Medicare could follow Kaiser's success in
promoting biosimilars by only covering one biosimilar for every biologic,
although this may require a change in the law because it currently requires
two drugs per class with biosimilars not considered a different drug. 473
This would likely be most successful if coupled with a patient incentive,
such as no patient co-pay for biosimilars. 474 Another possibility is to create
a specialty tier for generics and biosimilars to promote cost sharing.

469.

E.g., BRILL, supra note 6, at 5-9 (suggesting that this center engage in different Part B

payments as well as promote shared savings); see also Kip Piper, MedicareandMedicaidDemonstration Waivers, PIPER REP. (Aug. 12, 2018), https://piperreport.com/blog/2008/08/12/medi-
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470.
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The Case for Optimism in the U.S. Biosimilar Market, BIOSIMILAR DEV. (July 28,

2020),
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471. See supranotes 383-87 and accompanying text.
472.
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473.
Memorandum from Amy K. Larrick, Acting Director, Medicare Drug Benefit and C & D
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CONCLUSION

The successful and safe use of more cost-effective biosimilars to treat
more patients is an important, yet, thus far, elusive goal. This Article contributes to the literature by identifying the extent of existing bias against
biosimilars, as well as the effect of U.S. law, policy, and private insurers
on perpetuating bias and thus, barring broader U.S. adoption of biosimilars. Minimizing bias is difficult, and especially so because the current
status quo favors originator biologics. Nonetheless, this Article provides
multiple mechanisms to modify bias and change existing structures to effectively nudge desired action.

